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ABSTRACT
Oligonucleotide-mediated gene editing of 
Apolipoprotein A-I
Apolipoprotein A-I (ApoA-I) is the major protein constituent of high density 
lipoprotein (HDL) and controls reverse cholesterol transport, an important process in 
preventing atherosclerosis. A  natural point mutation, ApoA-lMiiano (A poA -Im) enhances 
the atheroprotective potential of HDL. Here, I attempt to introduce this specific 
modification into the genome of mammalian cells using the gene therapy strategy of 
oligonucleotide-mediated gene editing. I showed successful APOA-I gene editing in 
recombinant Chinese hamster ovary (CHO-AI) and human hepatocellular carcinoma 
(HepG2) cells by polymerase chain reaction restriction fragment length polymorphism 
(PCR-RFLP) analysis and sequencing. However, I was unable to isolate gene-edited cell 
clones or quantify gene editing. Therefore, I established a recombinant CHO cell line 
expressing mutated non-fluorescent enhanced green fluorescent protein (mEGFP) that 
demonstrates successful gene editing through restoration o f fluorescence.
Using flow cytometry, I studied the influence of transfection reagents and 
oligonucleotide design on gene editing efficiency and viability o f gene-edited cells. I 
found that Lipofectamine 2000 generated higher initial editing efficiencies with 
phosphorothioate (PTO) or locked nucleic acid (LNA) modifications, but unmodified 
oligonucleotides produced significantly more gene-edited clones. I also investigated 
ways o f increasing editing efficiencies or selecting for gene-edited cells independent of 
the target gene and demonstrated that I had introduced three specific nucleotide 
alterations by Southern blotting of genomic DNA from gene-edited cell clones. I 
established that the phenotype in these clones was unstable due to epigenetic down- 
regulation which was not specific to the gene-edited allele. Variegated gene expression 
in three mEGFP cell lines demonstrated that gene editing was positively associated with 
target gene expression. Isolation of ApoA-lM gene-edited cells using flow cytometry 
failed because an ApoA-lM homodimer antibody was not specific.
In summary, I demonstrated that oligonucleotide-mediated gene editing 
produces stable gene-edited cells in a reporter gene system. However, further research is 
needed before this method can be applied to non-selectable genes.
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CHAPTER 1: GENERAL 
INTRODUCTION
1.1 Cardiovascular disease and atherosclerosis
According to the British Heart Foundation,1 in 2004, cardiovascular disease (CVD) 
accounted for nearly 40% of deaths in the UK, 10% more than all forms of cancer taken 
together. The World Health Organization estimates that 30% of all deaths worldwide 
are due to CVD.2 Half of these deaths are caused by coronary heart disease (CHD) and a 
quarter by stroke.
Both have the same cause -  a blockage in an artery cuts off the blood supply to parts of 
the heart muscle or brain, resulting in oxygen and nutrient deprivation that can lead to 
irreversible tissue damage. The most common reason for arterial blockage is the build­
up of fatty streaks and their subsequent development into fibrous lesions on the inner 
walls of blood vessels in a process known as atherosclerosis. In a few cases the fibrous 
lesion itself grows large enough to block the blood flow in the artery, but usually it is 
the rupture or erosion of such a lesion that leads to the formation of an occluding blood 
clot.3
Atherosclerosis can be described as a chronic inflammatory response to injury o f the 
endothelial cell layer coating the luminal side of the artery wall.4 Lesion formation is 
initiated by decreased haemodynamic shear stress and increased turbulence in the blood 
flow caused by arterial branches and curvatures.5 In these areas the endothelial cell layer 
displays greater permeability to macromolecules such as low density lipoprotein (LDL) 
and raised production of reactive oxygen species primarily by NADPH oxidases. A 
simultaneous drop in endothelial nitric oxide synthase reduces the amount of available 
nitric oxide radicals normally responsible for scavenging reactive oxygen species.6
Interaction between reactive oxygen species and LDL trapped in the intima by 
aggregate formation and proteoglycan binding leads to oxidation of phospholipids on 
the LDL. This minimally modified LDL (mmLDL) induces overlying endothelial cells 
to express chemotactic proteins and vascular cell adhesion molecules that recruit 
monocytes and T lymphocytes to the intima.7 The monocytes mature into macrophages 
and proliferate as a result o f their exposure to growth factors such as colony-stimulating 
factor secreted by the activated endothelial cells and differentiated macrophages 
themselves.
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Myeloperoxidase, sphingomyelinase and secretory phospholipase further modify 
mmLDL to highly oxidized LDL (oxLDL) which is recognized by the macrophage 
scavenger receptor class A (SR-A) and CD36. Receptor-mediated internalization of 
oxLDL and subsequent formation of membrane-bound lipid droplets in the cytoplasm of 
macrophages triggers their differentiation into foam cells (Figure 1-1). CD40/CD40L 
cross talk between macrophages and T cells stimulates secretion of interferon-y from the 
latter which up-regulates the expression of the SR-A and CD36 receptors on the surface 
of macrophages.
Autocrine activation by tumour necrosis factor a  also plays a role in this positive 
feedback loop.8 Ultimately the bloated foam cells succumb to programmed cell death 
and the resulting lipid-rich cell debris forms the beginning of a necrotic core. Smooth 
muscle cells emigrate from the media into the intima as a result o f the cytokines and 
growth factors released by both T cells and macrophages. There they secrete extra­
cellular matrix proteins and give rise to a fibrous cap covering the necrotic core.
As the lesion progresses from a fatty streak to a fibrous necrotic plaque, the blood flow 
in the artery is further disturbed. This leads to continuous recruitment and infiltration of 
monocytes and T cells at the lesion shoulders. The newly arrived macrophages produce 
proteases such as collagenases, gelatinases, stromolysin and cathepsins that digest the 
extra-cellular matrix proteins.9 Ultimately, however, these macrophages also 
differentiate into foam cells and increase the lesion volume.
Lesion rupture frequently occurs at these foam cell rich shoulders, perhaps due to 
instability caused by a higher ratio of foam cells to smooth muscle cells in areas already 
suffering from a weakened extra-cellular matrix. Exposure of the necrotic core contents 
to the luminal blood promotes coagulation and thrombosis, which may lead to a local 
blockage. Alternatively, the blood clot might be swept away from the injury site and 
obstruct a smaller blood vessel downstream.
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Figure 1-1 Early steps in atherosclerosis development
LDL particles can break through the endothelial cell layer coating the luminal side of the artery 
wall in injured areas. Once in the intima, LDL particles are modified into oxLDL which attract 
macrophages. These engulf oxLDL and differentiate into cholesterol-laden foam cells. Ultimately, 
foam cells succumb to lipid overload and die, forming the cholesterol-rich necrotic core of an 
advanced fatty streak. Smooth muscle cells emigrate from the media into the intima and secrete 
extra-cellular matrix proteins that give rise to a fibrous cap covering the necrotic core.
Even though atherosclerosis is a dynamic process, already evident in the unborn foetus,7 
not every arterial wall injury progresses to a complicated and potentially fatal necrotic 
plaque. However, in the Framingham Heart Study smoking, high LDL-cholesterol 
levels, physical inactivity, obesity, diabetes mellitus and hypertension were all linked to 
increased risk of coronary heart disease.
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1.2 High density lipoprotein and apolipoprotein A-I are athero- 
protective
The Framingham Heart Study also determined that low levels of high density 
lipoprotein (HDL) were an independent predictor for CHD.10 Consistent with this 
finding, HDL and its main protein component apolipoprotein A-I (ApoA-I) were 
subsequently shown to stimulate production of endothelial nitric oxide synthase, to 
inhibit LDL oxidation and to suppress the expression of monocyte attracting 
chemokines and adhesion molecules in the smooth muscle cells of the arterial wall.11 
Nevertheless, it is still unclear how much these functions contribute to physiological 
ApoA-I/HDL-mediated atheroprotection.
It is widely believed that the key anti-atherogenic role of HDL is the removal of excess 
cholesterol from cells and its transport back to the liver, a concept originally proposed 
by Glomset12 and subsequently termed “reverse cholesterol transport” (RCT). A 
detailed explanation of RCT is provided in Figure 1-2 and Figure 1-3.
Based on the role o f ApoA-I in HDL maturation and reverse cholesterol transport it is 
not surprising that deletion of the APOA-I gene results in undetectable levels of HDL in 
humans.13 Moreover, very little ApoA-I or HDL is present in the plasma of patients with 
Tangier disease or familial HDL deficiency, genetic conditions caused by mutations in 
the ABCA1 gene.14 ApoA-I production is normal in Tangier disease patients, but it is 
catabolized extremely rapidly and thus very few mature HDL particles are formed.15 
Both APOA-I deletion and ABCA1 mutations are strongly linked with early-onset 
cardiovascular disease.13,16
Loss of lecithin:cholesterol acyltransferase (LCAT) function as seen in familial LCAT 
deficiency and fish-eye disease also results in reduced ApoA-I/HDL levels. Recent data 
based on measurement of intima media thickness (IMT), a validated surrogate marker 
for atherosclerotic vascular disease, suggest a moderately increased CVD risk for 
carriers o f LCAT  mutations.17 Indeed, IMT progression over family controls in carriers 
o f LCAT mutations was 0.0055 mm/year compared with 0.0082 for APOA-I deletion or 
0.0073 for ABCA1 mutations.18
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Figure 1-2 Reverse Cholesterol Transport -  Maturation of HDL
Lipid-poor monomolecular ApoA-I is secreted from enterocytes and hepatocytes and is 
immediately lipidated via ATP-binding cassette transporter A1 (ABCAl)-mediated efflux of 
phospholipid (PL) and free cholesterol (FC). This generates disc-shaped HDL particles consisting 
of a PL bilayer in the centre bordered by anti-parallel ApoA-I dimers in a looped belt formation.19 
The HDL-associated LCAT is activated by the presence of discoidal HDL and catalyzes the 
transfer o f 2-acyl groups from lecithin to free cholesterol on the surface of these particles.12
The cholesteryl esters (CE) created in this way are hydrophobic and consequently form an inner 
core, swelling the discoidal HDL initially into small spherical HDL3 and then larger HDL2 
particles.20 During this expansion the particles also acquire a third and fourth ApoA-I molecule. 
The HDL3 and HDL2 particles can then act as acceptors for further FC and PL efflux from 
peripheral tissues through the ATP-binding cassette transporters G1 and G421 or via gradient- 
dependent scavenger receptor B1 (SR-Bl)-mediated FC exchange (not shown).
Transfer o f CE and PL by cholesteryl ester transfer protein (CETP) and phospholipid transfer 
protein (PLTP) during lipoprotein lipase (LPL)-mediated lipolysis of the triglyceride (TG)-rich 
lipoproteins, chylomicrons and very low density lipoproteins (VLDL), also contributes to the CE 
and PL load of mature HDL particles. Figure taken from Rader.22
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Figure 1-3 Reverse Cholesterol Transport -  HDL catabolism and regeneration
Three possible mechanisms of HDL regeneration have been proposed.23 In the first option, large 
spherical HDL particles travel to the liver where they are taken up selectively through ApoA-I 
binding to SR-BI.24 Following removal of CE the depleted HDL is secreted and thus discoidal 
HDL particles are regenerated.
In an alternative pathway, HDL CE are exchanged for TG from ApoB-containing VLDL or LDL 
particles through the action of CETP. At least in vitro the efflux of CE to VLDL/LDL is higher 
than the influx o f TG thus reducing the core lipid content and HDL particle size. The resulting 
excess of surface components leads to shedding of lipid-poor ApoA-I. The CE in VLDL/LDL can 
then be taken up by the liver via the LDL receptor (LDLR). In hepatocytes CE is hydrolyzed to 
free cholesterol which can either be directly excreted into the bile duct or is converted to bile acid 
(BA) before excretion.
Lastly, lipid-poor ApoA-I and discoidal HDL particles are side-products of the already mentioned 
remodelling of TG-rich chylomicrons and VLDL by LPL and PLTP (not shown). Regenerated 
lipid-poor ApoA-I may be lost from the HDL lifecycle through excretion by the kidneys or it may 
be relipidated and so retained in the plasma. Relipidation is achieved either by fusion with existing 
HDL particles during LCAT-mediated maturation or by absorption of CE and PL as described in 
Figure 1-2. Figure taken from Rader.22
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Despite the fact that people with genetic HDL deficiencies show evidence of premature 
atherosclerosis, it is not as severe or extensive as would be expected from 
epidemiological data, which established that a 1% decrease in HDL is associated with a 
1-2% increase in CHD risk.25 Hence, it has been suggested that low HDL levels in 
patients with premature CHD may not be cause and effect but rather a concomitant 
phenomenon.26
However, a number of animal studies have shown that raising the levels of ApoA-I 
leads to an increase in HDL and a reduction in atherosclerosis or CHD risk. For 
example, weekly infusions of homologous HDL-VHDL fractions into cholesterol-fed 
rabbits markedly inhibited development of aortic fatty streaks and lipid deposition in the 
arterial walls without changing plasma lipid levels27 and also reduced the extent of 
established aortic atherosclerosis by 50%.28 Over-expression of human ApoA-I in 
transgenic rabbits29 and mice30,31 resulted in an increase in HDL concentration and 
protection against both diet-induced atherosclerosis29,30 and spontaneous atherosclerosis 
in the ApoE-deficient mouse.31
At the same time, several clinical trials were using fibrates such as gemfibrozil or 
bezafibrate to increase HDL levels in humans. Both the Helsinki Heart Study and the 
Veterans Affairs High density lipoprotein cholesterol Intervention Trial (VA-HIT)33 
demonstrated some clinical benefit that was dependent on elevated HDL levels using 
gemfibrozil. Even though results from the bezafibrate infarction prevention study34 were 
not significant despite an 18% increase in HDL concentration, a post-hoc analysis of 
patients with TG levels >200 mg/dL suggested a substantial benefit in this subgroup.
Since fibrates are amphipathic carboxylic acids that act as peroxisome proliferator- 
activated receptor a (PPARa) agonists, they boost the synthesis of ApoA-I, but also 
ApoA-II, LPL, ABCA1 and SR-BI,35 they reduce LDL and especially triglyceride 
levels in addition to the modest increase in HDL concentration. Thus, it was difficult to 
determine which changes in the lipid profile were responsible for the clinical benefits 
seen and the question of whether low HDL levels are cause and effect of CHD risk, or a 
concomitant phenomenon, could not be answered.
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Another class of drugs intended to raise HDL levels in patients are CETP inhibitors 
such as torcetrapib, anacetrapib and R1658 (also known as JTT-705). These drugs were 
developed after it was noted that genetic CETP deficiency, a defect common in the 
Japanese population, is associated with markedly increased levels of HDL and 
accumulation of HDL2 particles.36 This change in lipid profile was attributed to 
decreased removal of HDL CE and slower catabolism of ApoA-I.37
Inconsistent epidemiological evidence hinted that CETP deficiency may protect against 
atherosclerosis, provided that it is coupled with elevated HDL levels and that the HDL 
particles are functional.38 Results from studies in mice were also confusing, but given 
that mice normally lack CETP, this was not surprising. Studies in cholesterol-fed rabbits 
on the other hand were unequivocally positive, with a more than threefold increase in 
HDL levels and a 60% reduction in atherosclerosis.39 In addition, early clinical trials 
using torcetrapib were extremely encouraging, with significant increases in HDL (up to 
100% at the highest dose) and concurrent but smaller decreases in LDL levels.40,41
Therefore, both surrogate marker and end-point studies were commenced at the same 
time. Due to marketing considerations all studies combined torcetrapib with atorva- 
statin. Statins are widely used for the reduction of high LDL levels as they inhibit 3- 
hydroxy-3-methyglutary 1-coenzyme A reductase, an enzyme that is responsible for the 
biosynthesis of cholesterol. Unfortunately, the “Investigation of Lipid Level 
management to Understand its iMpact IN ATherosclerotic Events” (ILLUMINATE) 
trial had to be terminated early because of a 61% excess of deaths from cardiovascular 
and noncardiovascular causes in the torcetrapib/atorvastatin over the atorvastatin only 
group.42 Increased risk of death was associated with changes in serum electrolyte and 
aldosterone levels as well as increased blood pressure 43
Three other torcetrapib studies using intravascular ultrasound and carotid artery IMT as 
surrogate markers also disappointed as there was no treatment effect on atheroma 
volume or intimal media thickness. All studies showed a 50-60% increase in HDL and a 
20% reduction in LDL levels.43'46 It is not yet clear if  torcetrapib failed due to side- 
effects caused by the drug itself or by combination with atorvastatin, or if the 
mechanism of raising HDL by CETP inhibition is to blame. However, data from clinical 
trials with anacetrapib and R1658 showed similar modulation of HDL and LDL levels 
without significant blood pressure increases47"49
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What seems clear is that increasing HDL levels by any means does not necessarily 
correlate with protection against atherosclerosis. Apparently, our understanding of the 
intricate remodelling processes involved in the HDL lifecycle is still too incomplete for 
successful manipulation. Perhaps more direct methods need to be considered first.
One such direct method of raising HDL is based on intravenous infusion of 
reconstituted HDL-like particles (rHDL) made from recombinant ApoA-I or purified 
plasma ApoA-I and soybean phosphatidylcholine (PC). In the earliest studies Carlson50 
showed that a single injection of rHDL, corresponding to about 1.6 g of recombinant 
ApoA-I, improved HDL concentration by 20% in four patients with low plasma HDL. 
The same treatment transiently increased ApoA-I and HDL levels in four patients with 
heterozygous familial hypercholesterolaemia and was associated with excess cholesterol 
excretion of around 500 mg/d for at least nine days.51
Nanjee and colleagues also demonstrated that intravenous infusion of ApoA-I/PC discs 
increased small HDL particle concentration and stimulated RCT in healthy male 
volunteers,52,53 whereas lipid-free ApoA-I did not.54 Endothelial function in hyper- 
cholesterolaemic men55 and familial hypoalphalipoproteinaemia patients56 was restored 
by a single infusion of rHDL corresponding to 80 mg/kg bodyweight of plasma derived 
ApoA-I. No adverse side effects were reported in any of the studies.
These early clinical studies provided enough evidence to encourage a larger, 
randomized controlled trial - the “Effect of rHDL on Atherosclerosis - Safety and 
Efficacy” (ERASE) study.57 In this trial patients were randomly assigned to receive 
placebo (saline), 40 mg/kg or 80 mg/kg rHDL, but the higher dose group was 
discontinued early due to abnormalities in liver function tests. Although there was a 
3.4% or 5.3 mm3 reduction in total atheroma volume versus patient baseline the changes 
were not significant compared to the control group. However, both plaque 
characterization index on intravascular ultrasound and changes in coronary score on 
quantitative coronary angiography were substantially different between groups.57
Considering that the ERASE differences were potentially confounded because 90% of 
enrolled patients, including those in the control group, were also taking LDL-lowering 
medication, this outcome was very encouraging.
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1.3 Apolipoprotein A - I M iia n o ?  a natural variant of ApoA-1, is super- 
atheroprotective
A similar clinical trial,58 where patients were injected with 15 mg/kg or 45 mg/kg of 
recombinant apolipoprotein A-lMiiano (A poA -Im) and 1 -palmitoyl-2-oleoyl phosphate- 
idylcholine (POPC) complexes (ETC-216) once per week for five weeks, demonstrated 
a 4.2% decrease or 14.1 mm3 reduction in total atheroma volume that was statistically 
significant versus patient baseline, but not between treatment and control groups. In in 
vivo experiments, ETC-216 induced plaque regression in rabbits by 5-6%59,60 and also 
in mice, where it was attributed to a reduction in plaque lipid content. ’
ApoA-lM is a naturally occurring variant of ApoA-I believed to be super- 
atheroprotective. It was originally described in a man presenting with a high-risk lipid 
profile, specifically hypertriglyceridaemia and markedly decreased HDL, but no sign of 
atherosclerosis.63 Further investigation revealed that this protein contained an arginine 
to cysteine substitution at position 173, allowing formation of homodimers as well as 
heterodimers with ApoA-II via a disulphide bridge.64,65
The patient originally hailed from the small northern Italian village Limone sul Garda, 
an isolated community with a distinct genetic and clinical conformity due to high 
consanguinity. Sampling of the entire population of this village found 32 additional 
carriers, who all were descendants of a couple living in the second half of the eighteenth 
century.66 Inheritance was autosomal dominant. All carriers were heterozygotes and 
displayed the characteristic high-risk lipid profile of moderate hypertriglyceridaemia 
combined with very low HDL levels.66,67
When the IMTs of ApoA-lM carriers were compared with control subjects from the 
same kindred who did not have the mutation, there was no difference. Clinic patients 
and blood donors, both with hypoalphalipoproteinaemia, on the other hand had 
maximum IMT measurements up to twice as large.67 Prevalence o f atherosclerotic 
plaques too was significantly higher in these two groups than in ApoA-lM carriers or 
kindred controls.67 Relative to controls ApoA-lM carriers displayed a 17% higher 
cardiac output, possibly suggesting improved ventricular distensibility.67
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It is clear from these data that despite rather low HDL levels ApoA-I\i carriers do not 
have an increased risk of CVD, quite unlike patients with genetic ApoA-I deficiency or 
Tangier disease. How then does the ApoA-lM mutation mediate this increased 
atheroprotection?
Several explanations for this increased atheroprotection have been investigated in the 
literature. For example, studies have shown that the increased atheroprotection of 
ApoA-lM carriers is due to increased cholesterol efflux to the mutant protein.68'70 Other 
studies containing ostensibly contradicting data71'75 were also published, but careful 
reading and analysis allows two conclusions to be drawn. Firstly, ApoA-I and ApoA-lM 
exhibit similar cholesterol efflux ability in lipid-free and rHDL form70’72,73 and, 
secondly, ApoA-lM containing serum from human carriers or transgenic mice68,70,72 is 
significantly better than ApoA-I serum at both SR-B1- and ABCA1-mediated 
cholesterol efflux. Favari et al.10 attribute this finding to the presence of a unique 
protease-sensitive small HDL particle containing an ApoA-lM dimer in addition to 
normal amounts o f lipid-poor ApoA-I.
Another potential reason for the apparent atheroprotection of ApoA-lM carriers is 
increased metabolism of the mutant protein and thus more rapid RCT. Two papers76,77 
have investigated this possibility and agree in their findings. ApoA-IM was almost 
equally distributed between monomers, homodimers and heterodimers with ApoA-II in 
human carriers and all forms were more rapidly metabolized than ApoA-I monomers. 
Even though production rate was normal, wild-type protein constituted only about 30% 
of the total ApoA-I protein level. Hence wild-type protein too was metabolized faster in 
ApoA-lM carriers than in control subjects, perhaps because ApoA-I and ApoA-IM 
molecules often co-localize in the same particle. One explanation for increased HDL
7Rcatabolism may be the reduced reactivity of ApoA-lM with LCAT, which would 
inhibit HDL maturation.
Higher anti-oxidant and anti-inflammatory capabilities79 leading to decreased 
endothelial dysfunction have also been proposed to explain enhanced ApoA-lM 
atheroprotection, but this has been disputed.75 Nevertheless, a recent paper80 has shown 
that ApoA-IM HDL isolated from human carriers stimulated higher expression and 
activation o f endothelial nitric oxide synthase than HDL from kindred controls and was 
also more effective in down-regulating vascular cell adhesion molecule-1.
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Whatever the mode of action, the evidence supports the idea that ApoA-lM has 
beneficial effects on the outcome of CVD above that o f ApoA-I. However, a 
recombinant protein therapy requiring tens of grams per treatment is hardly practical in 
terms of cost and ease of manufacture for widespread chronic treatment of 
cardiovascular disease. Gene therapy would be an ideal alternative.
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1.4 Gene Therapy
Gene therapy was first proposed nearly thirty years ago as a method of manipulating 
cells at the molecular level in order to cure monogenetic diseases like cystic fibrosis, 
haemophilia and phenylketonuria. 81 Since then gene therapy has moved into treatment 
of acquired disorders such as cancer and cardiovascular disease with 66.5% and 9.1% of 
gene therapy clinical trials to date focused on these areas. 82 Other targets include 
infectious disease (6.5% of trials), particularly human immunodeficiency virus 
infection, neurological diseases such as multiple sclerosis, Alzheimer’s and Parkinson’s 
(1.5%) and ocular diseases including age-related macular degeneration (0.9% ) . 82
Gene therapy can be applied to either somatic or germ line cells, but even though germ 
line gene therapy has the advantage of being inherited by future generations, it is 
currently prohibited in human beings due to ethical issues. Somatic gene therapy, on the 
other hand, avoids the ethical implications o f germ line alterations, but has to be applied 
anew in each generation. Ex vivo gene therapy manipulates cells outside the body and 
then transplants the treated cells into the body, whereas in vivo gene therapy treats cells 
in situ.
Gene therapy can be divided into three broad classes: gene addition, gene targeting and 
gene modulation. Gene addition inserts extra functional copies of the target gene into 
affected cells to complement the loss of functionality caused by a defective endogenous 
gene, whereas gene targeting replaces the non-functional endogenous gene with a 
functional copy. A subclass of gene targeting, gene editing, aims to repair the loss-of- 
function mutation in situ and to return the non-functional endogenous gene to normal 
function in this way. Gene modulation alters the expression level of the target gene or 
changes splicing patterns and generally works at the transcriptional or translational 
level.
Up to now, the overwhelming majority of gene therapy clinical trials have used gene 
addition strategies, 82 although several gene modulation studies are underway and one 
gene modulation treatment has been approved. 83 Currently, gene targeting is widely 
used in the production of transgenic mouse lines, but no clinical trials employing this 
method are underway. Gene editing is still in the basic research phase, though some data 
from in vivo experiments are available.
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Each type of gene therapy offers certain advantages, but also suffers from specific 
limitations. Thus, gene therapy methods have to be carefully chosen depending on the 
intended application. In the following sections, each type of gene therapy including 
respective advantages and limitations will be discussed in more detail.
1.4.1 Gene addition
As stated in the section above, gene addition aims to introduce exogenous functional 
copies in addition to the non-functional endogenous gene. This can be achieved by 
either viral or non-viral vectors. Two thirds of clinical trials to date have used viral 
vectors, 82 in particular adenoviral and retroviral vectors, in an attempt to exploit the 
high efficiency of viral transduction and relative specificity of viral tissue targeting.
However, the efficiency of viral vectors may be inhibited by pre-existing immunity to 
the virus and viral proteins induce a cellular immune response against the transduced 
cells. Viral vectors may also have limits in transgene capacity and are expensive to 
produce. Non-viral vectors on the other hand, can be produced cost-effectively, induce 
limited host immune responses, have a larger capacity, but are very inefficiently 
delivered and thus require a delivery system. Both viral and non-viral gene addition 
strategies have encountered problems with sustaining transgene expression over longer 
periods o f time. If integrating viral or non-viral vectors are used, insertional 
mutagenesis may occur.
A problem with all gene addition strategies is loss o f transgene expression due to 
epigenetic gene silencing or the development o f host immune responses against the 
therapeutic gene product. Epigenetic silencing is mediated via de novo methylation of 
cytosines at CpG dinucleotides in the DNA sequence and may be induced by multiple
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copy transgene arrays, retro- or lentiviral sequences or bacterial sequences. ’ 
Solutions to the problem of epigenetic silencing include the use of tissue-specific or 
synthetic promoters instead of viral promoters, 88 optimizing bacterial DNA sequences 
for human codon usage89 or excision o f the transgene from bacterial sequences after 
gene transfer.90 Anti-transgene immune responses may be modulated by exploiting the 
microRNA (miRNA) regulatory pathways of cells.91
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1.4.1.1 Viral vectors
Viral vectors have been employed for gene therapy because viruses have evolved highly 
efficient mechanisms for infection of their target cells and have a clearly defined tissue 
tropism. Generally, viruses are made replication incompetent by replacing specific viral 
genes with the transgene cassette containing the gene of interest and a promoter.92 
Additional viral genes are removed to reduce the host cellular immune response, while 
genes that are required for in cis functions, such as viral capsid packaging or DNA 
integration, are left intact. During production of recombinant vector particles, the 
deleted viral genes are provided in trans by a separate helper construct which is either 
co-transfected with the vector genome or provided by packaging cells .93
Currently, there are five main groups of viral vectors based on retroviruses, lentiviruses,
09adenoviruses, adeno-associated viruses (AAV) and herpes simplex virus-1 (HSV-1). 
They all have varying properties (see Table 1-1 for a comparison) and are, therefore, 
suitable for different applications. One major distinction between the different groups is 
the ability to either integrate into the host genome or persist in the cell nucleus as extra- 
chromosomal episomes.
Vectors based on oncoretroviruses, for example Moloney murine leukaemia virus, were
09the first to be developed. Oncoretrovirus vectors permit stable transgene expression in 
dividing cells because they integrate into the host genome, but integration carries the 
risk of insertional mutagenesis. The extent o f this risk was demonstrated when 4 out of 
20 children with X-linked severe immunodeficiency treated with such a vector94,95 
developed a leukaemia-like disease96 because the vector had integrated near and 
activated an oncogene.97
In contrast to oncoretroviruses, lentiviral vectors derived from human immuno­
deficiency virus (HIV) or non-human lentiviruses can transduce non-dividing cells98,99 
as they are actively transported through nuclear pores. 100 Self-inactivating lentiviral 
vectors are considered particularly safe because a deletion in the downstream long- 
terminal repeat sequence has minimized the risk of creating replication-competent 
retrovirus.92 So far, lentiviral vectors have been used in a single phase I clinical trial 
where a 937 bp long antisense sequence to the HIV env protein was expressed. 101
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Table 1-1 The five main groups o f viral vectors
Comparison of the main features of the most commonly used viral vectors for gene therapy. Table taken from Thomas et al,92
Herpes simplex virus-1 is a human pathogen and particularly interesting as a viral 
vector because it can persist in a latent state as an episome for extended periods of time 
and its natural tropism is for neurons. 102 It also has a packaging capacity of up to 40 kb 
and simultaneous expression of multiple transgenes is possible. 103 However, there is a 
trade-off between long-term high-level transgene expression and cytotoxicity. 104 
Conversely, cytotoxicity is advantageous in the treatment of cancer. For example, a 
replication-defective HSV vector (OncoVEXGM CSF) has shown positive results in 
clinical trials for metastatic melanoma. 105,106
Recombinant adenoviral vectors are the most efficient gene transfer system in a broad 
range of tissues, infect both dividing and non-dividing cells and are retained as extra- 
chromosomal episomes. The main draw-back of these vectors is their potent immuno- 
genicity which caused the death of Jesse Gelsinger during a clinical trial for the 
treatment of ornithine transcarbamylase in 1999.107 To reduce vector-related immuno- 
genicity, progressively more viral genes were deleted108 and a helper-dependent 
adenoviral vector, with all viral genes deleted, was developed. 109
Adeno-associated viral vectors, on the other hand, have little immunogenicity and the 
host immune response is limited to the production of neutralizing antibodies. However, 
AAV vectors have the smallest packaging capacity and although they generally persist 
as episomal DNA in human cells, random integration and insertional mutagenesis have 
been reported in some studies using liver-directed AAV2. 110,111
Currently, eleven different serotypes (designated AAV1 to AAV11) with diverse tissue 
tropism have been identified. 112 Pseudotyping with receptor-binding proteins from other 
strains has become common practice partly to avoid wide-spread pre-existing humoral 
immunity to wild-type AAV2 in the human population. 113 Although relative late­
comers, AAV vectors have demonstrated their safety in a number o f clinical trials for 
diverse diseases such as haemophilia B, cystic fibrosis and Parkinson’s. 114
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1.4.1.2 Non-viral vectors
Non-viral vectors have long been discounted as a viable alternative to viral vectors, 
mainly because of low transfection efficiency and transient transgene expression. On the 
plus side, non-viral vectors are rather cheap to produce even in large quantities, their 
immunogenicity is minimal and recent advances have improved transduction efficiency 
and persistence of transgene expression. Historically, non-viral gene therapy has 
concentrated on the use of naked DNA, 82 usually plasmids, though polymerase chain 
reaction (PCR) products have also been used.
However, unlike viral vectors, naked DNA is not protected from the extra- and 
intracellular environments and does not have a specific tissue tropism or means of cell 
entry. Thus, transfection efficiency is lower than with viral vectors, but specialized gene 
delivery methods can be used to improve transduction. These methods will be discussed 
separately in the next section (section 1.4.2).
Transgene expression from transduced DNA is short-lived, mostly because plasmids are 
retained in the nucleus in an extra-chromosomal form and thus lost during the 
breakdown of the nuclear envelope at mitosis. Two different approaches aim to address 
this problem. In the first approach, a plasmid containing an SV40-ori sequence and the 
scaffold/matrix attachment region (S/MAR) from the human p-interferon gene cluster115 
is tethered to the nuclear matrix. 116 This ensures replication and episomal maintenance 
as well as preventing epigenetic silencing of the cytomegalovirus immediate-early 
(CMV) promoter. 117
In the second approach, loss of the vector DNA is prevented by integration into the host 
genome. This approach mainly uses transposons, mobile genetic elements that can re­
locate within the genome via a cut-and-paste mechanism mediated by an encoded 
transposase. The transposase gene can be replaced by up to 10 kb of exogenous DNA 
and the transposase is then provided either in cis on the same plasmid or in trans as 
protein or additional plasmid. 118
34
Long-term transgene expression has been reported in mice119,120 and embryonic stem 
cells121 after integration mediated by the Sleeping Beauty transposon. This transposon 
was reconstituted from an inactive Tel-like transposon recovered from fish122 and is 
currently the most active transposon available. 120 As with viral vectors, transposon- 
mediated integration carries the risk of insertional mutagenesis, but this could 
potentially be avoided by using a site-specific transposase that directs integration into 
defined DNA sequences. 123
1.4.2 Gene delivery
Cellular uptake of naked DNA is extremely inefficient due to electrostatic repulsion 
between the negatively charged cell surface and phosphate backbone of DNA. Other 
barriers to efficient DNA delivery are rapid hydrolysis o f the phosphodiester links in the 
DNA backbone by endo- and exonucleases and the need for DNA entering the cell via 
endosomal uptake to escape from these vesicles (Figure 1-4). Also, transfer of the 
therapeutic DNA into the nucleus is poor, but required for therapeutic effect in most
124cases.
To alleviate these problems, physical and chemical gene delivery methods have been 
developed. Physical methods, including mechanical and electrical techniques, require 
direct exposure of the target tissue and as such are largely limited to topical applications 
in vivo. A wide variety of chemical methods are available which can be roughly divided 
into cationic polymers and liposomes. 124
In general, the chemical delivery reagents are highly efficient in vitro, but there seems 
to be an association between transfection efficiency and cytotoxicity, suggesting that a 
certain level of cell damage is necessary for successful transduction. However, in vivo 
transfection efficiency using chemical gene delivery is poor compared to viral vectors, 
because systemic delivery of cationic polymers and liposomes lacks target cell 
specificity. Other barriers to efficient in vivo transfection include rapid clearance from 
the blood circulation, coating by plasma proteins and subsequent phagocytosis by 
macrophages, and difficulties with crossing vascular endothelial barriers. 125
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Figure 1-4 Barriers to efficient gene delivery
Gene delivery vehicles must protect the therapeutic DNA against the extra-cellular environment, 
bind to the target cells, be internalized efficiently (by endocytosis in the case of cationic polymers 
or membrane fusion for some liposomes), escape the degradative pathway and facilitate 
unpackaging and nuclear deliveiy of the DNA. Figure taken from Pack et al.126
1.4.2.1 Physical methods for gene delivery
Physical gene delivery techniques include particle bombardment, electroporation, 
ultrasound, microinjection and hydrodynamic injection. 127 Bombardment with DNA- 
coated gold particles, also known as “gene gun”, ensures direct penetration of the cell 
and nuclear membranes avoiding the endosomal pathway altogether. However, this 
method requires direct physical access to the target tissue and only mediates shallow 
tissue penetration. Therefore, the gene gun has mainly been used in DNA vaccination 
and immunotherapy. 128
Electroporation uses a combination of short high-voltage pulses followed by a series of 
longer, low-voltage pulses. The high-voltage pulses create transient hydrophilic pores in 
the cell membrane of target cells through which the DNA can enter, assisted by the 
electrophoretic effect of the low-voltage pulses.
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Electroporation was originally developed for in vitro transfection129 and is routinely
• • 110used for DNA transfer into cultured cells, but has now found application in vivo. 
Skeletal muscle is the preferred target tissue due to its ready access and ability to sustain 
long-tem expression of the episomal plasmid, but the electroporation effect is limited to 
the area between the electrodes.
Ultrasound is less invasive than the gene gun or electroporation and has already
demonstrated its safety during clinical application for diagnostic imaging and targeted
therapeutic purposes. However, it appears to be less effective than electroporation. 130
Microinjection, on the other hand, is extremely effective as it directly injects the DNA
into the cell nucleus, but is very labour-intensive because cells have to be treated one at
1^1a time. Thus, it has been used mainly in the creation of transgenic mice but recent 
progress in automating the process132 should encourage more wide-spread application.
Rapid, high volume injection of DNA, also known as hydrodynamic injection, into mice 
tail veins causes transient hyper-permeability of hepatocytes cell membranes due to the 
rise in venous pressure and subsequent enlargement of the fenestrae in the liver 
sinusoids. 133 Although not directly applicable to humans, hydrodynamic injection could 
be used in conjunction with isolated limb perfusion to enhance limb musculature 
transduction134 or the isolated segment of inferior vena cava approach for total liver 
transfection.
1.4.2.2 Chemical facilitation of gene delivery
One of the cheapest in vitro methods for DNA transfection is calcium phosphate 
precipitation, but multiple parameters such as DNA, calcium and phosphate 
concentrations, temperature, pH and reaction time affect the formation of the DNA- 
calcium phosphate co-precipitate and thus the reproducibility and efficiency of 
transfection . 136 Thus, calcium phosphate precipitation is mainly used in repeat or large- 
scale transfections with little inter-experimental variation, such as viral vector 
production.
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Cationic polymers, on the other hand, easily complex with the anionic DNA due to 
electrostatic interactions and form positively charged polyplexes that can then interact 
with the negatively charged cell surface. 124 Polyethylenimine (PEI), chitosan and 
atelocollagen are examples of such cationic polymers. In PEI every third atom is an 
amino nitrogen that can bind a DNA phosphate and PEI is therefore highly efficient at 
compacting DNA . 137 The partial nitrogen protonation at physiological pH acts as a 
“proton sponge” that causes osmotic swelling and subsequent rupture of endosomes, 
thus efficiently releasing the polyplexes into the cytoplasm . 138 Linear (LPEI; 
commercially available as jetPEI) and branched forms of PEI are available. Also, efforts 
to improve transfection efficiency and reduce toxicity have resulted in PEI 
modifications such as pegylated PEI139 or fully deacylated LPEI. 140
Chitosan, a natural linear amino-polysaccharide, is bio-compatible, bio-degradable and 
non-toxic. 141 Like PEI, chitosan and its derivatives form positively charged polyplexes 
with DNA that can interact with the cell membrane and mediate cellular uptake. A 
chitosan derivative, trimethylated oligomeric chitosan (TMO), demonstrated very low 
cytotoxicity compared to lipoplexes and improved transfection efficiency in some cell 
lines. 142 Particularly interesting is the possibility of using TMO with antennary 
galactose residues for specific targeting to HepG2 cells. 143
Atelocollagen is another bio-compatible and bio-degradable polymer with low 
toxicity . 144 It is derived from collagen which has been used extensively for medical and 
cosmetic applications. In atelocollagen, the telopeptides that are the main antigenic sites 
o f collagen are removed, giving it an even better safety profile . 144 Remarkably, 
atelocollagen mediated high levels of oligonucleotide-mediated gene editing in HepG2 
cells (up to 1 1 % ) , 145 although this efficiency has yet to be duplicated by other 
researchers.
Another class of chemical delivery agents are cationic liposomes. Amphipathic 
phospholipids spontaneously form lipid bilayers in aqueous solutions and encapsulate 
any DNA present in the solution due to electrostatic interactions. Generally, cationic 
liposomes contain a mixture of cationic and zwitterionic lipids, with the former 
mediating DNA condensation and cellular association while the latter perturb the cell 
membrane and thus help with membrane fusion.
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Commonly used cationic lipids include l,2-dioleoyl-3-trimethylammonium propane 
(DOTAP) and N-[l-(2,3-dioleyloxy) propyl]-N,N,N-trimethylammonium chloride 
(DOTMA), while 1,2-dioleoyl-phosphatidylethanolamine (DOPE) is an example of a 
zwitterionic lipid . 124 A large variety of cationic lipids with proprietary formulations are 
commercially available, e.g. Lipofectamine 2000, 146 FuGene and Trojene. 147 Trojene is 
a mixture of N-l-cholesteryloxycarbony 1-3,7-diazanononane- 1,9-diamine (CDAN) with 
DOPE and has been shown to be significantly less cytotoxic than Lipofectamine 
2000. 148 Lipofection is one of the most commonly used in vitro transfection methods, 
but has also been used in 7.6% of clinical trials to date. 82
1.4.3 Gene modulation
Unlike gene addition or gene targeting, gene modulation does not interact directly with 
the target gene, but exerts indirect influence on the expression of an endogenous gene at 
the transcriptional or translational level. As such it is mostly limited to the treatment of 
abnormal endogenous gene expression or prevention of gene expression from 
exogenous viral DNA with the exception of correcting abnormal pre-RNA splicing. 149
Gene modulation is mostly achieved by short RNA or DNA segments. Since RNA and 
DNA sequences are subject to endo- and exonucleases in the extra- and intracellular 
environment, various chemical backbone modifications have been developed to improve 
stability. Typically used backbone modifications for RNA and DNA oligonucleotides 
include phosphorothioate (PTO), locked nucleic acid (LNA) and morpholino backbone 
modifications (Figure 1-5), as well as the use of 2’-modified pyrimidines.
Phosphorothioate modified nucleotides contain a sulphur instead of an oxygen anion as 
one o f the non-bridging ligands in the linking phosphate groups. 150 In LNA nucleotides 
the ribose is locked in the 3'-endo structural conformation by an extra bridge connecting 
the 2' and 4' carbons, 151 whereas in morpholino oligonucleotides the riboses have been 
replaced by morpholine rings that are linked through phosphorodiamidate groups 
instead of phosphates. 152 Pyrimidines can be modified at the 2’ position with fluoro, 
amino or methyl groups. 153
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Figure 1-5 Chemical structure of oligonucleotide backbone modifications
In phosphorthioate (PTO) modifications, sulphur replaces an oxygen anion in the linking 
phosphate group. Locked nucleic acids (LNA) contain bridges connecting the 2 ’ and 4 ’ carbons o f  
the 2-deoxyribose that lock the ribose into the 3 ’-endo structural conformation. In morpholino 
(MOR) oligonucleotides the riboses have been replaced by morpholine rings that are linked 
through phosphorodiamidate groups instead o f phosphates.
Small interfering RNA (siRNA), short double-stranded RNA sequences that are 
complementary to the mRNA of the target protein, can induce degradation of the 
mRNA as well as suppressing protein synthesis and transcription of the target gene by 
appropriating the cellular RNA interference (RNAi) machinery (Figure 1-6). It has been 
suggested that RNAi is an ancient genome immune system against exogenous nucleic 
acids154 and this could explain some of the difficulties with sustaining transgene 
expression. SiRNA is probably the best-known and most widely applied gene 
modulation method in vitro, because of its easy and convenient application. However, 
off-target effects can mediate down-regulation of sequence-related genes. 155 
Nevertheless, several siRNA therapeutics are in clinical trials. 155
Antisense oligonucleotides that bind to regions of a messenger RNA (mRNA) due to 
sequence complementarity can interfere with ribosomal initiation and thus prevent 
translation . 124 Successful examples of this mode of action include fomivirsen sodium 
(Vitravene), an inhibitor of the immediate early region 2 of human CMV, which has 
been approved for treatment of CMV retinitis in acquired immune deficiency syndrome 
patients156 and AP 12009 which targets the mRNA of human transforming growth factor
1 cn
(32 and has shown significant benefits in patients with high grade gliomas.
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Figure 1-6 The RNAi machinery
The Dicer and RISC complexes are central to the protection against invading viral double-stranded 
RNA (©), the elimination of transcripts from transposons (©), the blockage of protein synthesis 
mediated by cellular miRNAs ((D), and the RNAi-mediated suppression of transcription (©). 
Exogenous siRNA (© ) can usurp the RNAi machinery to inhibit the activity of specific genes. 
Figure taken from Daneholt.158
Antisense oligonucleotides may also interfere with pre-mRNA processing by preventing 
the binding of small nuclear ribonucleoproteins at the intron borders. This process has 
been exploited to correct or even induce aberrant mRNA splicing in order to restore the 
correct reading frame or exclude exons containing mutations. A clinical trial using a 
morpholino oligonucleotide to skip exon 51 of the human dystrophin gene with the 
purpose of treating Duchenne muscular dystrophy (AVI-4658) has been initiated. 159
Aptamers are another therapeutic application of oligonucleotides. They are nucleic acid 
sequences that have been selected over multiple rounds to bind specifically to targets 
such as proteins, nucleic acids or small molecules. 153 Unlike antibodies, aptamers can be 
produced by chemical synthesis, are more sensitive to conformational changes160 and 
may bind to sites that are sterically inaccessible to antibodies. 161 The first therapeutic
aptamer approved for clinical use is pegaptanib (brand name Macugen), a vascular
0-1
endothelial growth factor inhibitor for treatment of age-related macular degeneration.
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Ribozymes are catalytic RNA molecules that are capable of sequence-specific cleavage
of mRNA. Several RNAzymes such as HERzyme which targets human epithelial
growth factor 2 or ANGIOzyme, a vascular endothelial growth factor receptor 1
1
inhibitor, are in clinical development.
1.4.4 Gene targeting
Ultimately, however, gene therapy aspires to permanently repair the faulty gene in situ 
without the need for additional sequences or genome modifications. The gene would 
then remain under control of its endogenous regulatory elements and the natural 
expression pattern would be unchanged. Thus, gene expression in inappropriate cells 
and subsequent activation of host immune responses, as seen with gene addition 
strategies,91 would be avoided.
The term gene targeting usually refers to the targeted exchange between an exogenous 
donor and a homologous endogenous acceptor DNA sequence which is mediated by 
homologous recombination (HR; see section 1.4.4.1). However, conventional gene 
targeting suffers from low efficiency, as typically only one cell in 1 0 5- 1 0 7 treated cells 
is successfully altered163 and unspecific integration of the donor DNA via non- 
homologous end joining (NHEJ; see section 1.4.4.1) occurs in one per 102-104 cells. 163 
Thus, additional non-homologous sequences providing the necessary selection markers 
must be included in the donor DNA and this may result in epigenetic down-regulation.
To address these problems, a number of alternative gene targeting strategies have been 
developed (Figure 1-7). These are small fragment homologous replacement (SFHR), 
AAV-mediated gene targeting, and stimulation of HR by zinc finger nucleases (ZFN). 
Other approaches use triplex-forming oligonucleotides (TFO), chimeric RNA/DNA 
oligonucleotides (chimeraplasts) or single-stranded oligonucleotides (ssODN). At 
present it is unclear if the latter three approaches are mediated by HR or other cellular 
DNA repair pathways. Also, they aim to repair or edit the disease-associated 
mutation(s) only and do not replace extended parts of the endogenous gene sequence. 
Thus, these approaches are considered a subclass of gene targeting and herein are 
termed ‘gene editing’; they will be discussed in section 1.4.5.
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.Figure 1-7 O verview o f gene targeting strategies
The size o f the homologous (blue) and non-homologous (open blue) donor DNA as well as the 
endogenous DNA (red) sequences for each strategy are indicated by the size bars. During gene 
targeting, the genetic information of the donor DNA is transferred to the endogenous DNA. 
Binding o f triplex-forming oligonucleotide (TFO; orange) to the target DNA stimulates 
recombination whereas zinc finger nucleases (ZFN; green) create sequence-specific double-strand 
breaks (DSB) to increase homologous recombination (HR). Figure taken from Olsen.164
1.4.4.1 DNA damage response pathways relevant for gene editing
A short explanation of HR, NHEJ and other relevant DNA damage response pathways 
is provided here to aid understanding of the issues involved in therapeutic gene 
targeting. Mammalian cells are constantly exposed to a wide range of DNA damaging 
external and internal sources, such as reactive oxygen species or certain types of 
radiation. To maintain genome stability, cells have evolved a variety of DNA damage 
response pathways; among them mismatch repair (MMR), nucleotide excision repair 
(NER) and the double-strand break repair pathways of HR and NHEJ.
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Base mismatches and small insertion/deletion loops in the DNA are removed by the 
MMR system. In mammalian cells, various heterodimers of MSH2, MSH3 and MSH6  
recognize specific mismatch or loop lesions. 165 Thus, the MutSa complex (MSH2- 
MSH6 ) is responsible for detection of base-base mismatches and small loops, while 
MutSp (MSH2-MSH3) identifies larger loops. The subsequent steps remain to be 
elucidated, but the MutLa complex (MLH1 and post-meiotic segregation protein 2), 
exonuclease I, proliferating cell nuclear antigen, replication factor C, DNA polymerase 
8  and DNA ligase I are all implicated. 165
DNA lesions affecting only one DNA strand are repaired by the NER system which is 
subdivided into global genome and transcription-coupled repair. The latter is initiated 
by stalling of the RNA polymerase II and depends on the ERCC6  and ERCC8  proteins. 
However, proteins further down-stream in both pathways are thought to be identical. 
The helicases ERCC2 and ERCC3 unwind the DNA around the lesion while the 
endonucleases ERCC1-ERCC4 and ERCC5 make incisions on the 5’ and 3’ side o f the 
lesion, respectively. Thus, the lesion is released as an oligonucleotide and repair is 
completed by DNA synthesis and ligation. 166
Double-strand breaks occur in the cell as part of the recombination between 
homologous chromosomes during meiosis, during the V(D)J recombination of 
lymphocyte maturation, or as a result of collapsed replication forks. DSB can be 
repaired by HR, a template-dependent and therefore error-free pathway that is most 
active during the late S phase and G2 phase when the cell contains two DNA copies. 168
In HR, DSB are first processed by the MRN complex (MRE11-RAD50-NBS1) which 
generates single-stranded 3’ overhangs. The ssDNA is then coated with replication 
protein A and RAD52, which assist in loading RAD51 and RAD54. Other proteins 
implicated in this process are BRCA1 and 2, as well as the RAD51 paralogs XRCC2 
and 3 . 169 The resulting nucleoprotein filament invades the undamaged homologous 
dsDNA and forms Holliday junctions. DNA polymerase extends the ssDNA ends using 
the homologous sequence as template, followed by branch migration, Holliday junction 
resolution and DNA ligation. 169
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In contrast to HR, NHEJ is template-independent and thus very error-prone. This repair 
pathway is initiated by binding of the Ku70/86 (also known as Ku70/80) heterodimer to 
the damaged DNA ends and subsequent recruitment of DNA-PKcs (DNA-dependent 
protein kinase catalytic subunit). The resulting DNA-PK holoenzyme activates Artemis, 
an endonuclease that can process unsuitable DNA ends. Lastly, DNA ligase IV and 
XRCC4 catalyze ligation of the DNA ends. 169
Cell cycle checkpoints are triggered by the presence of DSB or ssDNA in the cell and 
thus progression through the cell cycle is dependent on the success of DNA repair 
systems in restoring genome integrity. 170 The protein kinases, ATM and ATR, play 
central roles in the signalling pathway between DNA damage and cell cycle regulation 
as they phosphorylate and thus, activate CHK1, CHK2 and p53 among others. In turn, 
CHK1 and CHK2 phosphorylate and hence inactivate the CDC25A phosphatase which 
ultimately prevents replication initiation and triggers cell cycle arrest, while p53 is 
responsible for maintaining the arrest. 167 Eventually, cell cycle will resume or cells will 
undergo programmed cell death.
1.4.4.2 Conventional gene targeting
Conventional gene targeting is now routinely used in the production of transgenic
171animals for functional studies of genes or as disease models. As such, the technology 
has had an immense influence on biological and medical research and this was 
recognized by awarding Mario Capecchi, Martin Evans and Oliver Smithies the Nobel 
prize in Physiology or Medicine 2007 for their pioneering work in this area. 172
However, conventional gene targeting relies on specially designed targeting vectors that 
contain the gene o f interest with the intended modifications together with selectable
173marker genes and restriction endonuclease sites for screening. In addition to the 
already mentioned problem with down-regulation of bacterial and viral sequences, 
vector production and screening of integrants is labour-intensive. 174
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1.4.4.3 Small fragment homologous replacement
In contrast to conventional gene targeting, the donor DNA in SFHR is relatively short 
(usually 400-1000 bp175,176) and only contains homologous DNA sequences with the 
exception of the intended sequence alterations. Thus, production of donor DNA is 
simplified. Although first applied to the targeted correction of mutations in the cystic 
fibrosis trans-membrane conductance regulator gene, 175’176 SFHR has been shown to 
mediate gene targeting in the dystrophin, 177 P-globulin178 and survival of motor neuron
1 genes. 179 Evidence showing integration of the donor DNA into an episomal target
180sequence supports a homologous recombination mechanism.
Chromosomal gene targeting efficiencies of up to 20% have been described in some 
studies, 175,177 but another laboratory demonstrated that their own results showing similar
1Q1
efficiencies were in fact due to false positive results caused by a PCR artefact. In this 
study, one o f the PCR primers was chosen inside the region of homology between the 
exogenous and endogenous DNA sequences, as had been done in the studies showing 
high efficiency . 175,177 Also, phenotypic evaluation of chromosomal targeting in 
recombinant reporter gene cell lines yielded much lower efficiencies (<0 .0 2 % ) . 182' 185
1.4.4.4 Adeno-associated virus vectors
In an effort to exploit the efficiency of viral gene entry into cells, retroviral, 186
1 0*7 1 QQadenoviral and AAV vectors have been evaluated for use in gene targeting. Only 
AAV vectors showed significantly improved efficiency (0.1-1%189) compared to 
conventional transfection approaches. Although AAV-mediated gene targeting mostly 
introduced only the intended nucleotide alterations at the target site, the ratio of random 
integration to gene targeting was found to be around 10:l . 190 Thus, non-homologous 
sequences coding for selectable markers and employing promoter trap strategies have 
been added to the donor DNA.
On the other hand, AAV-mediated gene targeting has been confirmed by Southern blot 
analysis in mammalian cells189,191 and in two different mouse models, though in vivo 
efficiency was below one per 104 cells. 192 The primary mechanism of AAV-mediated 
gene targeting appears to be HR, as RNAi-mediated down-regulation of RAD54L, 
RAD54B and XRCC3 significantly reduced or abolished long-term expression. 193 It 
also seems that random integration and gene targeting are distinct mechanisms, 194 so 
perhaps AAV can be engineered to avoid the former and enhance the latter.
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1.4.4.5 Zinc-finger nucleases
In 1994 it was shown that the homing endonuclease Seel from Saccharomyces 
cerevisiae induced DSB in mammalian cells at specific sites containing its 18 bp long 
recognition site195 and that this stimulated HR196 and gene targeting. 197 However, most 
mammalian genes do not contain homing endonuclease recognition sites. At the same 
time, chimeric restriction endonucleases consisting of 3-4 DNA-binding zinc finger 
motifs and a FokI cleavage domain were created. 198,199 Since the FokI nuclease requires 
dimerization o f the cleavage domain, two ZFN subunits must bind on opposite strands 
of the DNA in close proximity, creating an 18-24 bp recognition sequence.200
When mammalian cells were transfected with plasmids encoding engineered ZFN and 
donor DNA, ZFN-mediated gene targeting resulted in up to 10% in a mutated EGFP 
system . 201 Targeting of the interleukin 2 receptor y gene with optimized 4-finger ZNF 
yielded 18% corrected cells in K562 and 5% in primary human T cells without any 
selection.202 However, ZNF-mediated gene targeting suffers from high levels of 
cytotoxicity, likely caused by excessive and non-specific DNA cleavage due to
203imperfect target site recognition or dimerization of the ZFN.
Also, DSB induced by endonucleases are not always repaired using only the intended 
homologous donor DNA only, as parts of the plasmid ZNF vector, especially of the 
CMV promoter, were also used as donor.204 Furthermore, simultaneous delivery of two 
different ZFN subunits and a donor DNA is a major challenge for current gene delivery 
systems. Thus, further optimization of ZFN and homing endonuclease design as well as 
of delivery systems is necessary before this technique can be applied to the clinic.
1.4.5 Gene editing
In contrast to gene targeting, which generally replaces large parts of the target gene, 
gene editing aims to replace or repair the sequences immediately surrounding the 
disease-associated mutation only and is thus limited to modifying 1-4 nucleotides in 
close proximity. Gene editing is mediated by oligonucleotides of various structures such 
as TFO, chimeraplasts and ssODN. In contrast to plasmids, oligonucleotides can freely 
diffuse into the nucleus of mammalian cells due to their small size, enabling high in 
vitro transfection efficiencies. It is not yet clear if the oligonucleotide-based gene 
editing methods described here are mediated by HR.
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1.4.5.1 Triplex-forming oligonucleotides
TFO can bind to the major groove of double-stranded homopurine-rich DNA in a 
sequence-specific manner resulting in a triple helix structure. These reagents have been 
used to inhibit gene transcription, 205 induce mutagenesis206 or stimulate HR with the 
TFO alone207 or coupled to a mutagen such as psoralen. 208 Also, a bifunctional TFO 
containing an oligonucleotide as donor DNA was shown to mediate up to 0.1% gene 
editing in a recombinant single copy reporter gene cell line.209
A recent paper reported that LNA-modified TFO linked to orthophenanthroline, a DNA 
cleaving molecule, induced sequence-specific DSB and that in the presence of 
homologous donor DNA more than 1.5% of targeted cells demonstrated gene 
targeting.210 So far, application of TFO-mediated gene targeting has been limited by the 
target sequence requirement of 15-30 bp long pure polypurine stretches and by their
binding inefficiency at physiological pH, but progress has been made in addressing both
211issues.
1.4.5.2 Chimeraplasts
Chimeraplasts are synthetic RNA/DNA chimeric oligonucleotides, typically 6 8  
nucleotides long that can form a double hairpin with its target sequence as shown in 
Figure 1-8. The first paper using chimeraplasts for gene-editing was published in 1996 
and provided evidence for up to 30% editing efficiency in an episomal assay.212 A 
second paper, published in the same year, presented data from a PCR restriction 
fragment length polymorphism (PCR-RFLP) analysis suggesting up to 50% gene 
editing efficiency when targeting the (3-globin gene in lymphoblastoid cells from a 
sickle cell anaemia patient.213
However, both papers were soon criticized for their lack o f controls to exclude PCR 
artefacts, the absence of data showing gene editing in isogenic cell lines and, in the 
second paper, inconsistencies in the sequencing data, suggesting cell culture 
contamination as the real cause of the observed nucleotide alterations. 214,215 Indeed, the 
senior investigator on both papers, Eric Kmiec, himself admitted in an author reply that 
contamination with wild-type cells was a likely explanation for the sequencing data 
irregularities.215
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Figure 1-8 Design of chimeraplasts
An example chimeraplast designed to edit the wild-type ApoA-I and resulting in the ApoA-IM 
sequence (which differs from ApoA-I by C-»T; Argl73—»Cys). The bottom all-DNA sequence is 
complementary to the APOA-I genomic sequence with the exception of a central mismatched T 
(underlined). The top chimeric strand of the double-stranded molecule contains 2 ’-0-methylated 
protected RNA residues (lower case), which provide strong RNA-DNA hybridization, and hence 
efficient targeting, as well as resistance to RNase H-mediated degradation. Its complementary A 
(underlined) to the T mismatch in the all-DNA strand is in the middle of a 5-base-DNA region 
between the 10-base RNA sequences. The structure is stabilized by a pentameric G/C clamp, while 
polyT hairpin caps provide flexibility.
Papers from another laboratory described the use of chimeraplasts for targeting the 
alkaline phosphatase gene in human hepatoma cells, with up to 43% initial gene editing 
efficiency as determined by colony lift hybridization analysis216 and targeting the wild- 
type factor IX gene in rats, resulting in up to 40% editing efficiency and a subsequent 
50% reduction in blood coagulation.217 However, another group attempting 
chimeraplast-mediated gene editing, using a wide variety of experimental conditions 
was unable to isolate clones containing the intended sequence alterations in experiments 
where PCR-RFLP or allele-specific PCR had detected 2-10% gene editing.218
Without showing any supporting data, they concluded that their results from the PCR- 
based analysis must have been due to PCR artefacts and suggested, therefore, that PCR- 
based analysis of gene editing was suspect in general.218 They further suggested that the 
reduction in blood coagulation seen by Kren et al.2]1 was caused by liver toxicity of the 
transfection reagent or antisense effects of the oligonucleotide.218
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Others also questioned if 40% gene editing efficiency was realistically achievable in 
vivo considering the problems with liver gene delivery and an assumed maximal 
efficiency of 50% based on the proposed MMR-mediated mechanism .219 On the other 
hand, further proof of gene editing was obtained by targeting a mutant tyrosinase gene 
resulting in black pigmentation in albino mice melanocytes220 and the skin of albino 
mice.221 In both studies, analysis by PCR-RFLP three months after the chimeraplast 
treatment confirmed single allele conversion. Thus, it is highly unlikely that these 
results were caused by PCR-based artefacts. Also, several independent groups from 
around the world showed chimeraplast-mediated gene editing in the dystrophin,222,223 
tyrosinase224 and (3-globin225 genes.
O'}*}
As reports of failures have kept coming over the past years, " it has become clear 
that chimeraplast-mediated gene editing suffers from poor reproducibility among 
different research groups and even within the same group as seen in our own laboratory. 
For example, we showed that the dysfunctional apoE2 isoform was efficiently converted 
to wild-type apoE3 in recombinant CHO cells as demonstrated by genomic sequencing 
and iso-electric focusing gel-electrophoresis of secreted protein .234 However, attempts 
to extend the work and correct the human e4 allele, 235 which causes a dominant 
hyperlipidaemia or introduce the E2 and E4 mutations into wild-type cells, were 
disappointing.
Conversions were noted, but were unstable and cloned cells could not be isolated. ’ 
On the other hand, we could show that the PCR-RFLP results were not artefactual, as 
spiking experiments with chimeraplast or even degraded chimeraplast did not yield any 
false-positive PCR products.235 Similarly, the APOA-I gene was successfully targeted to 
generate ApoA-IM, but the result could not be reproduced in subsequent experiments.237 
These problems were attributed to a poorer quality of chimeraplast, consistent with
237changes to production methods of these difficult-to-synthesize reagents.
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1.4.5.3 Single-stranded oligonucleotides (ssODNs)
Introduction
In 1989, Campbell et a lP % described the use of ssODN for gene editing of episomal 
targets in mammalian cells, but the technique did not gain much attention until 
experiments by Gamper et al.m  revealed that the all-DNA strand was the functionally 
active domain in chimeraplasts and that ssODN containing PTO linkages at both ends 
were up to 3.7 times more effective in mediating gene editing in cell-free extracts than 
chimeraplasts. Another paper also showed that ssODN with 2’-0-methyl RNA 
nucleotides at both ends could correct a mutant lacZ gene in up to 0.1% of recombinant 
CHO cells, whereas chimeraplasts did not.240
Two other comparisons have shown that ssODN can reliably edit chromosomal DNA in 
mammalian cells, while chimeraplasts resulted in little or no gene editing even in 
episomal assays. 183,241 Since then, gene editing research has shifted from using 
unreliable chimeraplasts as the functional reagent to the much cheaper and easier to 
produce ssODN and several independent groups have reported consistent and 
reproducible gene editing efficiencies. 184,241 248 In response to the potential of possible 
false-positive results from PCR-based detection, cell lines expressing mutated forms of 
EGFP have been developed (e.g. CHO-mEGFP cells; see also chapter 4 ) 228>249’250
However, the best chromosomal gene editing frequencies described in such systems are 
less than five percent in cell lines with multiple copy integration251 and around 0 .1 -0 .2 % 
in cells with low copy number integrations of the target gene .241 These results are 
nowhere near the gene editing efficiencies previously reported with chimeraplast- 
mediated gene editing and PCR-based detection and thus reinforce the belief that the 
high efficiencies previously seen were due to PCR artefacts.
Sequencing results demonstrating the presence of specific base changes in pools of 
treated cells were similarly suspected of being caused by PCR artefacts.218 Furthermore, 
it was inferred that gene editing introduced transient changes only and that genomic 
conversions were not heritable;252 this was seemingly endorsed by the observation that 
gene-edited green fluorescent cells were quickly lost from the total population of 
targeted CHO-mEGFP cells. 242
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In response to these and other criticisms of chimeraplast-mediated gene editing, 
Albuquerque-Silva et al.227 proposed four experimental criteria for rigorous validation. 
First, the targeting oligonucleotide must introduce a rare mutant genotype to rule out 
spontaneous reversion events. Second, this genotype should not exist in cells within the 
laboratory to prevent cross-contamination artefacts. Third, mutated clones must be 
studied individually to exclude PCR and sequencing artefacts caused by large molar 
amounts of targeting oligonucleotides. Fourth, editing efficiency must be confirmed at 
the protein level in pooled cells at time points that eliminate artefacts of selection and 
expansion of rare spontaneous mutations.
These criteria are equally applicable to ssODN mediated gene editing but, so far, only 
one paper has studied individual gene-edited clones. 241 Unfortunately, this study used a 
mEGFP containing a premature stop codon and the gene-edited genotype did not allow 
exclusion of spontaneous reversion events, though a down-stream sequence tag 
excluded contamination with a wild-type EGFP .241 Thus, unequivocal confirmation of 
genotype alteration is still lacking.
Oligonucleotide design
Design of the targeting ssODN has critical effects on the resulting gene editing 
efficiency and the viability of edited cells. Typically, targeting oligonucleotides are 25- 
30 nucleotides long, as longer ssODN have only shown slightly higher gene editing 
efficiencies, 240’243 and not in all cases. 183,246,253 Moreover, longer oligonucleotides are 
more expensive and require purification because of the increased percentage of -1  
product.
In general, ssODN contain 3-6 PTO linkages or 2 ’-0-methyl nucleotides at each end to 
protect against exonuclease digestion, 239,240 though in a direct comparison of the two 
chemistries the PTO backbone modifications mediated more episomal gene editing in 
CHO cells.245 Other oligonucleotide modifications such as LNA residues have also been 
used, but there is disagreement as to whether these are more efficient than PTO- 
modified ssODN . 184,246 A recent paper showed that 5’ acridine-conjugated 
oligonucleotides were significantly more effective than either LNA-modified, psoralen- 
conjugated or peptide-nucleic acid containing oligonucleotides.254
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However, modifications may influence viability of gene-edited cells, as PTO-modifled 
ssODN were found to induce more cell death than unmodified ssODN and, in contrast 
to longer or modified ssODNs, 13- or 19-mer unmodified ssODNs did not seem to 
induce any growth inhibition.241 Also, targeting of mutS homolog 2 (MSH2) deficient 
embryonic stem cells containing a mutated neomycin gene with unmodified ssODN 
yielded 2-7 times more G418 resistant colonies.243
Several papers have reported that the optimal location for the mismatch to the target 
sequence is in the centre or slightly towards the 3’ end of the oligonucleotide as shifts to 
the 3’ end were less disruptive than shifts towards the 5’ end and in some cases even 
increased efficiency. ’ ' Curiously, blocking the 3’ end with octyl or 3’ hydrogen 
groups reduced editing efficiency significantly, but only in the presence of PTO 
linkages, whereas 5’ octyl or phosphate groups had little influence 251,259
It has also been shown that 2-4 nucleotide mismatches between ssODN and target 
sequence are corrected together if they are in close proximity, whereas this conversion 
linkage decreases with increased separation.243,244,247,255 Some publications even found 
that increasing the number of mismatches in close proximity increased 
efficiency.242,260,261 The two papers from the te Riele laboratory attributed this 
phenomenon to decreased recognition by the MMR .260,261
Generally, the sequence of the targeting ssODN is complementary to the non­
transcribed strand, i.e. it has the same sequence as the antisense strand, as numerous 
papers have reported a strand bias favouring this orientation . 183,240,246,251,262,263 However, 
in some reports no strand bias184,241,243 or opposite strand bias253,264 was observed.
Mechanism o f  ssODN-mediated gene editing
The detailed mechanisms involved in oligonucleotide-mediated gene editing are thus far 
not fully understood, but recent evidence points to some degree of physical sequence 
substitution with the genomic sequence as the initial step (Figure 1-9). For example, the 
fact that blocking the 3’ end results in massive reductions in gene editing efficiency, 
while a 5’ block does not, suggests that elongation at the 3’ end is necessary.251,259
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Figure 1-9 Mechanism of ssODN-mediated gene editing
The targeting oligonucleotide (brown) is thought to access the double-strand helix (grey) during 
transcription and/or replication. The ssODN then binds to its complementary sequence (with the 
exception of the intended mismatch) and is integrated in an as yet undefined process. The
mismatch with the endogenous sequence is resolved in a second step.
Also, in an elegant experiment, Radecke et al.259 captured genomic DNA fragments 
isolated from gene-edited cells that had been treated with a biotin-labelled ssODN using 
streptavidin-beads. PCR-amplification from these DNA fragments using target gene 
specific primers resulted in a defined PCR product, demonstrating that the biotin-
labelled ssODN had been integrated into the genomic sequence.
Olsen164 speculated that if the ssODN was physically integrated into the homologous 
genomic sequence, then an antisense ssODN incorporated into the transcribed strand 
would lead to expression of the gene-edited phenotype before the mismatch between 
ssODN and genomic sequence was resolved. Integration of sense ssODN, on the other 
hand, would necessitate repair of the mismatch prior to expression of the edited 
phenotype. Thus, gene editing using sense ssODN could simply take longer and hence 
variation in time to analysis could explain strand bias.
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He established that in cases where antisense strand bias was found, analysis was 
performed 24-48 h after treatment, whereas no bias or sense bias was found when 
analysis was carried out 7-10 days after transfection. 164 However, Sorensen et al.253 
observed opposite strand bias for two nucleotide alterations in the same gene in an 
episomal CHO cell system, whilst Andrieu-Soler et a / . 184 observed antisense strand bias 
for a blue fluorescent protein gene, but no bias for the retinal degeneration gene 1 at the 
same chromosomal locus. This suggests that sequence context may play a role in 
oligonucleotide strand bias.
Influence o f  Transcription and Replication
Strand bias has also been associated with transcription and replication of the target gene. 
In theory, both processes open up the DNA helix and enable access of the ssODN to the 
homologous endogenous sequence without the need for double-strand invasion. During 
active transcription access to the transcribed strand is blocked by the transcription 
complex while the non-transcribed strand is accessible.265 Indeed, Liu at al.262 showed 
that in E.coli T7 phage polymerase displaced sense ssODN from the transcribed strand 
of a plasmid, but the antisense ssODN remained hybridized to non-transcribed strand.
Several papers have also observed an association between gene editing efficiencies and 
transcription in S. cerevisiae 262 E. coli 266 mammalian episomal targets267 and in 
individual cell lines derived from the same parent population, but containing disparate 
copy numbers of the target gene.263,268 On the other hand, Olsen et al.242 did not observe 
gene editing in G 1 arrested cells suggesting that transcription without replication may 
not lead to successful gene editing.
Assuming physical integration of the ssODN into the transcribed strand as discussed on 
the previous page, this observation could suggest that the mismatch between integrated 
ssODN and endogenous sequence is not easily resolved and that only replication results 
in a completely altered sequence in one of the daughter cells. This was seemingly 
confirmed by data showing that in CHO-mEGFP cells only one daughter cell of 
dividing gene-edited cells remained strongly green fluorescent.242
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In E.coli X-Red recombination systems oligonucleotide-mediated gene editing appears 
to be replication dependent and strand bias is for ssODN hybridizing to the template
i^/Q 9A7
strand for lagging strand synthesis. However, in mammalian episomal and chromo­
somal251 systems strand bias is not dependent on chromosomal position or lagging 
strand synthesis. Yet, there is a clear correlation between replication and gene editing, 
as cells synchronized in the S phase showed higher gene editing efficiencies242,268,270
9^1and treatment with aphidicolin, a polymerase inhibitor, significantly reduced rates.
971Also, slowing replication fork movement by incubation with thymidine or 2’3’- 
dideoxycytidine272 increases gene editing, while completely stopping replication with 
1 -p-D-arabinofuranosylcytosine does not.272 Other DNA damaging agents such as
a ^ a  079 97 A .
hydroxylurea, etoposide, camptothecin, bleomycin and methyl methane- 
sulphonate275 increase gene editing as well. These findings support a central role for 
HR-mediated DSB-break repair which is mainly active in the S phase276 and can be 
induced by introducing DSB into the genome. 197
Influence o f  DNA damage response pathways
Notwithstanding, a recent paper demonstrated that Scel-induced HR DSB-repair was 
completely inhibited by caffeine and pentoxifylline whereas ssODN-mediated gene 
editing was only partially repressed. 277 Both reagents are inhibitors of the ataxia 
telangiectasia mutated (ATM)/ataxia telangiectasia and Rad3 related (ATR) damage 
response pathway .278 Furthermore, Wang et al.211 showed that although thymidine 
addition increased gene editing, it actually reduced DSB-repair. These findings indicate 
that in contrast to DSB-induced HR repair, gene editing is not dependent on activation 
of the ATM/ATR pathway.
On the other hand, data presented by Ferrara et al.219 hinted that the checkpoint kinases 
CHK1 and CHK2 which are down-stream substrates for ATM/ATR are only 
phosphorylated and hence activated in gene-edited cells. Also, chimeraplast-mediated 
gene editing was increased 2 -fold compared to wild-type in cells over-expressing 
RAD51, a central protein in HR , 249 while low editing levels in CHO cells deficient for 
the RAD51 paralog XRCC2 could be rescued by complementation with XRCC2 
cDNA .250
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In S. cerevisiae, over-expression of RAD51 raised editing efficiency 3-fold and a 
mutated RAD51 with higher affinity for its partner RAD54 amplified editing levels 100- 
fold.280 Moreover, co-injection of recombinant RAD51 and/or RAD54 with ssODN 
produced recombinant mouse embryos, whereas ssODN alone did not.248 A similar 
finding was reported in zebra fish, where only ssODN annealed with a RAD52 mutant 
protein resulted in recombinant embryos.258 However, suppression of NHEJ by co­
injection with Ku70/86 antibodies generated the highest number of mouse embryos with 
altered sequence.248
Conversely, the MMR pathway seems to have an inhibitory effect on oligonucleotide- 
mediated gene editing. Dekker et al. could show successful editing in MSH2243 or 
MSH3260 deficient mouse embryonic stem cells but not in wild-type cells which had 
also shown little or no repair in previous publications. 183,245 Also, expression of mutL 
homolog 1 (MLH1) in HEK293T cells known to be deficient in this MMR protein,281 
reduced editing levels by 50-70% (P. Olsen, unpublished data). Transient down- 
regulation of MSH2 in mouse embryonic stem cells using RNAi also increased gene 
editing significantly, but the increase was dependent on the number of mismatches.
This antagonistic effect of MMR proteins on oligonucleotide-mediated gene editing is 
generally attributed to their role in preventing heteroduplex formation between 
homologous sequences with sequence discrepancies. However, siRNA-mediated 
suppression of MSH2 in CHO-mEGFP cells did not affect ssODN-induced G2 arrest 16 
h after treatment, though it did result in a higher proportion of cells resuming a normal 
cell cycle 40 h after transfection (I. Papaioannou, unpublished data). Thus, MMR might 
instead play a role in the second step o f gene editing, when the mismatch between 
integrated ssODN and endogenous sequence has to be resolved.
Recently, Igoucheva et al. 283 have shown that CHO cells deficient in the excision repair 
cross-complementation group (ERCC) 1, 2, 5 or 6  proteins exhibited reduced episomal 
gene editing efficiency compared to the parental cell line. The ERCC1 and 4 genes 
encode a 5’ endonuclease, ERCC5 a 3’ endonuclease and ERCC6 , the Cockayne 
syndrome B protein, which couples excision repair and transcription. Lack of two 
helicases (ERCC2 and 3), which are involved in unwinding DNA near a lesion, did not 
affect gene editing. Thus, the nucleotide excision repair pathway (NER) may also play a 
role in oligonucleotide-mediated gene editing.
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1.5 Aims of thesis
Gene therapy strategies for the introduction of sequence specific modifications in the 
genome of mammalian cells hold great promise for lasting therapeutic treatment of 
many diseases. In this study I explore the use of oligonucleotide-mediated gene 
editing to introduce the anti-atherogenic point mutation ApoA-lM into the genomic 
sequence o f ApoA-I. Additionally, I investigate various aspects o f oligonucleotide- 
mediated gene editing using mEGFP model systems.
In particular, I will
1. Demonstrate successful gene editing in vitro using either CHO-AI or HepG2 
cells by PCR-RFLP and sequencing.
2. Confirm that the RFLP results are not artefacts.
3. Evaluate the influence of experimental conditions such as transfection reagent 
and oligonucleotide design on gene editing efficiency and viability of edited 
cells using a mEGFP model system.
4. Investigate ways to elevate the gene editing efficiency or select for edited 
cells independent of a marker gene.
5. Validate oligonucleotide-mediated gene editing using the experimental 
criteria set out by Albuquerque-Silva.
6. Show that the observed loss of green fluorescent cells from the population of 
edited cell clones is due to phenotypic instability in the mEGFP model 
system and is not specific to the gene-edited allele.
7. Verify that gene editing efficiencies in three mEGFP systems were 
significantly underestimated due to the phenotypic instability.
8. Exploit the phenotypic instability to show a positive association between 
target gene expression and gene editing efficiency in three mEGFP cell lines.
9. Assess an ApoA-lM homodimer specific antibody for use in flow cytometry 
to isolate gene-edited cell lines expressing ApoA-lM-
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CHAPTER 2: MATERIALS AND 
METHODS
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2.1 Materials
2.1.1 Cell Biology
2.1.1.1 Cell lines, plasmids and antibodies from non-commercial sources
CHO-AI and CHO-AIM are adherent cell lines derived from CHOdhfr‘ cells by stable 
transfection with the plasmids p7055.AI and p7055.AIM, which express ApoA-I and 
ApoA-lM, respectively.237 This expression vector also contains the DHFR gene, thus 
allowing selection by incubation in hypoxanthine and thymidine lacking medium.
• 237Clones were isolated by limiting dilution and screened for protein secretion.
The CHO-mEGFP and HEK293T-mEGFP cell lines as well as the pmEGFP plasmid 
were kindly provided by Prof. Stefan Krauss (Cellular and Genetic Therapy Research 
Group, Institute of Microbiology, Rikshospitalet, Oslo, Norway). The CHO-mEGFP 
cells have been described previously.242,251 In brief, a Tyr66 (TAC) to Ser66 (TCC) 
missense mutation was introduced in the pEGFP-Cl plasmid (Clontech, Takara Bio) to 
give non-fluorescent, full-length EGFP (mEGFP). CHO-K1 (ATCC CCL-61) cells were 
stably transfected with this plasmid and individual clones were selected with 400 pg/ml 
G418. CHO-mEGFP cells contain 38 copies of the mEGFP transgene.251
To produce the HEK293T-mEGFP cell line, HEK293T cells (ATCC CRL-11268) were 
transfected with a pS66-IRES-puro construct made by cloning the EGFP-S66 fragment 
into the pIRES-puro3 vector (BD Biosciences/Clontech) which contains the internal 
ribosome entry site (IRES) of the encephalomyocarditis virus. After selection in 500 
pg/ml puromycin, individual clones were isolated. The mEGFP transgene copy number 
has not been determined in these cells.
HepG2 cells were acquired from the European Collection of Cell Cultures (ECACC 
85011430). The red fluorescent protein (RFP) expressing plasmid was kindly provided 
by Dr. Takis Athanasopoulous (Royal Holloway, University of London).
The monoclonal mouse anti-human ApoA-lM antibody (clone 17F3) was kindly made 
available by Dr. Paul L. Barclay at Pfizer Global Research & Development, Groton, 
USA. It is of the IgG2a subclass with Kappa light chains.
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2.1.1.2 Cell culture reagents
Alpha minimal essential medium (Alpha-MEM lnvitrogen, Paisley, UK)
Caltag Fix&Perm solution (lnvitrogen)
Dimethylsulphoxide (DMSO; Sigma, Gillingham, UK)
Dulbecco’s modified Eagle’s medium (DMEM; lnvitrogen)
Draq5 (Biostatus, Shepshed, UK)
Fetal bovine serum (FBS, heat-inactivated for 30 min at 55 °C; lnvitrogen)
Hoechst 33342 (lnvitrogen)
Normal goat serum (Abeam, Cambridge, UK)
G-418 sulphate (lnvitrogen)
Glutamax (lnvitrogen)
Ham F12 (lnvitrogen)
HEPES buffer (lnvitrogen)
HT supplement (lnvitrogen)
Iscove’s DMEM (Sigma)
L-glutamine (Sigma)
Non-essential amino acids (lnvitrogen)
Opti-MEM (lnvitrogen)
Propidium iodide (PI; Sigma)
Rabbit polyclonal anti-EGFP (ab6556 from Abeam)
Rabbit polyclonal anti-human C-reactive protein (A-0073 from Dako, Ely, UK) 
Sodium butyrate (Sigma)
Streptomycin (10 mg/ml) and penicillin (10,000 units/ml) solution (Sigma)
Trypan blue (Sigma)
Trypsin-EDTA (Sigma; 0.25% (w/v) trypsin and 0.02 % (w/v) EDTA)
Zenon Alexa Fluor 647 Rabbit IgG Labelling kit (lnvitrogen)
Zenon Alexa Fluor 488 Mouse IgG2a Labelling kit (lnvitrogen) 
5-aza-2’-deoxycytidine (Aza-dC; Sigma)
2.1.1.3 Transfection reagents
jetPEI (Autogen Bioclear, Caine, UK)
Lipofectamine 2000 (lnvitrogen)
Deacylated LPEI (kindly provided by Dr. Maya Thanou, Imperial College London) 
CD AN/DOPE (also provided by Dr. Maya Thanou)
Atelocollagen (Koken, Tokyo, Japan)
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2.1.2 Molecular Biology
2.1.2.1 Molecular biology kits and reagents
Agarose (Biogene, Kimbolton, UK)
[a-32P] dCTP (GE Healthcare, Amersham, UK)
Ampicillin sodium salt (Sigma)
Bovine serum albumin (BSA; Sigma)
DH5a chemically competent E.coli (lnvitrogen)
DNeasy Tissue Kit (Qiagen, Crawley, UK) 
dNTP set (lnvitrogen)
Ethidium bromide (Sigma)
Hybond XL nitrocellulose membrane (GE Healthcare)
Illustra ProbeQuant G-50 microcolumns (GE Healthcare)
Isopropanol (Sigma)
IPTG (Sigma)
Kanamycin (Sigma)
Kodak Biomax-MS autoradiography film (GE Healthcare)
Metaphor high resolution agarose (Cambrex Bio Science, Wokingham, UK) 
Microcon YM-100 centrifugal filter units (Millipore, Watford, UK) 
NuPAGE Novex 20% Tris-borate polyacrylamide gels (lnvitrogen)
Pfu Turbo DNA polymerase (Stratagene, Amsterdam, The Netherlands) 
pGEM-T Easy vector (Promega)
Proteinase K (Sigma)
QIAquick gel extraction kit (Qiagen)
QIAquick spin miniprep kit (Qiagen)
Rapid Hybridization buffer (GE Healthcare)
Ready-to-go DNA labelling beads (GE Healthcare)
RNase A (Sigma)
Restriction endonucleases (New England BioLabs, Ipswich, MA, USA)
Taq DNA polymerase (Promega, Southampton, UK)
Tween 20 (Sigma)
T4 DNA Ligase (New England BioLabs)
X-gal (Sigma)
100/G Genomic tips (Qiagen)
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2.1.2.2 Buffers and solutions
Table 2-1 Qiagen buffers for DNA extraction and purification
Cl 1.28 M sucrose, 40 mM Tris-HCl [pH 7.5], 20 mM MgCl2, 
4% Triton X-100
G2 800 mM guanidine HC1, 30 mM Tris-HCl [pH 8], 30 mM 
EDTA [pH 8], 5% Tween-20, 0.5% Triton X-100
QBT 750 mM NaCl, 50 mM MOPS [pH 7], 15% isopropanol, 
0.15% Triton X-100
QC 1 M NaCl, 50 mM MOPS [pH 7], 15% isopropanol
QF 1.25 M NaCl, 50 mM Tris-HCl [pH 8.5], 15% isopropanol
PI 50 mM Tris-HCl [pH 8], 10 mM EDTA, 100 pg/ml RNase A
P2 200m M NaOH, 1% SDS (w/v)
Table 2-2 Electrophoresis buffers
lOx TBE running buffer 108 g/L Tris base (trizma), 55 g/L boric acid, 40 ml 0.5 M 
EDTA [pH 8.0]
Novex TBE Hi-Density Sample 
Buffer (lnvitrogen)
18 mM Tris base, 18 mM boric acid, 0.4 mM EDTA, 3% 
Ficoll, 0.02% bromophenol blue, 0.02% Xylene Cyanol
UltraPure lOx TAE running 
buffer (lnvitrogen)
400 mM Tris-acetate, 10 mM EDTA
lOx Bluejuice Gel Loading 
Buffer (lnvitrogen)
65% sucrose, 10 mM Tris-HCl, 10 mM EDTA, 0.3% 
bromophenol blue
Table 2-3 Southern blot buffers and solutions
20x SSC 175 g/L NaCl, 88 g/L Na3citrate*2H20 , adjust pH to 7.0 
with 1 M HC1
Alkaline Transfer Buffer 0.4 M NaOH, 1 M NaCl
SB wash Buffer I 2x SSC, 0.1% (w/v) SDS
SB wash Buffer II O.lxSSC, 0.1% (w/v) SDS
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T ab le  2-4 B acteria l grow th  m edia
Lysogeny broth (LB; Sigma) 10 g/L tryptone, 5 g/L yeast extract, 10 g/L NaCl
LB agar (Sigma) 10 g/L tryptone, 5 g/L yeast extract, 10 g/L NaCl, 15 g/L 
agar
Super optimal catabolite repres­
sion broth (S.O.C; lnvitrogen)
20 g/L tryptone, 5 g/L yeast extract, 10 mM NaCl, 2.5 mM 
KC1, 10 mM MgCl2, 20 mM MgSQ4, 20 mM glucose
T ab le  2-5 O ther buffers
Electroporation buffer 120 mM Na2HP04 [pH 7.2], 40 mM mannitol, 15 mM NaCl, 
5 mM KC1
Phosphate-buffered saline (PBS) 138 mM NaCl, 10 mM Na2HP04, 1.75 mM KH2P04, 7.2 
mM KC1 [pH 7.4]
0.5 M EDTA [pH 8.0] 186.1 g/L Na2EDTA*2H20 , adjust pH to 8.0 with ~ 50 ml 10 
M NaOH
2.1.2.3 DNA ladders
All ladders were purchased from lnvitrogen.
10 bp
-330 bp 
-220 bp 
-150 bp 
-100 bp
-50 bp
-20 bp 
- 10 bp
25 bp 100 bp
- 2652 bp
- 500 bp
- 2072 bp
- 1500 bp
- 600 bp
-125 bp 
- 25 bp
- 100 bp
Figure 2-1 DNA ladders
6 4
2.1.2.4 PCR primers
Table 2-6 ApoA-I primers
Primer Sequence 5’ to 3’ G/C content in % Tm in °C
AI2F GGTGG AGCCGCT GCGCGC 83 79
AMR GCCAGTCTGGCGCCGCCG 83 79
ApoAIouterF GAGGCAAGAGATGAGCAAGG 55 64
ApoAIouterF2 GAAGAAGTGGCAGGAGGAGA 55 63
ApoAIinnerF AAGAGAAGCTGAGCCCACTG 55 64
ApoAIinnerR CGCCGTT CT CCTT G AGAG 61 64
ApoAIinnerR
2 GGCCTT GGCGT GGTACTC 67 66
ApoAIouterR C AGG A AGCT G ACCTT GA AGC 55 64
Table 2-7 pEGFP primers
Primer Sequence 5’ to 3’ G/C content in % Tm in °C
pEGFP- 
241 for AGT ACGCCCCCT ATT GACG 58 64
pEGFP- 
603for CGCC ACC AT GGT G AGC AAGGG 67 76
pEGFP-
844for CACAT GAAGCAGCACGACTT 50 61
pEGFP-
754rev GAATTTCAGGGTCAGCTTGC 50 64
pEGFP- 
1261 rev CGCGCTTCTCGTTGGGGTC 68 72
pEGFP-
1380rev GGT ACCGT CG ACT GC AG AAT 55 64
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2.1.2.5 Gene editing oligonucleotides
Phosphorothioate links are denoted with a *, LNA modifications with a +, correcting 
nucleotides are in bold and underscored.
Table 2-8 ApoA-I to ApoA-IM editing oligonucleotides
ssODN Sequence 5’ to 3’
huApoA-IM-Cy 5-49NT - 
PTO
Cy5-
G*A*G*CCTCAAGGCGCGCGGCCAAGCACTGGCGC 
a  r . r T r n T r n r T r , T  a  * n * r t * n
huApoA-IM-49NT GAGCCTCAAGGCGCGCGGCCAAGCACTGGCGC
AGCTCGTCGCTGTAGGG
huApo A-Im-49NT-PTO G*A*G*CCTCAAGGCGCGCGGCCAAGCACTGGCGC
AGCTCGTCGCTGTA*G*G*G
huApoA-lM~49T-PTO C*C*C*TACAGCGACGAGCTGCGCCAGTGCTTGGC
CGCGCGCCTTGAGG*C*T*C
Table 2-9 mEGFP to edEGFP editing oligonucleotides
ssODN Sequence 5’ to 3’
mEGFP-2A-NT GAAGCACTGCACGCCATAGGTCAGGGT
mEGFP-2 A-NT-PTO G*A*A*GCACTGCACGCCATAGGTCAG*G*G*T
mEGFP-2A-NT-LNA +G AAGC ACTGC ACGCC AT AGGTC AGGG+T
mEGFP-Cy3-2A-NT-PTO Cv3-G*A*A*GCACTGCACGCCATAGGTCAG*G*G*T
mEGFP-3A-NT GAAGCACTGCACGCCATATGTCAGGGT
mEGFP-3 A-NT-PTO G*A*A*GCACTGCACGCCATATGTCAG*G*G*T
mEGFP-Cy5-3A-NT-PTO Cv5-G*A*A*GCACTGCACGCCATATGTCAG*G*G*T
mEGFP-3 A-NT-LNA +GAAGCACTGCACGCCATATGTCAGGG+T
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Table 2-10 mEGFP to edEGFP control oligonucleotides
ssODN Sequence 5’ to 3’
mEGFP-Ctr-NT GAAGCACTGCACGCCGGAGGTCAGGGT
mEGFP-Ctr-NT-PTO G*A*A*GCACTGCACGCCGGAGGTCAG*G*G*T
mEGFP-Ctr-NT-LNA +G AAGC ACT GC ACGCCGG AGGTC AGGG+T
2.1.3 Equipment
BioRad iCycler (Bio-Rad, Hemel Hempstead, UK)
Class II microbiological safety cabinet (Envair Ltd., Lancashire, UK)
Compact X4 Automatic X-ray film processor (X-ograph Healthcare, Tetbury, UK)
Cytopulse PA-4000 electroporator (Labtech International, Ringmer, UK)
FACScan flow cytometer with CellQuest v3.1 software (BD Biosciences, Oxford, UK) 
FACSCalibur flow cytometer with CellQuest Pro software (BD Biosciences)
Heraeus Megafuge 1 .OR (Fisher Scientific, Loughborough, UK)
Heraeus Biofuge Pico (Fisher Scientific)
Horizon gel apparatus (Life Technologies, lnvitrogen)
Inverted phase-contrast microscope (Nikon TMS, Jencons-PLC)
Inverted fluorescence microscope (Nikon Eclipse TE200) with LUCIA G image analysis 
software
Nalgene Cryo 1°C Freezing Container (Fisher Scientific)
NanoDrop ND-1000 UV/Vis Spectrophotometer (Labtech, Ringmer, UK)
Partec PAS flow cytometer (Partec, Munster, Germany)
UVP Epi Chem II Darkroom (Jencons-PLC) with Labworks UVP image analysis software 
Xcell SureLock Mini-Cell gel apparatus (lnvitrogen)
37 °C incubator (Jencons Millenium C02 incubator, Jencons-PLC, Leighton Buzzard, UK)
67
2.2 Methods
2.2.1 Cell Biology
2.2.1.1 Culture maintenance
Cell culture work was performed in a class II microbiological safety cabinet using 
disposable sterile plastic ware. All cell lines are adherent and were cultured in a 37 °C 
incubator with a humidified atmosphere of 5% CO2 with addition of streptomycin (100 
pg/ml) and penicillin (100 U/ml) to all media. Cells were split by trypsinisation when 
semi-confluent. After a quick wash with warm PBS, cells were incubated with 1 ml of 
0.25% (v/v) trypsin-EDTA per 25 cm2 of growth area, generally for 2 - 3 min at room 
temperature (RT). An equal volume or more of pre-warmed fresh growth medium 
containing FBS was added to neutralise the reaction and cells were split at the ratios 
indicated for each cell line.
CHOdhfr' cells were maintained in Iscove’s DMEM containing 10% (v/v) dialysed FBS, 
1% (v/v) HT supplement (final concentration 16 pM thymidine, 100 pM sodium 
hypoxanthine) and 1% (v/v) non-essential amino acids. Cells were split 1:4 to 1:6 twice 
a week.
CHO-AI and CHO-AIM were maintained in Iscove’s DMEM supplemented with 10% 
(v/v) FBS, 2 mM L-glutamine and 1% (v/v) non-essential amino acids. Cells were split 
1:4 to 1:6 twice a week. CHO-mEGFP and CHO-K1 cells were cultured in Ham’s F12 
medium containing 2 mM L-glutamine and 5% (v/v) FBS. Cells were split twice a week 
at 1:6 to 1:8 ratios.
HEK293T and HEK293T-mEGFP cells were grown in DMEM with 10% (v/v) FBS, 2 
mM L-glutamine and 4.5 mg/ml glucose, but without sodium pyruvate. Cells were split 
every 4-6 days at 1:4 to 1:6 ratios.
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HepG2 cells were grown in DMEM augmented with 10% (v/v) FBS and 2 mM L- 
glutamine or, where indicated, in “Super HepG2 medium” (alpha-MEM containing 
nucleosides, 10% (v/v) FBS, 3.5 iu/ml insulin, 0.3 mg/ml Glutamax, 50 mg/ml 
BSA/linoleic acid, 10'7 M sodium selenite, 10'6 M hydrocortisone, 10'6 M thyrotropin- 
releasing hormone and 1.25 mg/ml D-glucose). Cells were split 1:10 to 1:20 every 4 - 6  
days by trypsinisation (5 min at 37 °C). After trypsinisation HepG2 cells were squeezed 
3 - 5  times through a 21G needle to break up cell clumps and ensure homogeneous 
plating. HepG2-mEGFP cells were cultured in Super-HepG2 medium.
2.2.1.2 Cryopreservation and Reconstitution
For cryopreservation, 106 to 107 cells were pelleted at 300 g  for 5 min and re-suspended 
in 1 ml 10% (v/v) DMSO in FBS (15% for HepG2 cells). DMSO lowers the freezing 
point and encourages intracellular dehydration, thus allowing cells to be slowly cooled 
without damage. The cell suspension was pipetted into 1.8 ml cryovials and these were 
placed in a Nalgene Cryo 1 °C Freezing Container at -80 °C overnight. These special 
containers limit temperature reduction to 1 °C per min when stored at -80 °C and thus 
avoid damage to cells caused by latent heat of fusion. The cryovials were then 
transferred to liquid nitrogen for long-term storage.
For reconstitution, cryovials were removed from liquid nitrogen and rapidly warmed in 
a 37 °C water bath. As soon as the cell suspension was thawed, it was diluted 1:10 in 
fresh pre-warmed culture medium and transferred to culture flasks. Cells were allowed 
to adhere overnight before the medium was replaced with fresh medium.
2.2.1.3 Cell counting and viability
When cell counts were necessary, prior to plating for transfection or to assess cell 
viability, Trypan blue was used. This dye cannot pass through the membrane of live 
cells as it is a bis-azo dye and negatively charged at physiological pH, but it can traverse 
the membrane of dead cells. It appears as a blue stain under the phase-contrast 
microscope and thus allows simultaneous determination of cell count and viability. The 
haemocytometer chambers were prepared by firmly attaching a cover-slide with a drop 
o f oil. Cells were trypsinised and resuspended to give a cell concentration of > lx l0 6/ml.
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A mix of 50 pi Trypan blue, 40 pi PBS and 10 pi of this cell suspension was pipetted 
into the haemocytometer chambers and observed under an inverted phase-contrast 
microscope. The number of viable cells was counted in eight 1 mm2 squares with a total 
volume of 10'4 cm3. The average number of cells per square was then multiplied by the 
dilution factor and 104 to give the number of cells per ml. To calculate the total number 
of cells, the number of cells per ml was multiplied by the volume (in ml) of the cell 
suspension. Generally the concentration of the cell suspension was adjusted to lxlO6 for 
pre-plating by subtracting the volume (in ml) of the cell suspension from the total 
number of cells (expressed as xlO6) and then adding the resulting number in ml of fresh 
medium to the cell suspension.
2.2.1.4 Transient transfection
Transfections were either performed on cells plated the previous day or using “reverse 
transfection”,284 where cells are trypsinised, counted and plated immediately before 
addition of the transfection complexes, rather than pre-plated. Transfection optimisation 
experiments showed that reverse transfection did not improve transfection efficiency of 
CHO cell lines, but instead caused increased toxicity. However, transfection efficiency 
was enhanced moderately in HEK293T cells and significantly in HepG2 cells if cell 
clumps were broken up by repeated passage through a 21G needle. This increase was 
probably due to the disruption of the dense growth pattern and tight cell-to-cell contacts 
in HepG2 cells that would normally preclude complete cell surface exposure to 
transfection agents, as happens with pre-plated cells. Slight membrane damage caused 
by the homogenisation might also make cells more permissible.
Transfections using Lipofectamine 2000, a cationic lipid, were carried out as follows: 
typically, DNA (4-6 pg o f oligonucleotide or 1-4 pg o f plasmid) and Lipofectamine 
2000 at a w/v ratio of 1:2 were diluted in 250 pi Opti-MEM each in separate microfuge 
tubes. After 5 min incubation the solutions were mixed together gently and incubated at 
room temperature for 20 min to allow complex formation. During the incubation step, 
the normal growth medium was removed from the pre-plated cells and replaced with 1 
ml of growth medium without antibiotics to avoid cytotoxicity associated with 
concomitant up-take of antibiotics.
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For reverse transfection, cells were trypsinised as usual and an aliquot was taken for 
counting while cells were pelleted by 5 min centrifugation at 500 g. Cells were then 
resuspended in culture medium without antibiotics at a concentration of lx l0 6/ml and 1 
ml was added per well of a 6-well plate. Then 500 pi of the DNA-Lipofectamine 2000 
solution was added drop-wise to the cells in each well and the cultures were incubated 
at 37 °C. The number of cells that were transfected and incubation times are detailed in 
Table 2-11. After incubation, cells were washed with 2 ml pre-warmed PBS and fresh 
culture medium containing antibiotics was added.
Table 2-11 Cell numbers and incubation times for transfection
Cell line
Number o f cells per 6-well Incubation
timepre-plated reverse transfected
CHO-AI 2xl05 2 h
CHOdhfr‘ 2xl05 2 h
CHO-AIM 2xl05 2 h
CHO-K1 2xl05 2 h
CHO-mEGFP 2xl05 2 h
HEK293T 5x10s overnight
HEK293T-mEGFP 5xl05 overnight
HepG2 lxlO6 overnight
HepG2-mEGFP lxlO6 overnight
Transfections using jetPEI were carried out as follows: typically, 4-12 pg of 
oligonucleotide and jetPEI at a N/P ratio of 5:1 were each diluted in 100 pi NaCl. After 
gently mixing each separately, jetPEI was added to ssODN and the two solutions were 
mixed together. Following 15 min incubation at room temperature the combined 
transfection complexes were added to the cells.
For transfection with CD AN/DOPE, a cationic lipid similar to Lipofectamine 2000, but 
supposedly less cytotoxic, the reagent was diluted in 250 pi PBS and incubated 5 min, 
before mixing with the ssODN in volume to weight ratios of 1:1 and 2:1. The ssODN 
had also been diluted in 250 pi PBS. The solution was incubated 5-10 min at room 
temperature and then added to the wells. All transfected wells were washed into normal 
medium 3 h later.
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2.2.1.5 Cell synchronization
CHO-mEGFP cells were synchronized using 48 h serum starvation and 100 pM 
mimosine as described in Olsen et al.242 Cells were seeded at a density of lx l0 5 cells 
per 6-well and cultured in full growth medium containing 5% FBS for 24 h. Then the 
medium was changed to reduced serum medium (0.2% FBS) and cells were cultivated 
for a further 48 h. Subsequently, the medium was changed back to full growth medium 
and 100 pM mimosine was added. Cells were transfected 24 h later.
2.2.1.6 Fluorescence resonance energy transfer (FRET)
Fluorescence energy transfer (FRET) occurs when one fluorochrome (the donor) excites 
another fluorochrome (the acceptor) through direct resonance energy transfer. This can 
only happen if the emission spectrum of the donor overlaps significantly with the 
excitation spectrum of the acceptor, both partners are in close physical proximity (<10 
nm or 100 A) and the emission and acception dipoles are not perpendicular to each 
other. In conjunction with the ability to tag proteins of interest with fluorescent proteins 
such as EGFP or RFP, FRET allows determination of the interactions of two tagged 
proteins in living cells with a higher certainty than can be reached by microscopic 
colocalization alone.
2.2.1.7 Loading cells with Cy3-dCTP
When using electroporation, lxlO6 cells in 100 pi electroporation buffer containing 2 pi 
of Cy3-dCTP were subjected to 2 pulses at 250 V for 0.4 s, and 6 pulses at 125 V for 
0.075 s, with 0.5 s intervals. Following electroporation, 200 pi of complete medium was 
added directly into the cuvette and, after thorough mixing, the cell suspension was 
transferred into a 6-well containing 2 ml growth medium.
CHO-mEGFP cells were also loaded with Cy3-dCTP using the Influx Pinocytic Cell- 
loading reagent from lnvitrogen. This reagent utilizes a combination of hypertonic and 
hypotonic extra-cellular conditions to induce cells to take up small molecules. 
Hypertonic extra-cellular conditions create a salt concentration gradient that results in 
water efflux from cells due to osmotic pressure, whereas hypotonic extra-cellular 
conditions result in influx of water to the cells.
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Hypertonic loading medium was prepared by melting the waxy substance in one of the 
supplied tubes at 80 °C and adding 4.7 ml of Ham F12 medium without serum while 
vortexing for 5 min. Then 250 pi serum and 100 pi of 0.5 M HEPES buffer [pH 7.2] 
were added, the solution was vortexed again and filter sterilized. For the hypotonic lysis 
solution, Ham F12 medium was mixed with de-ionized water at a 6:4 ratio.
Per sample, lxlO6 cells were pelleted by centrifugation for 1 min at 300 g. Cells were 
resuspended in 20 pi hypertonic loading medium containing 2 pi of Cy3-dCTP and 
incubated 10 min at 37 °C. Then 1 ml of hypotonic lysis medium was added and 0.5 ml 
of the suspension were immediately transferred into 2 ml microfuge tubes containing 1 
ml hypotonic lysis medium. After incubation for 1.5 min at 37 °C, cells were pelleted 
by centrifugation for 1 min at 300 g. The supernatant was removed and cells were 
resuspended in 1.5 ml of full growth medium before plating in 6-well plates.
2.2.1.8 Flow cytometry
Principles o f  flow cytometry
Flow cytometry is a technique for analysing and sorting microscopic particles (e.g. 
mammalian cells) in a hydro-dynamically focused stream of fluid. A single wavelength 
beam of light, usually from a laser, is aimed at the stream and excites fluorescent 
chemicals or proteins contained or attached to the particles passing in the stream, 
provided the wavelength matches the excitation spectrum of the fluorophore. The 
excited fluorophore then emits light at a longer wavelength which is measured by 
detectors aimed at the point where the stream passes through the light beam.
Typically, one detector is in line with the light beam (Forward Scatter or FSC) and 
several are perpendicular to it to measure Side Scatter (SSC) and the emission 
wavelengths of one or more fluorophores. Forward Scatter correlates with cell volumes 
and SSC depends on the inner complexity of the particle (i.e. shape of the nucleus, the 
amount and type of cytoplasmic granules or the membrane roughness). Flow cytometers 
can analyse several thousand particles per second and quantify the intensity of 
fluorescent emission from each particle accurately.
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The resulting data can then be plotted either as a single dimensional (histogram) or two 
dimensionsal plot. Often, two dimensional plots are modified to represent a certain 
number of cells with the same fluorescent intensities by defined colours (density or 
contour plots). Selected subsets of events can be analysed separately by creating “gates” 
around the population of interest.
Generally, FSC vs. SSC plots and DNA cycle plots have linear scales as the signal 
differences are small, whereas plots showing fluorescent intensities are logarithmic as 
differences can span several magnitudes. Flow cytometers also employ complex 
arrangements of di-chroic splitting and band pass filters to isolate the emission spectra 
o f different fluorophores. Excitation wavelengths and band pass filters for the dyes used 
here are summarized in Table 2-12.
Nevertheless, the emission spectra of different fluorescent dyes can overlap, so signals 
at the detectors have to be compensated. This can be done electronically by changing 
acquisition settings on the flow cytometer or computationally after data has been 
aquired. The latter is preferred as it avoids operator prejudice.
Table 2-12 Excitation wavelengths and band pass filters (in nm)
Excitation Filter Dyes
350 485/30 Hoechst 33342
488 530/30 EGFP, Alexa Fluor 488
585/42 PI, RFP
633 660/16 Alexa Fluor 647
General flow  cytometry
Flow cytometric analysis was performed on either a FAC Scan equipped with a 488 nm 
argon laser or a FACSCalibur with a 488 nm argon laser and a 633 nm red helium-neon 
laser. Cells were trypsinized, washed once with PBS and resuspended in at least 200 pi 
PBS at an approximate concentration of lx l0 6 cells/ml.
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Before analysis, 2 pg/ml propidium iodide (PI) was added for dead cell discrimination 
unless otherwise stated. Data were acquired with CellQuest 3.1 (FACScan) or CellQuest 
Pro (FACSCalibur) software without compensation and analysed using WinMDI 2.8 or 
WinList 6.0 software. Cells were always gated based on FSC versus SSC as well as PI 
to exclude cell debris and dead cells from the analysis. Where necessary, compensation 
was applied using the automatic compensation function of WinList 6.0.
Cell cycle analysis
Cell cycle studies were performed on a Partec PAS flow cytometer equipped with a 488 
nm argon laser and a HBO lamp for UV excitation. Cells were washed once in PBS and 
stained with 5 pg/ml Hoechst 33342 for 30 min at 37 °C before analysis. Typically, 
lx l0 4 events were acquired and flow rate was kept below 1000 events per second to 
minimize the coefficient of variation of the DNA histogram peaks.
Intracellular staining
Cells were trypsinized, washed in cold PBS and re-suspended in PBS at a concentration 
of lx l0 6/100 pi. An equal volume of Caltag Fix&Perm solution A was added and cells 
were incubated for 15 min. Cells were washed once with PBS containing 5% normal 
goat serum and re-suspended in 100 pi of Caltag Fix&Perm solution B.
Per sample 250 ng of rabbit polyclonal anti-GFP antibody (or 0.5 pi rabbit polyclonal 
anti-human C reactive protein antibody) labelled with the Zenon Alexa Fluor 647 
Rabbit IgG kit was added. Cells were incubated in the dark for 20 min, washed with 
PBS containing 5% normal goat serum and analyzed immediately. Data were acquired 
without compensation on a FACSCalibur flow cytometer. CHO-K1, HEK293T and 
HepG2 cells were used as negative controls to determine expression levels in CHO-, 
HEK293T- and HepG2-mEGFP cells. Typically, l-8x l06 events were acquired.
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2.2.1.9 Fluorescence-activated cell sorting (FACS)
Fluorescence-activated cell sorting (FACS) is the application of flow cytometry to 
physically separate cells based on specific light scattering and fluorescent 
characteristics. As with flow cytometry, cells are hydro-dynamically focused in a fluid 
stream, but this stream is then broken up into individual droplets by vibration. 
Excitation of fluorophores and analysis of resulting emission are also done the same 
way. However, cell sorters can apply electrical charges to individual droplets containing 
cells of interest. The charged droplets can then be directed into separate collection 
containers based upon their charge.
All cell sorting was performed at the Flow Core laboratory of the Institute for Cancer 
Research. Single green fluorescent gene-edited cells were isolated using a FACSAria 
with DiVa software and a 488 nm laser. Cells were gated based on FSC/SSC, Live/Dead 
(DAPI) and doublet discrimination (fluorescent signal area/width). Cells were cultured 
for at least four weeks before further analysis.
2.2.1.10 Production of HepG2-mEGFP cells
Attempts to isolate HepG2-mEGFP cell clones grown in DMEM or conditioned DMEM 
containing 20% FBS had failed, but following a recommendation by Dr. Demetra 
Mavri, HepG2 cells were grown and selected in Super HepG2 medium. Cells were 
transfected with 2 pg pmEGFP using Lipofectamine 2000 as described in section 
2.2.1.4. Fluorescence microscope examination of a control transfection with pEGFP 
showed that the transfection efficiency was around 50%.
Antibiotic selection pressure was applied 2 d after transfection by addition of 500 pg/ml 
G418 and cells were plated in 6 cm plates at varying densities. In a mock-transfected 
control sample treated the same way, complete cell death was reached 10 d after the 
start of incubation. At this time, over 100 colonies were picked from the transfected cell 
sample and transferred into the wells of a 96-well plate. Selection pressure was 
maintained for a further 3 weeks until the clones had proliferated enough to grow in 
flasks. Clones were tested for stable integration of the transgene by transfection with 4 
pg of the editing oligonucleotide mEGFP-3A-NT-PTO and flow cytometric 
quantification o f the resulting green fluorescence cells.
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2.2.1.11 Fluorescence microscopy
Fluorescence was examined on an inverted fluorescence microscope (Nikon Eclipse 
TE2000) equipped with a mercury arc lamp using the filter sets detailed in Table 2-13. 
In EGFP editing experiments, autofluorescence was controlled for by visual 
examination of cells transfected with control oligonucleotides. For other experiments, 
mock-transfected control samples were used. Phase contrast and fluorescence pictures 
of the same field were acquired and, if required, overlayed with Lucia G software.
Table 2-13 Fluorescence microscope filters
Excitation Emission Dyes
480/20 510/20 EGFP
546/10 580/30 RFP
540/25 605/55 Cy3
625/40 700/40 Cy5
2.2.1.12 Confocal microscopy
CHO-mEGFP cells were grown on cover-slides and transfected with Cy3-mEGFP-2A- 
PTO using Lipofectamine 2000. Cell nuclei were counterstained by adding 5 pM Draq5 
to culture medium and incubating for 10 min at 37 °C. The cover slides were briefly 
rinsed in PBS and mounted onto slides using Citifluor. Confocal pictures were taken 
with a Zeiss LSM 510 Meta system.
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2.2.2 Molecular Biology
2.2.2.1 Extraction and purification of DNA from mammalian cells
Cells ( lx l0 6 for small scale or 2xl07 for large scale extraction) were trypsinized, 
pelleted by 5 min centrifugation at 500 g and washed once in PBS. The supernatant was 
taken off and DNA extraction was either performed directly or cell pellets were stored 
at -20 °C.
For small scale extraction, cell pellets were resuspended in 200 pi PBS and extraction 
was performed using the DNeasy tissue kit according to the manufacturer’s protocol. 
This kit uses spin columns for 1.5 ml microfuge tubes that contain silica membranes. 
DNA binds to silica in the presence of high chaotropic salt concentrations, but can be 
eluted easily by low salt conditions.
To digest proteins and thus protect DNA from nucleases during cell lysis, 20 pi 
proteinase K (600 mAU/ml) were added to the suspension. Contaminating RNA was 
removed by incubation with 4 pi RNase A (lOOmg/ml) for 2 min before 200 pi lysis 
buffer AL (containing guanidine hydrochloride) was added and samples were incubated 
for 10 min at 56 °C. After addition of 200 pi ethanol (96-100%) to precipitate the DNA, 
the samples were vortexed vigorously, pipetted into a spin column and centrifuged for 1 
min at >6000 g. Samples were washed sequentially with 500 pi AW1 and AW2 to 
remove contaminating proteins. Flow-through and collection tubes were discarded after 
each wash. After the last wash, samples were centrifuged for 3 min at 20,000 g to 
remove residual ethanol from the membrane. Genomic DNA was eluted from the 
purification column with 200 pi 10 mM Tris-HCl [pH 8.5].
Large scale DNA extraction was performed using Qiagen 100/G Genomic tips 
according to the manufacturer’s protocol. This kit uses anion-exchange columns that 
bind DNA under low-salt and pH conditions. Genomic DNA is eluted in high-salt 
buffer and then concentrated and desalted by isopropanol precipitation.
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Pellets of 2xl07 cells were resuspended in 2 ml PBS, mixed with 2 ml ice-cold buffer 
Cl and 6 ml ice-cold distilled water and then incubated 10 min on ice to lyse cells, but 
preserve nuclei. After centrifugation for 15 min at 1300 g and 4 °C, the supernatant was 
discarded and samples were washed with 1 ml buffer Cl and 3 ml distilled water to 
remove all contaminating cell debris. The pellet was then resuspended in 5 ml buffer G2 
to lyse the nuclei and denature proteins, 95 pi proteinase K was added and the 
suspension was incubated for 45 min at 56 °C to digest the denatured proteins.
Meanwhile, the required number of Genomic tip 100/G columns was equilibrated with 4 
ml of buffer QBT. The samples were added to the columns and allowed to enter the 
resin by gravity flow. Columns were then washed twice with 7.5 ml buffer QC and 
genomic DNA was eluted in 5 ml buffer QF. DNA was precipitated with 3.5 ml 
isopropanol, recovered with glass hooks and transferred into 600 pi 10 mM Tris-HCl 
[pH 8.5]. To dissolve the genomic DNA, samples were placed on a rotational shaker 
overnight.
2.2.2.2 Determination of DNA concentration
The concentration of DNA solutions was determined by measuring the absorbance at 
260 nm (A260) with a Nanodrop ND-1000 spectrophotometer and applying Beer’s law. 
The measurements were blanked with the solution buffer and samples were mixed 
before 1 pi was pipetted onto the light path. The ratio of sample absorbance at 260 nm 
and 280 nm was used to assess the purity of DNA solutions (optimal 1.8 for DNA). The 
nucleic acid concentration was automatically given as ng/pl, but is derived from the 
following formula:
Cone, (ng/pl) = (A 260 x extinction coefficient fo r  DNA in ng-cm/pl) /path length in cm
The extinction coefficient for DNA is 50 ng-cm/pl and the path length is 0.1 cm on a 
Nanodrop.
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2.2.2.3 Polymerase chain reaction (PCR)
Principles o f  PCR
A polymerase chain reaction is a process by which a section of DNA can be amplified 
in a sequence-specific manner. The selected region of a genome can be amplified a 
billion-fold with the use of short oligonucleotide primers of 15-30 bases in length, 
which are complementary to the target sequence. The primers lie on opposite strands of 
DNA and flank the region to be amplified.
Each cycle of the reaction requires a heat denaturation step to separate the double­
stranded DNA and this is achieved by heating the target DNA to 94 °C or more. To 
allow the oligonucleotide primers to anneal specifically to their complementary 
sequences the reaction is then cooled to the annealing temperature which is typically 
chosen 5 °C below the melting temperature (Tm) of the primers. The reaction is then 
heated to the optimal working temperature for the thermo-stable DNA polymerase 
(usually 72 °C) and the primers are extended with the complementary sequence as 
template.
Thus, the extension reaction creates two double-stranded hybrids between a strand of 
target DNA and a shorter PCR product that begins with a primer sequence. After a 
second denaturation step, the strands starting with a primer sequence can function as 
templates for annealing of the other primer. Hybridization and extension then produces 
double-stranded molecules that comprise the stretch o f target region flanked by the two 
primers.
Repeated cycles of heat denaturation, primer annealing and extension exponentially 
amplify the target fragment of DNA. After 20-40 such cycles a final ‘polishing o ff 
extension step at 72 °C for 5 min completes the PCR.
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Generally, PCR is performed in 20-100 pi reaction volumes which contain the 
following components: a reaction buffer providing optimised conditions for the DNA 
polymerase, 1-4 mM MgCb (low concentrations yield less product but higher 
concentrations increase non-specific product), 200 pM dNTPs (an equimolar mixture of 
dATP, dCTP, dGTP and dTTP), 0.1-1 pM primers, 1.5 U/50 pi DNA polymerase and 
0.01-1 ng plasmid DNA or 0.1-1 pg genomic DNA template. Reactions are made up to 
required volumes with nuclease-free water. Adjuvants such as 5-10% DMSO may be 
added to the reaction of GC-rich templates as it facilitates strand separation by 
disrupting base pairing and thus increases efficiency.
Primer3, a primer design tool (http://frodo.wi.mit.edu) was used to design primers. This 
tool provides essential information such as melting temperature (Tm), and potential 
secondary structure and primer-dimer formation. Melting temperatures are dependent on 
GC content as well as length of the primers and should be similar within a pair. 
Secondary structure and formation of primer-dimers will reduce the quantity of PCR 
product. Primers should be around 18-22 bases long, though in some cases they might 
be longer to accommodate non-complementary nucleotides.
Thermo-stable polymerases are purified from thermophilic bacteria (for example Taq 
polymerase from Thermus aquaticus) or archaea (Pfu from Pyrococcus furiosus) and 
remain stable at high temperatures. Unlike Taq polymerase, Pfu possesses 3’-5’ 
exonuclease proof-reading activity.
All PCRs were pipetted on ice, where possible as master mixes, and sample tubes were 
directly transferred to a Bio-Rad iCycler already at 94 °C. This machine has a heated lid 
to prevent loss of sample through evaporation upon heating. A PCR control sample 
without DNA template was always included and only PCRs with a clean control, as 
determined by gel electrophoresis, were used for subsequent analysis. In order to 
minimise contamination, gloves were worn at all times, filter-protected pipette tips were 
used and the reactions were prepared in a designated PCR room.
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Reaction conditions fo r  PCRs
Table 2-14 ApoA-I/ApoA-lM with primers AI2F and AMR
Temperature Time Cycles
95 °C 5 min
94 °C 1 min
35x62 °C 30 s
72 °C 30 s
72 °C 5 min
4 °C 00
Reaction component
1 Ox PCR buffer lx
MgCl2 2 mM
dNTPs 400 pM
AI2F primer 0.5 pM
AMR primer 0.5 pM
Taq DNA polymerase 1.5 U
Genomic DNA 5 pi
Total volume 50 pi
Table 2-15 ApoA-l/ApoA-IM with primers ApoAlinnerF and ApoAIinnerR2
Temperature Time Cycles
95 °C 5 min
95 °C 1 min
35x68 °C 30 s
72 °C 30 s
72 °C 5 min
4 °C 00
Reaction component
lOx PCR buffer lx
MgCl2 2 mM
DMSO 5% (v/v)
dNTPs 200 pM
ApoAlinnerF primer 0.3 pM
ApoAIinnerR2 primer 0.3 pM
Taq DNA polymerase 3 U
Genomic DNA 5 pi
Total volume 30 pi
Table 2-16 Southern blot probes from pmEGFP
Reaction component
lOx PCR buffer lx
MgCl2 2 mM
dNTPs 200 pM
Forward primer 0.5 pM
Reverse primer 0.5 pM
Taq DNA polymerase 6 U
pmEGFP DNA 1 ng
Total volume 300 pi
Temperature Time Cycles
95 °C 5 min
95 °C 1 min
3 Oxc* 00 o O 30 s
72 °C 1 min
72 °C 5 min
4 °C 00
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Table 2-17 Amplification of EGFP alleles from the genomic DNA of edited clones
Temperature Time Cycles
95 °C 5 min
95 °C 1 min
C/l 00 o O
i i I
1 min 15x
72 °C 1 min
72 °C 5 min
o O 0 0
Reaction component
lOx PCR buffer lx
MgCl2 2.5 mM
dNTPs 200 pM
pEGFP-241 for 0.5 pM
pEGFP-1380rev 0.5 pM
Pfu Turbo DNA polymerase 2 U
Genomic DNA 100 ng
Total volume 300 pi
The reaction was diluted 1:200 and then used as template in a second amplification step.
Temperature Time Cycles
95 °C 5 min
95 °C 1 min
25x58 °C 1 min
72 °C 1 min
72 °C 5 min
4 °C 00
Reaction component
lOx PCR buffer lx
MgCl2 2.5 mM
dNTPs 200 pM
pEGFP-241 for 0.5 pM
pEGFP-1380rev 0.5 pM
Pfu Turbo DNA polymerase 12 U
Diluted PCR product 10 pi
Total volume 300 pi
Table 2-18 Amplification of EGFP alleles from plasmid DNA
Reaction component
lOx PCR buffer lx
MgCl2 2 mM
dNTPs 200 pM
pEGFP-241 for 0.5 pM
pEGFP-1380rev 0.5 pM
Taq DNA polymerase 2 U
Pooled denatured bacteria 2 pi
Total volume 20 pi
Temperature Time Cycles
95 °C 5 min
95 °C 1 min
20x58 °C 1 min
72 °C 1 min
72 °C 5 min
4 °C 00
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2.2.2.4 Restriction endonuclease digestion of DNA
Restriction endonucleases are enzymes purified from bacteria that recognise and cleave 
specific and short nucleotide sequences within double-stranded DNA. Restriction sites 
typically comprise palindromes of 4, 5, 6 or more bp with an axis of rotational 
symmetry. Cleavage by a restriction enzyme produces either cohesive (having either a 
5' or 3' single-stranded protrusion) or blunt-ended (no single-stranded protrusion) 
fragments. Usually, these ends have 5’-phosphate and 3’-hydroxyl ends, although 
exceptions are known. Cohesive fragments can be subsequently ligated to each other if 
their single-stranded protrusions or ‘overhangs’ are compatible. All blunt-ended 
fragments can be ligated to each other.
Restriction endonuclease reactions contain optimal buffer conditions for the specific 
enzyme (varying concentrations of Tris-HCl [pH 7.5], NaCl, dithiothreitol and MgCk), 
100 pg/ml bovine serum albumin (BSA) if required by the enzyme, the target DNA, 
nuclease-free water and the enzyme itself. One unit of enzyme is defined as the amount 
needed to digest 1 pg of X.-DNA per hour, but for optimal use the manufacturer often 
recommends lOx or 20x over-digestion. However, enzymes are supplied in 50% 
glycerol and the concentration of glycerol in the reaction should not exceed 5% as 
higher glycerol concentrations can inhibit enzyme activity or induce “star” activity 
(relaxed specificity). The reagents were mixed and the reaction was incubated at 37 °C 
for an hour or where indicated overnight.
The enzymes used in this study and their required conditions are detailed in Table 2-19. 
When DNA had to be digested with two restriction enzymes, a double digest was 
performed and the buffer that resulted in the most activity for both enzymes was 
selected. For Southern blot, samples were digested with the amounts of enzyme 
recommended by the manufacturer, taking into account the suggested over-digestion. 
Total digestion volumes were adjusted with H2O to keep glycerol concentrations below 
5%. Reactions were incubated overnight at 37 °C with 5% (v/v) enzyme and another 5% 
was added for 2 h in the morning. Reactions were stopped by heat inactivation for 20 
min at 65 °C.
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Table 2-19 Restriction endonuclease cleavage sites and reaction conditions
Restriction enzyme Cleavage site Reaction conditions for optimal activity
Haell (20 U/pl) R GCGC/Y* 
Y/CGCG R
NEBuffer 4 at 37 °C, + BSA; lOx over­
digestion
Ndel (20 U/pl) CA/TA TG 
GT AT/AC
NEBuffer 4 (or Buffer 2) at 37 °C; 20x 
over-digestion
Mfel (10 U/pl) C/AATT G 
G TTAA/C
NEBuffer 4 at 37 °C; 20x over-digestion
Dral (20 U/pl) TTT/AAA
AAA/TTT
NEBuffer 4 at 37 °C; 20x over-digestion
Xbal (20 U/pl) T/CTAG A 
A GATC/T
NEBuffer 2 at 37 °C, + BSA; 20x over­
digestion
*R = A or G; Y = C or T
2.2.2.5 Polymerase chain reaction restriction fragment length polymorphism
Polymerase chain reaction restriction fragment length polymorphism (PCR-RFLP) 
analysis was employed in this study to detect point mutations introduced by 
oligonucleotide-mediated gene editing The nucleotide alterations destroy the Haell 
restriction site previously present in the wild-type sequence and thus result in the 
presence of undigested DNA fragments which can be visualized with gel 
electrophoresis.
PCR products gained as explained in section 2.2.2.3 were digested with 5% (v/v) of 
restriction endonuclease Haell as described above. Reactions were incubated overnight 
at 37 °C and another 5% (v/v) of enzyme was added for 2 h in the morning. Results are 
representative of at least two independent experiments, each analyzed at least twice to 
ensure that PCR-RFLP bands did not arise from contamination during PCR.
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2.2.2.6 Concentrating DNA samples
The large sample volumes resulting from digestion of genomic DNA for Southern Blot 
had to be concentrated in order to fit into the wells of the agarose gel. This was 
accomplished by pipetting the samples into Microcon YM-100 centrifugal filter units 
seated in 1.5 ml microfuge tubes followed by centrifugation for 30-45 min at 500 g. 
When the sample volumes were reduced to approximately 30 pi, the filter units were 
placed upside down in new tubes and centrifuged for 3 min at 1000 g to recover the 
concentrated samples.
2.2.2.7 Agarose gel electrophoresis
Generally, PCR products or restriction endonuclease digests were analysed using TBE- 
buffered agarose (1%) gel electrophoresis to facilitate quick resolution of 500 bp-3 kb 
fragments. Double-stranded DNA molecules migrate through the gel matrix from the 
cathode to the anode and separate according to their electrophoretic mobility which is 
inversely proportional to the logio of the number of base pairs. The length of the DNA 
molecules can be ascertained by comparison to molecular weight standards of known 
molecule sizes.
The percentage of agarose in gels may be adjusted to accommodate optimal resolution 
of fragments larger than 10 kb (0.5%) or smaller than 400 bp (2%). Ethidium bromide, 
when added to the gel, intercalates between adjacent base pairs of DNA and allows 
visualisation of distinct DNA bands when viewed under ultraviolet (UV) light.
A minigel electrophoresis apparatus was set up as recommended by the manufacturer. 
For a 1% agarose gel, 0.5 g o f agarose was dissolved in 50 ml of lx  TBE buffer by 
heating in a microwave. Ethidium bromide was added at a concentration of 0.5 pg/ml, 
the gel solution was poured into the gel cassette and a comb with the required number 
and size of wells was added. When the gel had set, the comb was removed and a 
sufficient volume of lx  TBE buffer was added to cover the surface of the gel. The DNA 
samples were mixed 9:1 with lOx Bluejuice Gel Loading Buffer and 10-20 pi of 
sample, or 1 pg DNA ladder, were loaded per well. Gels were run at 15 V/cm until the 
bromophenol blue front had migrated a sufficient distance and visualised on a UV trans­
illuminator connected to a computer-operated camera with image analysis software.
86
MetaPhor high resolution agarose was used when DNA fragments of less than 200 bp 
needed to be extracted from the gel. Gels were prepared according to the manufacturer’s 
instructions. For Southern blotting, gels were prepared as described above with lx TAE 
buffer substituted for lx TBE and with an electrical field strength of 3.5 V/cm instead of 
15 V/cm.
2.2.2.8 Polyacrylamide gel electrophoresis
Pre-cast 20% polyacrylamide TBE gels were used for the routine detection of PCR and 
restriction endonuclease digestion products of less than 250 bp as these gels offer 
particularly good resolution of small DNA fragments. Gels were inserted into the XCell 
SureLock Mini-Cell gel electrophoresis apparatus and 200 ml of lx TBE running buffer 
was added to the upper reservoir and 600 ml to the lower. DNA samples were mixed 
with 5x Novex Hi-Density Sample Buffer (final concentration lx) and loaded into the 
respective wells along with an appropriate DNA ladder.
Gels were run at 200 V for 45-90 min depending on the size of the expected bands, 
removed and stained with 0.5 pg/ml ethidium bromide for 10 min on a shaker. DNA 
bands were visualised on a UV transilluminator connected to a computer-operated 
camera with image analysis software.
2.22.9 Extraction and purification of DNA from gels or enzymatic reactions
The QIAquick Gel Extraction Kit was used for the purification of DNA from agarose 
gel or directly from a PCR and restriction enzyme digest reaction. Gels intended for 
extraction of DNA bands were poured and run without ethidium bromide. Bands were 
cut out with a scalpel after a short incubation in ethidium bromide solution and exposure 
to UV light was kept to a minimum to avoid DNA degradation.
The gel pieces were weighed, buffer QG was added to the gel slice at a ratio of 3:1 (e.g. 
300 pi QG to 100 mg gel) and the mixture placed at 50 °C to dissolve the gel. The 
buffer contains the high concentration of chaotropic salt necessary for binding of DNA 
to a silica-membrane and also a pH indicator as binding only occurs below pH 7.5. One 
gel volume of room temperature isopropanol was then added to the solution. If DNA 
was purified directly from a PCR or restriction enzyme digest, an additional 3 volumes 
of QG solution and 1 volume of isopropanol were added to the reaction mix.
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The solution was then transferred to a QIAquick spin column and centrifuged at 16,000 
g  for 1 min to allow binding of DNA to the silica-membrane. The flow-through was 
discarded and the column was washed with 0.75 ml of buffer PE to remove excess salt. 
The supernatant was removed and the column was centrifuged for an additional 2 min to 
remove any remaining traces of ethanol. The DNA was eluted with 30 pi 10 mM Tris- 
HC1, [pH 8.5].
2.2.2.10 Southern Blot (alkaline transfer)
Genomic DNA was extracted from cells as in section 2.2.2.1, quantified using a 
Nanodrop ND-1000 (section 2.2.2.2) and double digested with the restriction 
endonucleases Ndel and Mfel, Ndel and Dral, or Ndel and Xbal (section 2.2.2.4). The 
endonuclease digestion reactions were concentrated with Microcon YM-100 centrifugal 
filter units (section 2.2.2.6) and 15 pg per lane, as well as 2 pg of 100 bp DNA ladder, 
were loaded onto a 1.5% TAE-agarose gel. Gels were prepared and run as described in 
section 22.2.1  and photographed on the UV-transilluminator together with a fluorescent 
ruler. The ruler was necessary to establish the size of bands on the blot in comparison 
with the size o f marker bands on the gel.
Extraneous parts of the gel were removed with a scalpel and the DNA on the gel was 
prepared for transfer by denaturation in alkaline transfer buffer with gentle agitation for 
2x 15 min. As the expected fragment sizes were well under 10 kb depurination was 
deemed unnecessary. During the denaturation step the blotting apparatus for capillary 
transfer o f the DNA to Hybond XL, a positively charged nylon membrane, was set up as 
detailed in Figure 2-2 with alkaline transfer buffer in the reservoir.
Air bubbles were avoided by gently rolling a sterile 5 ml pipette over each layer. 
Alkaline transfer was chosen because of increased sensitivity and because the 
membrane does not require baking or UV-crosslinking for DNA fixation. After 
overnight transfer, the apparatus was carefully taken apart and the position of wells, 
comers and DNA side was labelled with a pencil on the membrane. The membrane was 
then soaked in 2x SSC for 15 min and pre-hybridised in Rapid-hybridization buffer (100 
pl/cm2) at 65 °C for 30 min in a rotational hybridization oven.
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Figure 2-2 Blotting apparatus for Southern blot
Figure from the Open University, Milton Keynes, UK
Southern blot probes were prepared by PCR with primer pairs pEGFP-24 lfor/pEGFP- 
754rev (Probe A) and pEGFP-844for/pEGFP-1380rev (Probe B) from pmEGFP 
plasmid (section 2.2.2.3) and purified as described in section 2.2.2.9. For each blot 50 
ng of probe was diluted in 45 pi of nuclease-free water. The sample was denatured for 2 
min at 100 °C, placed on ice for another 2 min and spun down.
Behind a p-radiation shield, the sample was added to a tube containing a Ready-to-go 
DNA random-prime labelling bead and 5 pi [a-32P] dCTP (3000 Ci/mmol). The reaction 
was incubated 30 min at 37 °C and then stopped by the addition of 5 pi 0.2 M EDTA 
[pH 8.0]. Unincorporated nucleotides were removed by centrifugation through an 
Illustra ProbeQuant G-50 size exclusion microcolumn.
The probe was denatured again, as described above, and added to the pre-hybridization 
solution. After 2 h hybridization at 65 °C, unbound probe was removed by washing in 
SB wash buffer I at room temperature followed by two washes in SB wash buffer II at 
65 °C. Pre-flashed Kodak Biomax-MS film was exposed to the membrane for 2 - 24 h at 
-70 °C. The size of bands on the blot was established by determining the distance 
marker bands had migrated from the wells on the photographed gel with the help of the 
fluorescent ruler.
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2.2.2.11 Recovery of EGFP alleles from gene-edited clones
Addition o f  3 '-A overhangs to PCR product (A-tailing)
Because the proofreading Pfu Turbo polymerase was used in the PCR amplifying the 
EGFP sequence from the genomic DNA of gene-edited clones, products lacked 3’-A 
overhangs ordinarily added by Taq polymerase. As these products were to be ligated 
into the T-tailed plasmid vector pGEM-T Easy, such overhangs had to be added. This 
can be achieved by a short incubation with dATP and Taq polymerase. To avoid 
interference by the Pfu Turbo 3’-5’ exonuclease activity, samples were purified as 
described in section 2.2.2.9. The A-tailing reaction was made up as detailed in Table
2-20 and incubated 30 min at 37 °C. As an unspecific band was visible on a test agarose 
gel, samples were then purified as described in section 2.2.2.9.
Table 2-20 Components o f the A-tailing reaction
PCR product 1350 pg
Taq DNA polymerase 25 U
PCR buffer lx
dATP 200 pM
MgCl2 1.5 mM
Total volume 50 pi
Ligation
To insert a desired stretch of DNA or PCR product into a vector, ATP-dependent 
formation of a phosphodiester bond between the 3’hydroxyl end of a double-stranded 
DNA fragment and the 5’phosphate end of the same or another DNA fragment is 
necessary. This reaction is catalyzed by T4 DNA ligase and can take place between 
fragments that possess complementary cohesive ends or blunt ends to produce circular 
recombinant molecules.
A molar ratio of 3:1 (insertivector) is recommended for ligation of DNA fragments with 
complementary cohesive ends such as T-tailed vector and A-tailed PCR product. The 
following equation was used to determine the required amount of plasmid and insert for 
given fragment sizes:
(ng o f vectorx kb size o f insert/kb size o f vector) x molar ratio (insert .vector) = ng o f insert
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Figure 2-3 Vector map of pGEM-T Easy
The pGEM-T Easy vector is 3015 bp (Figure 2-3) and the EGFP PCR product 1139 bp 
long. Thus, 50 ng EGFP PCR product and 50 ng pGEM-T Easy have a 3:1 molar ratio. 
The reaction components detailed in Table 2-21 were mixed and incubated overnight at 
room temperature. A control reaction mix containing every component apart from the 
insert DNA was also prepared to assess the background level of re-circularised plasmid.
Table 2-21 Components o f the ligation
PCR product 50 ng
pGEM-T Easy vector 50 ng
Rapid ligation buffer lx
T4 DNA Ligase 1.5 mM
Total volume 10 pi
Transformation o f  plasmid DNA into competent E. coli
After ligating the DNA of interest into a vector, the resulting plasmid is inserted into 
competent bacterial cells for easy amplification. Typically, competent bacteria are made 
permeable to DNA by incubation in ice-cold CaCE solution and are kept frozen at -80 
°C as they are extremely fragile in this state. Thus, the DH5a chemically competent 
E.coli were thawed on ice and 5 pi of the ligation reaction were gently added to 100 pi 
of bacteria.
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After incubation on ice for 30 min to permit diffusion of the plasmid into the cells, 
samples were heat-shocked for 90 sec in a 42 °C water bath to reverse the 
permeabilization. The reactions were placed on ice for 2 min, then 900 pi S.O.C 
medium was added and samples were incubated for 1 h at 37 °C in a shaking incubator 
to allow time for expression of the antibiotic resistant gene encoded by the plasmid.
Usually, 50 pi o f the transformation mix is then spread onto LB agar plates containing 
100 pg/ml ampicillin. The ampicillin exerts selection pressure, so only bacteria that 
contain vectors carrying an ampicillin resistance gene survive. However, self-ligated 
vectors also contain a functional ampicillin resistance gene. To distinguish further 
between plasmids carrying the intended insert or self-ligated vectors, a- 
complementation, also known as blue/white screening, was employed.
a-Complementation (blue/white screening)
The pGEM-T Easy vector contains a multiple cloning region within the a-peptide 
coding region for the enzyme p-galactosidase (LacZ gene). Inactivation of the a-peptide 
by the insert leads to formation of non-functional P-galactosidase enzyme. Thus, vectors 
without an insert express functional enzyme that converts substrates such as X-gal to a 
blue coloured product, whereas vectors with inserts express non-functional enzyme that 
cannot convert X-gal.
Here, 40 pi of X-gal (20 mg/ml) and 6  pi of IPTG (100 mM) were added directly to pre­
made LB agar plates supplemented with 100 pg/ml ampicillin and spread over the entire 
surface. The plates were then incubated 30 min at 37 °C for the solution to be absorbed. 
Then the plates were inoculated with the transformed bacteria and placed in the 37 °C 
incubator overnight.
PCR screening
Single white colonies were used to inoculate the wells of a 96-well plate containing 100 
pi LB medium supplemented with 100 pg/ml ampicillin. The plate was covered with a 
plastic film and incubated overnight. The next morning, 1 pi of cultures in the same row 
or column were pooled and diluted in 1 0 0  pi H2O.
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After heat denaturation for 10 min at 95 °C, the EGFP alleles contained in each colony 
were amplified by PCR with primers pEGFP-241for and pEGFP-1380rev (section
2.2.2.3). PCR products were digested with Ndel (section 2.2.2.4) and examined by 
electrophoresis. Correlation of positive row samples with positive column samples 
identified bacterial colonies carrying the edited EGFP allele (edEGFP).
Extraction and purification ofplasmid DNA
DNA purification with the QIAquick spin miniprep kit is based on alkaline lysis of 
bacterial cells and subsequent binding of DNA to a silica membrane under high salt 
conditions. Colonies carrying the edEGFP or control mEGFP alleles were streaked out 
on LB agar plates supplemented with 100 pg/ml ampicillin and incubated overnight at 
37 °C. Single colonies from each bacterial clone were picked and used to inoculate 5 ml 
LB medium containing 100 pg/ml ampicillin.
Cultures were grown overnight, but no more than 12-16 hours to prevent ampicillin 
depletion (hydrolysis) in the culture. Bacteria were pelleted by 10 min centrifugation at 
5,000 g  and resuspended in 250 pi ice-cold Buffer PI containing RNase A. Samples 
were mixed vigorously until no cell clumps were visible and 250 pi Buffer P2 was 
added to denature proteins and to solubilize the phospholipids in the cell membrane. 
The tubes were inverted gently and incubated for exactly 5 min.
Chromosomal DNA and cell debris were precipitated with 350 pi Buffer N3, which also 
stops the lysis and adjusts the salt conditions. The solution was mixed thoroughly and 
centrifuged 1 0  min at 16,000 g  before the supernatants were loaded onto the supplied 
spin columns. Columns were centrifuged for 30 sec and washed with 750 pi of Buffer 
PE. The flow-through was discarded and the columns were centrifuged for an additional 
1 min to remove residual ethanol. Plasmid DNA was eluted with 50 pi 10 mM Tris- 
HC1, [pH 8.5].
2.2.2.12 Sequencing
Analysis of samples was carried out by the UCL Wolfson Institute for Biomedical 
Research sequencing service using a Beckman Coulter CEQ 8000 sequencer.
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2.3 Picture editing
Gel images, scanned X-Ray films and microscope pictures were edited with Adobe 
Photoshop CS2. Typically, images were cropped to show only the area of interest and 
levels were adjusted equally across the whole image to optimize contrast between bands 
and background. No bands were added or removed.
2.4 Statistical analysis
Statistical analysis was performed using GraphPad Prism 5. One-way ANOVA was 
chosen when comparing more than two values, as it is more accurate than Student’s t- 
test for multiple comparisons. Values in text, tables and figures were expressed as the 
mean±standard deviation (SD) and reflected either duplicates, triplicates or two 
independent experiments each with triplicates as stated in the text.
Repeat experiments were compared to each other using two-way ANOVA and if 
significant difference was found, both experiments were normalized to account for 
experimental variation by setting the highest gene editing efficiency to 100%. The 
resulting values were then analysed by one-way ANOVA. Two-way ANOVA was also 
used to analyse samples differing in two independent conditions, such as time to 
measurement and oligonucleotide backbone modification. Bonferroni post-tests were 
included in every ANOVA statistical analysis to determine p  values.
Where stated, data were analysed using contingency tables. This method numerically 
states the results of an experiment in which the outcome is a categorical variable (results 
are grouped into mutually exclusive categories). Fisher’s exact test rather than chi- 
square test was applied to each contingency table to determine P  values as it gives the 
exact value.
Generally, a P<0.05 was considered to be significant. For easy visualization, P  values 
are expressed as * (P<0.05), ** (P<0.01) and *** (PO.OOl) in Tables and Figures.
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CHAPTER 3: EVALUATION OF 
APOA-I GENE EDITING WITH 
PCR-RFLP
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INTRODUCTION
As I discussed in the general introduction, ApoA-lM is more atheroprotective than 
ApoA-I and gene therapy would be more cost efficient than administering recombinant 
ApoA-IM/POPC complexes as a treatment. I also examined the advantages and 
disadvantages o f the different types of gene therapy and argued that gene editing would 
be the ideal solution in this case, if problems with reproducibility of chimeraplast- 
mediated gene editing could be solved. Indeed, previous experiments in this laboratory 
demonstrated low and inconsistent levels of ApoA-I to ApoA-lM gene conversion with 
chimeraplasts in HepG2 cells .237 However, recent reports have shown that the DNA and 
not the RNA strand of chimeraplasts is the active domain which mediates gene 
editing, 239’240 suggesting that consistent and repeatable conversions might be achieved if 
single-stranded oligonucleotides (ssODNs) were used instead of chimeraplasts.
Closely following the conditions described in Manzano et a lP 1 I evaluated the ability 
of ssODNs to induce the ApoA-I to ApoA-IM mutation in recombinant CHO-AI (see 
section 2.1.1.1) and HepG2 cells. Unfortunately, in my hands the primers used by 
Manzano et a lP 1 caused unspecific bands that interfered with the analysis of the 
polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). 
Therefore, I designed new primers and optimised PCR conditions to avoid unspecific 
bands.
Using the newly optimised PCR-RFLP and sequencing of diagnostic bands I showed 
that oligonucleotide-mediated gene editing induces at least a temporary change in the 
genomic DNA of targeted CHO-AI and HepG2 cells. I further excluded the possibility 
that PCR-based artefacts gave rise to the diagnostic bands by various spiking 
experiments.
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3.1 Optimisation of PCR-RFLP analysis for the detection of ApoA-I 
to ApoA-IM gene conversion by ssODNs
3.1.1 Results
CHO-AI cells expressing human ApoA-I were transfected with 6  or 12 pg of huApoA- 
Im-49T-PTO and huApoA-lM-49NT-PTO oligonucleotide using LPEI as described in 
Section (2.2.1.4). Cells were harvested 24 h after transfection, genomic DNA was 
extracted and samples were analysed using PCR-RFLP.
Figure 3-1 explains the ApoA-I/ApoA-IM PCR-RFLP in more detail. The 2385 bp 
genomic DNA of ApoA-I consists of four exons, which encode an 893 bp coding 
sequence generating a 243 amino acid long protein. PCR utilizing the primers AI2F and 
AMR amplifies a 216 bp product from the ApoA-I coding sequence which has two 
Haell restriction endonuclease recognition sites (5’-RGCGC/Y-3’). Digestion with 
Haell yields three fragments of 166 bp, 41 bp and 9 bp length.
If the amplified PCR product has the C to T mutation associated with the ApoA-lM 
genotype, the first of these Haell recognition sites is changed to 5’-RGCGT/Y-3’ and 
consequently cannot be cut by the enzyme; this results in fragments of 207 bp and 9 bp. 
However the 207 bp band could also arise from incomplete digestion and it is therefore 
important to have a pure ApoA-I sample (i.e. mock-transfected CHO-AI cells) as a 
digestion control and to sequence this band before successful conversion can be 
claimed. The Milano mutation changes an amino acid from Arginine (R) to Cysteine 
(C) at position 173, so this particular PCR-RFLP is called R173C PCR-RFLP.
In this experiment the 216 bp PCR fragment was amplified with the primers AI2F and 
AMR (as described in Manzano et a lP 7) and an annealing temperature of 65 °C.
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Figure 3-1 Schematic o f R173C PCR-RFLP
The ApoA-I gene is represented above with boxes for its four exons. The primers AI2F and AMR 
amplify a 216 bp product, which yields Haell digestion fragments o f 166, 41 and 9 bp for wild- 
type ApoA-I or 207 and 9 bp for ApoA-IM.
Figure 3-2a shows that the resulting PCR product was 216 bp, exactly as expected from 
the position o f the primer binding sites in the sequence (see Figure 3-3). The PCR 
products were then digested with the restriction endonuclease Haell as described in 
Section (2.2.2.4) and the resulting fragments were resolved on a 20% TBE gel (Figure 
3-2b)
The expected bands at 166 bp and 41 bp signifying the presence o f the ApoA-I 
sequence in the genomic DNA were present in all samples except AIM and were easily 
identifiable. Identification o f the 207 bp band was complicated by a strong unspecific 
band in close proximity, which was estimated to be -195  bp. The 207 bp band denoting 
the presence o f the Milano mutation could be seen in all samples except the mock- 
transfected cells and therefore this band was most likely not due to incomplete 
digestion. Thus, it seemed that successfully converted cells were present in the treated 
cells from which the genomic DNA samples were extracted.
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Figure 3-2 R173C PCR-RFLP with primers AI2F and AMR
a) PCR product from genomic DNA of treated CHO-AI cells resolved on a 1% agarose gel. L: 100 
bp ladder. Ctr: mock-transfected CHO-AI cells. Lanes 1-4: Cells transfected with 6 pg, 12 pg 
huApoA-Im-49T-PTO, 6 pg, 12 pg huApoA-IM-49NT-PTO. AIM: pcDNA3.1-ApoA-IM.
b) 20% TBE gel resolving the Haell restriction fragments. Ctr: mock-transfected CHO-AI cells. 
Lanes 1-4: Cells transfected with 6 pg, 12 pg huApoA-IM-49T-PTO, 6 pg, 12 pg huApoA-IM- 
49NT-PTO; AIM: pcDNA3.1-ApoA-IM. L: 25 bp ladder. An asterisk marks the diagnostic 207 bp 
band in lanes 4 and AIM.
However, the presence o f the unspecific bands cast doubt on the data obtained in this 
PCR-RFLP. To obtain clear results the unspecific bands had to be eliminated. An 
investigation into the causes o f the unspecific bands revealed that both the AI2F and 
AMR primer form self-annealing dimers with a AG = -11 kcal/mol as well as duplexes 
with a AG = -5 kcal/mol. Furthermore, their melting temperatures were elevated at 79°C 
due to a G/C content o f 83% (section 2.1.2.4).
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To achieve greater PCR amplification specificity new primers were designed to be used 
instead of AI2F and AMR and also as primer sets in a nested PCR. Primers had to fulfil 
the standard primer design rules (see section 2.2.2.3) and ensuing PCR and Haell 
digestion products had to result in distinct gel bands.
Potential mispriming on the hamster ApoA-I sequence was also taken into account. The 
ApoA-I genomic sequence of Cricetulus griseus (Chinese Hamster) from which CHO 
cells were derived was not available in databases. Hence, the sequence of the close 
relative Mesocricetus auratus (Syrian Hamster) was substituted in a comparison with H. 
sapiens (Figure 3-3) to assess the potential cross-species mispriming of selected primer 
sequences.
Primers were chosen with the help of the primer3 design program285 and were screened 
against the human and rodent mispriming libraries available in this program. Table 3-1 
summarizes possible combinations of PCR primers and resulting Haell digestion 
products. Combinations including the primer ApoAIinnerR were disregarded as this 
primer’s binding site overlaps with the target sequence of the correcting ssODN and 
therefore could lead to mispriming events during the PCR.
Primers ApoAIouterF2 and ApoAIouterR were selected to avoid inter-species 
mispriming; however, the Haell digestion bands distinguishing ApoA-I from ApoA-lM, 
205 and 246 bp respectively would be difficult to separate on either agarose or TBE 
gels. On agarose gels, these fragment sizes are at the lower detection limit and a high 
amount of fragment would be required for visualisation; whereas on TBE gels the 
fragment sizes are at the upper detection limit and gels would need to be run for 
extended times to get good resolution, causing smears, distortions and brittleness in the 
gels.
Therefore, the ApoAIouterF2 and ApoAIouterR primers were intended as outer primer 
set in nested PCRs only. ApoAIinnerF and ApoAIinnerR2 were selected as inner 
primers for nested PCRs, because the expected Haell restriction fragment sizes would 
be easily resolved on TBE gels.
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Figure 3-3 ApoA-I sequence comparison between H. sapiens and M. auratus
Blue background: Sequence differences between species. Black background: Site of Milano 
mutation C—►T. Grey background: binding site o f the editing oligonucleotide. Red boxes: Haell 
restriction endonuclease recognition sites. Blue boxes: AI2F and AMR primer binding sites; 
Green: ApoAIinnerR and ApoAIinnerF; Purple: ApoAIouterF2 and ApoAIinnerR2; Brown: 
ApoAIouterF and ApoAIouterR.
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Forward primer Reverse primer PCRproduct
Haell digest 
ApoA-I
Haell digest 
ApoA-lM
ApoAIouterF ApoAIouterR 444 273,41,130 314,130
ApoAIouterF ApoAIinnerR2 342 273,41,28 314,28
ApoAIouterF ApoAIinnerR 310 273,41 314
ApoAIouterF2 ApoAIouterR 376 205,41,130 246,130
ApoAIouterF2 ApoAIinnerR2 274 205,41,28 246,28
ApoAIouterF2 ApoAIinnerR 246 205,41 246
ApoAIinnerF ApoAIouterR 277 106,41,130 147,130
ApoAIinnerF ApoAIinnerR2 175 106,41,28 147,28
ApoAIinnerF ApoAIinnerR 143 106,41 147
Table 3-1 Possible combinations of ApoA-I PCR primers
Selected primer pairs in bold; primer pairs including ApoAIinnerR are in grey.
Temperature gradient PCRs (Figure 3-4) were utilised to optimise the annealing 
temperature for both primer sets. The annealing temperatures ranged from 55-68 °C, 
more specifically, from left to right 55/56/57.5/59.8/63.1/65.5/67.1/68 °C. The PCR 
product (annealing temperature 65.5 °C) indicated with an arrow (Figure 3-4a) was 
diluted 1:100 and 2 pi of this dilution was used as template for each 20 pi PCR reaction 
in the second temperature gradient using the ApoAIinnerF and ApoAIinnerR2 primers 
(Figure 3-4b).
As demonstrated in Figure 3-4a an unspecific band was present even when annealing 
temperatures higher than the calculated Tm of the primer set were used (see section
2.1.2.4). Notably, a band at around -210 bp is present in equal measure in all samples of 
the second gradient PCR (Figure 3-4b).
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Figure 3-4 Temperature gradient PCRs with new primers
a) Primers ApoAIouterF2 and ApoAIouterR. Annealing temperature 55-68 °C from left to right. 
Template was genomic DNA from mock-transfected CHO-AI cells. The arrow indicates the 
sample used as template in the second temperature gradient PCR which is shown in b).
b) Second temperature gradient PCR with primers ApoAIinnerF and ApoAIinnerR2. Annealing 
temperature 55-68 °C from left to right. An unspecific band of around 210 bp is present in all 
samples.
To determine if  this ~210 bp unspecific band arose from the faint unspecific band at 
around 440 bp which can be seen in the sample indicated with an arrow (Figure 3-4a), a 
temperature gradient PCR using the primers ApoAIinnerF and ApoAIinnerR2 for 
amplification directly from the genomic sequence was carried out. This PCR yielded 
bands similar to those seen in Figure 3-4b but the 210 bp unspecific band was less 
prominent (data not shown). Therefore, further experiments utilized the primers 
ApoAIinnerF and ApoAIinnerR2 for amplification directly from genomic DNA.
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The -210 bp unspecific band could be seen in all PCR products using this primer set, 
irrespective of amplification from CHO-AI or HepG2 cells (Figure 3-1 la). Attempts to 
sequence the unspecific band with either the ApoAIinnerF or ApoAIinnerR2 primer 
generated no detectable sequence trace. As the unspecific band did not result in visible 
bands after Haell digestion it was ignored in further investigations.
3.1.2 Discussion
The experiments described in this chapter were undertaken to determine if ssODNs 
were active in targeted gene editing of the ApoA-I gene when chimeraplasts were 
inactive. Experimental conditions described in Manzano et a lP 1 were followed closely 
and the same primer sequences were used for this PCR-RFLP analysis.
However, as demonstrated in Figure 3-2, the primers AI2F and AMR proved unsuitable 
for the evaluation of ssODN gene targeting activity, as several unspecific bands could 
be seen after the restriction endonuclease digest. In particular, two equally strong bands 
close together with sizes around 2 0 0  bp made it difficult to identify which of them was 
the expected 207 bp band. Careful comparison with the 207 bp band in the AIM control 
sample strongly suggested that the upper of these two bands was equivalent to 207 bp. 
The lower band was estimated to be around 195 bp.
False identification of these bands would completely change the outcome of the 
experiment, as the lower band was still present in the digestion control sample as well 
as the treated samples. If the lower band was the correct 207 bp band then the bands in 
the treated samples would be due to incomplete digest and would not indicate successful 
gene targeting. Thus the presence of these unspecific bands cast doubt on the data 
obtained in this PCR-RFLP. To obtain clear results the unspecific bands had to be 
eliminated.
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It is unclear why these unspecific bands were present on this analytic gel but not the 
gels shown by Manzano et a l231 even though the conditions and reagents reflected the 
published ones. A possible explanation is the use of different Taq polymerases, which 
could influence enzyme-DNA affinity or mispriming. Another possibility is the 
percentage of DMSO in the PCR mixture. Based on personal experience, I added 5% 
DMSO to the PCR in this analysis to help with the strand separation of genomic DNA 
during the denaturing step. Different PCR machines or PCR tubes may also have 
influenced the PCR conditions.
The biggest problem however seemed to be the primers itself. A check of the AI2F and 
AMR primers revealed that both primers form self-annealing dimers and duplexes and 
have melting temperatures of 79 °C. I reasoned that the selection of better primers was 
the quickest way of eliminating unspecific bands from PCR-RFLP analytic gels. 
Choosing the right primer sets and set combinations proved rather difficult as I had to 
take a number of different requirements into account. Following standard primer design 
rules, such as similar melting temperatures and no primer dimer or duplex formation, 
were less of a problem, but it proved difficult to find primers with only -50%  G/C 
content. The 500 bp sequence stretch surrounding the Haell site of interest has an 
average G/C content o f 67% and this severely limited the choice of primers.
A further limiting factor was the sequence homology between H. sapiens and M. 
auratus. Primers specific for the human sequence should ideally have at least 3 
mismatches with the hamster sequence, preferably as close to the 3’ end as possible. 
Primer sequences were also screened against the human and rodent mispriming libraries 
in primer3, again reducing the number o f possible primers. Furthermore, Haell 
digestion fragment sizes for ApoA-I and ApoA-lM had to be easily distinguishable on 
either agarose or TBE gels.
Fulfilling all requirements seemed impossible with only one primer set, so a nested PCR 
with outer and inner primers sets was designed. However, experimental data showed 
that a PCR with the inner primer set alone resulted in clean Haell digestion bands, so all 
further analysis was done in this way.
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The remaining -210 bp unspecific band that was seen in the PCR product but not after 
Haell digestion could not be identified. It could not have been due to mispriming on the 
hamster sequence, as it was also present in PCRs using genomic DNA from the human 
HepG2 cell line as template. I considered possible amplification of an apolipoprotein 
family member as an explanation since this family of genes is closely related, but the 
mispriming function in primer3 was supposed to exclude this. In the end, this unspecific 
band did not interfere with evaluation of the PCR-RFLP, so I deemed further 
investigation into the causes of this band unnecessary.
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3.2 Conversion of ApoA-I to ApoA-IM in CHO-AI cells and 
persistence of gene edited cells in the population
3.2.1 Results
CHO-AI cells expressing human ApoA-I were transfected with 6 or 12 pg of huApoA- 
Im-49T-PTO and huApoA-lM-49NT-PTO oligonucleotide using LPEI. Cells were 
trypsinised 24 h after transfection and one-third of the cells were re-plated while 
genomic DNA was extracted from the other two-thirds. Samples were analysed by a 
R173C PCR-RFLP assay using the primers ApoAIinnerF and ApoAIinnerR2 and 68 °C 
annealing temperature (Figure 3-5).
The predicted bands at 106 and 41 bp demonstrating the presence of the ApoA-I wild- 
type sequence were present in all samples except the AIM control (Figure 3-5). The 147 
bp band denoting the presence of the Milano mutation was strongly visible in lanes 3, 4 
and AIM, but barely detectable in the mock-transfected control sample (Ctr). Therefore, 
it was assumed that all samples were completely digested and that the 147 bp bands still 
visible were not due to incomplete digestion. Thus, targeted gene conversion was seen 
in cells transfected with 6 pg of huApoA-lM-49NT-PTO although it seemed to be less 
pronounced in cells treated with 12 pg of the same ssODN. Cells transfected with 
huApoA-lM-49T-PTO did not show conversion, as the extremely faint 147 bp band was 
less detectable than the Ctr sample. Results were consistent in two independent 
experiments and three separate PCR-RFLP analyses.
To establish the persistence of the introduced nucleotide change, samples for genomic 
DNA extraction were taken at every passage (days 1, 4, 7 and 11). The level of 
conversion diminished during passage 1-3, but was still evident in passage 4 (Figure
3-6).
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Figure 3-5 R173C PCR-RFLP with new primers
a) The ApoA-I gene is represented above with boxes for its four exons. The primers ApoAIinnerF 
and ApoAIinnerR2 amplify a 175 bp product, which yields Haell digestion fragments of 106, 41 
and 28 bp for wild-type ApoA-I or 147 and 28 bp for ApoA-IM.
b) 20% TBE gel resolving the Haell digestion fragments. Ctr: mock-transfected CHO-AI cells. 
Lanes 1-4: Cells transfected with 6 pg, 12 pg huApoA-IM-49T-PTO, 6 pg, 12 pg huApoA-IM- 
49NT-PTO; AIM: CHO-AIM cells. L: 25 bp ladder.
For the ApoA-IM sequence positive control, genomic DNA was extracted directly from defrosted 
CHO-AIM cells without growing the cells in culture. Thus, any potential contamination of CHO- 
AI with CHO-AIM cells was avoided.
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Figure 3-6 R173C PCR-RFLP for cells treated with huApoA-lM-49NT-PTO
Ctr: mock-transfected CHO-AI cells. Lanes 1-4: Cells transfected with 6 pg huApoA-IM-49NT- 
PTO, 1st, 2nd, 3rd and 4th passage. AIM: CHO-AIM cells. L: 25 bp ladder. The expected bands at 
106 and 41 bp are present in all samples except AIM. The 147 bp band denoting the presence of 
the Milano mutation is present in lanes 1-4 and AIM, but not in the control.
Sequencing was carried out to determine if the 147 bp band in lane 4 of Figure 3-6 was 
indeed due to a true nucleotide change and not incomplete digestion. Genomic DNA 
from mock-transfected CHO-AI cells, cells from the 4th passage after transfection with 6 
pg huApoA-IM-49NT-PTO (same sample as in Figure 3-6 lane 4) and CHO-AIM cells 
was PCR amplified with the primers ApoAIinnerF and ApoAIinnerR2.
The PCR products from 4th passage huApoA-IM-49NT-PTO and CHO-AIM cells were 
digested with Haell and resolved on a 3.5% MetaPhor Agarose gel. The 147 bp band 
was excised, eluted with the QiaQuick Kit and used in sequencing (section 2.2.2.12). 
Sequencing from the mock-transfected cells was performed directly from the PCR 
product. Haell digestion of this PCR product would result in termination of the 
sequence trace at nucleotide 591 in the coding sequence of ApoA-I, only two 
nucleotides downstream of the expected mutation (see Figure 3-3). Therefore, this PCR 
product was not digested with Haell.
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Figure 3-7 Sequencing of PCR-RFLP band
© Mock-transfected cells. © 4th passage huApoA-IM-49NT-PTO cells. (D CHO-AIM cells. The 
nucleotides coding for amino acid Arg173 (CGC; ApoA-I) and Cys173 (TGC; ApoA-IM) are ringed.
Figure 3-7 shows the sequencing traces from nucleotides 585 to 593 for all three 
samples. Genomic DNA from mock-transfected CHO-AI cells codes for CGC at 
nucleotides 589-591 translating into Arginine at amino acid position 173. CHO-AIM 
cells carried a TGC codon instead, which codes for Cysteine. Sequencing of the 147 bp 
band from the 4th passage huApoA-lM-49NT-PTO cells showed a clear C/T double peak 
at nucleotide 589 and therefore established the presence of successfully gene targeted 
cells 11 days after transfection.
3.2.2 Discussion
Using the new primer set ApoAIinnerF and ApoAIinnerR2, gene editing could be 
demonstrated in CHO-AI cells transfected with huApoA-IM-49NT-PTO. Cells 
transfected with the huApoA-IM-49T-PTO ssODN did not show any detectable 
correction, but this was not surprising as strand bias has been described 
previously.183,240 Strand bias seems to predominantly favour ssODNs complementary to 
the non-transcribed strand, possibly because of increased accessibility of this strand 
during transcription.263 Replication orientation of the target gene has also been 
investigated as the possible cause for this phenomenon,251,267 but Sorensen et al.253 
recently reported opposite strand bias for two mutations in the same gene.
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An interesting finding is the apparent lack of dose-response in this experiment. 
Transfection with 6 pg of huApoA-lM-49NT-PTO appears to give a higher correction 
rate than transfection with 12 pg of the same ssODN. However, it is problematic to use 
PCR-RFLP for quantification of gene targeting efficiencies because of variables in the 
PCR reaction, potentially incomplete Haell digestion and difficulties in measuring band 
intensity at saturation. Additionally, the C/T double peak seen in the sequencing trace 
could be caused by incomplete digestion or by formation of heteroduplexes between 
ApoA-I and ApoA-IM strands during PCR. Both possibilities would certainly cause a 
significant overestimation o f gene editing efficiencies. Potentially, detection of the 
diagnostic bands in the experiments presented here would be impossible without this 
phenomenon.
One could speculate that heteroduplex formation would also take place in PCR-RFLP 
analyses based on the creation of restriction sites. These heteroduplex sequences would 
not be cut efficiently by restriction endonucleases and thus low gene editing efficiencies 
would be concealed in the band diagnostic for non-edited cells. On the other hand, 
heteroduplex formation can be avoided by primer excess during the later cycles of PCR, 
which is generally the case in nested PCRs or re-ampliflcation of low cycle reactions. 
Thus, differing PCR conditions could at least in part explain why some laboratories are 
unable to repeat published results.
Nevertheless, the purely qualitative difference stated here is supported by the 
consistency of the results in two experiments and at least two separate PCR-RFLP 
analyses each, which suggests that the difference between the 6 and 12 pg samples was 
not caused by an artefact. Furthermore, the band intensity of the smaller digestion 
fragments in both samples has not reached saturation and can therefore be used for 
comparison. One possible explanation for the lack of dose-response could be 
cytotoxicity caused by the higher concentration of ssODN on the cells and visual 
examination of the cells during the experiment supported this conclusion.
When genomic DNA was extracted from the treated cells at passages 2 and 3, a marked 
reduction in the correction efficiency was observed in comparison to the first passage. 
With such a faint 147 bp band in the 3rd passage sample, it seemed that corrected cells 
had been largely lost from the population by that time. However, when genomic DNA 
was extracted in the 4th passage, the conversion was still evident.
I l l
Originally, this puzzling result was attributed to incomplete digest of the 4th passage 
sample, but when repeated PCR-RFLP analysis resulted in similar band intensities, the 
147 bp from this sample was sequenced. The sequence trace confirmed the presence of 
successfully corrected cells in the population 11 days after transfection. This was 
extremely encouraging, as previous experiments in our lab had shown that corrected 
cells are lost from the population over several passages and attempts to clone out 
corrected cell lines had been unsuccessful.235
I concluded that successful correction had taken place, but that the correction event 
itself somehow had inhibited cell survival and proliferation of the affected cells. Thus 
the normal proliferation of the vast number of non-corrected cells in the population 
simply diluted out the limited number of growth inhibited corrected cells. This 
conclusion is supported by three recently published papers. Olsen et a l242 showed that 
corrected cells accumulated at the G2/M checkpoint and that the majority of these cells 
subsequently succumbed to apoptosis. Only ~5% of corrected cells had divided 24 h 
after transfection, but this percentage rose to 30% when cells were treated with the 
Chkl/Chk2 inhibitor G66976. Chkl and Chk2 are downstream mediators in the 
ATM/ATR DNA damage response pathway and involved in the G2/M cell cycle 
checkpoint regulation.
Ferrara et al.219 confirmed that Chkl and Chk2 were highly activated in corrected cells, 
but not in uncorrected cells, and that corrected cells did not actively replicate their DNA 
24 h after introduction of targeting oligonucleotide. Engstrom et a l2%1 showed that this 
selective arrest was responsible for the observed reduction in correction efficiency over 
time and that replication was reactivated in these cells after several days. She also 
demonstrated that 48 h incubation with 2 mM thymidine after targeting suppressed 
replication in uncorrected cells and that the percentage of corrected cells in the 
population could thus be stabilised for up to 6 days.
In addition, the finding that successfully corrected cells are present in the population 11 
days after treatment provides evidence that the diagnostic bands in the PCR-RFLP 
analysis are not due to PCR artefacts caused by the correcting oligonucleotide as 
previously suggested.218 Phosphorothioate oligonucleotides are protected against 
exonuclease, but not against endonuclease attack, and half-life in the cell nucleus is ~ 24 
h as determined with a fluorescently labelled ssODN (section 4.1).
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3.3 Diagnostic bands in the R173C PCR-RFLP are not due to PCR 
artefacts
3.3.1 Results
It was previously reported that PCR-RFLP could lead to false positive results because
2 14  218the correcting chimeraplast was acting as a template m the PCR reaction. ’ 
Subsequent experiments in our lab did not produce such artefacts when ApoE4-to- 
ApoE3 chimeraplast was spiked into the genomic DNA from ApoE4 expressing CHO 
cells before PCR-RFLP.235 Neither did artefacts arise when the parental cell line CHO- 
K1 was transfected with chimeraplast and extracted genomic DNA mixed with genomic 
DNA from CHO-ApoE4 cells at various ratios. Nevertheless, the set of experiments 
described on the following pages attempted to determine if ssODNs could be the cause 
of such misleading results in the R173C PCR-RFLP.
PCR reactions using genomic DNA from mock-transfected CHO-AI cells as a template 
were spiked with 300 ng, 3 ng and 30 pg of huApoA-lM-49NT-PTO before 
amplification (Figure 3-8a). The amount of 300 ng was determined by dividing the 
maximum amount of ssODN transfected into cells (12 pg) by the volume genomic DNA 
was eluted in (200 pi), multiplied by 5, as 5 pi of genomic DNA were generally used 
per PCR reaction. Thus, 300 ng of ssODN in a PCR reaction should reflect the 
theoretical maximum amount available for mispriming under the conditions used.
This theoretical maximum amount of ssODN should vastly exceed the amount actually 
present, as losses incurred during transfection (non-transfected complexes are washed 
off), cell culture (ssODN will be digested by endonucleases) and purification of 
genomic DNA (fragments of less than 100 bp are not efficiently retained by the 
purification column) were not taken into account.
As shown in Figure 3-8a, a very prominent band at around 100 bp is present in the 300 
ng sample as well as fainter bands at -70  bp, -400 bp and -1 kb. The expected 175 bp 
and the -210 bp unspecific band were present in all three lanes. When these PCR 
products were digested with Haell (Figure 3-8b), a faint 147 bp band was seen in lane 1, 
but not in 2 or 3. In fact, lanes 2 and 3 displayed the typical restriction pattern 
associated with ApoA-I, whereas lane 1 showed a prominent -80  bp band and an 
unusually strong 28 bp band as well as faint -60  bp and -26  bp bands.
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Figure 3-8 R173C PCR-RFLP spiked with huApoA-IM-49NT-PTO before PCR
a) Lane 1-3: 300 ng, 3 ng and 30 pg of huApoA-IM-49NT-PTO were spiked into PCR reactions 
containing 5 pi genomic DNA from mock-transfected CHO-AI cells. PCR products are shown. L: 
25 bp ladder.
b) Lanes 1-3: Haell digestion of samples from a). AIM: CHO-AIM cells. L: 25 bp ladder.
To determine if these unspecific bands seen in lane 1 were due to the presence of such a 
high amount of DNA in the PCR reaction or were indeed caused by the ssODN acting 
as a template, mock-transfected CHO-AI cells were harvested and spiked with 4 pg of 
huApoA-lM-49NT-PTO or huApoA-lM-49T-PTO before genomic DNA extraction. The 
PCR products were as expected (Figure 3-9a) but a faint 147 bp band was present in the 
huApoA-IM-49NT-PTO sample after the Haell digest (Figure 3-9b lane 2).
Another control experiment explored the possibility that PCR artefacts could be caused 
by cleavage products of ssODNs produced during incubation in cells. CHOdhfr' cells, 
from the parental cell line for CHO-AI, were transfected with 4 pg of huApoA-lM- 
49NT-PTO or huApoA-IM-49T-PTO using Lipofectamine 2000. Transfection efficiency 
was controlled with a Cy5-tagged ssODN and determined to be -95% (data not shown). 
Cells were harvested 24 h post transfection and genomic DNA was extracted. For the 
PCR reactions shown in lanes 3-5 of Figure 3-10 the genomic DNA from transfected 
CHOdhfr' was mixed with genomic DNA from mock-transfected CHO-AI cells at 
various ratios (1:3, 1:1 and 3:1).
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Figure 3-9 R173C PCR-RFLP spiked before genomic DNA extraction
a) Lane 1-3: mock-transfected CHO-AI cells, CHO-AI cells spiked with 4 pg huApoA-IM-49NT- 
PTO, CHO-AI cells spiked with 4 pg huApoA-IM-49T-PTO. L: 25 bp ladder.
b) Lanes 1-3: Haell digestion of samples from a). L: 10 bp ladder.
A faint 175 bp PCR product was produced by CHOdhfr' cells transfected with 4 pg 
huApoA-IM-49NT-PTO or huApoA-IM-49T-PTO, but no Haell digestion fragments 
could be detected in these samples. There was a clear reduction in amount of PCR 
product when increasing amounts of CHOdhfr' genomic DNA were mixed with 
decreasing amounts of CHO-AI genomic DNA. The Haell digestion pattern of the 
mixed samples was as expected from ApoA-I DNA, with no evidence of the 147 bp 
band characteristic for ApoA-IM.
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Figure 3-10 R173C PCR-RFLP of treated CHOdhfr cells mixed with CHO-AI cells
a) Lane 1,2:  CHOdhfr' cells transfected with 4 pg huApoA-IM-49NT-PTO or huApoA-IM-49T- 
PTO. Lanes 3-5: CHO**' cells transfected with 4 pg huApoA-IM-49NT-PTO mixed with CHO-AI 
cells at 1:3, 1:1 and 3:1 ratio. L: 25 bp ladder.
b) Lanes 1-5: Haell digestion of samples from a). L: 25 bp ladder.
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3.3.2 Discussion
Control experiments were carried out to determine if ssODNs could cause PCR 
artefacts. When 300 ng of huApoA-IM-49NT-PTO were spiked directly into a PCR 
reaction using genomic DNA from mock-transfected CHO-AI cells, it seemed as if this 
did indeed result in a false-positive 147 bp band after Haell digestion. Strikingly though 
a very strong ~80 bp band and an unusually strong 28 bp band could also be seen. Thus 
the restriction enzyme pattern was distinctly different from the one established 
previously for either ApoA-I or ApoA-lM-
Moreover, when the PCR products of this spiking reaction were resolved on a TBE gel, 
several unspecific bands could be detected. In particular, a very strong -100 bp band 
and a weak ~75 bp were observed. Again, this pattern did not agree with the one 
demonstrated in earlier experiments or by the other samples in the same analysis.
These data suggested that the high amount of ssODN present in the PCR reaction in this 
particular sample did interfere with the normal reaction parameters. Considering that 
300 ng ssODN was equivalent to the theoretical maximum amount present in treated 
cells and that the resulting peculiar PCR products and Haell digestion patterns did not 
appear in any of the experimental PCR-RFLP analyses, it seemed appropriate to use the 
sample spiked with 3 ng ssODN as the proper control. A s the 3 ng PCR reactions did 
not result in a 147 bp band characteristic for ApoA-lM, the possibility of false-positive 
PCR artefacts was rejected.
Nonetheless, a further control experiment was carried out, where mock-transfected 
CHO-AI cells were harvested and spiked with ssODN before genomic DNA extraction. 
When the PCR products were resolved on a 20% TBE gel, the typical banding pattern 
characterized by a strong 176 bp and a -210 bp unspecific band was observed. The 
Haell digestion fragments demonstrated the expected restriction pattern, but a very faint 
147 bp could be seen in the sample spiked with huApoA-lM-49NT-PTO. However, very 
faint -65 bp and 176 bp bands were also present, suggesting incomplete digest even 
after extended Haell digestion.
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Another control experiment explored the possibility that PCR artefacts could be caused 
by cleavage products of ssODNs produced by exo- or endonucleases in the cells. 
Genomic DNA was extracted from CHOdhfr' cells that had been transfected with 
huApoA-lM-49NT-PTO or huApoA-lM-49T-PTO and mixed with genomic DNA from 
mock-transfected CHO-AI cells before a PCR-RFLP analysis was carried out.
A weak 176 bp PCR product could be seen in the CHOdhfr' cells transfected with 
ssODN, even though these cells did not contain the human ApoA-I sequence. This was 
likely due to amplification o f the hamster ApoA-I in lieu of the human sequence. When 
these PCR products were digested with Haell no bands were visible on the analytical 
gel, probably because the amount of digestion fragments derived from such a small 
quantity of PCR product was below the detection limit.
It is unclear if this small amount of cross-species mispriming would also occur in the 
presence of the human ApoA-I sequence. Considering that the CHO-AI cell line has 
multiple copies of the human ApoA-I sequence stably integrated into its genome 
compared to the two hamster alleles, and taking into account the greater sequence 
homology of the primers with the human sequence, this seems unlikely. Even if cross­
species mispriming was not influenced by the presence of the human ApoA-I sequence 
in the PCR reaction, the digestion fragments produced from the misprimed PCR 
products would not interfere with the evaluation of the PCR-RFLP analysis, as 
demonstrated by the lack o f visible bands after Haell digestion.
In the mixed genomic DNA samples a clear dose-response to the presence of CHO-AI 
genomic DNA could be seen: the more CHO-AI genomic DNA in the reaction, the 
more PCR product was produced. There was no evidence of the 147 bp band 
characteristic for ApoA-lM after Haell digestion. Thus, fragments of ssODN produced 
by nuclease digestion in the cells did not cause any PCR artefacts.
In summary, the evidence presented here strongly suggests that the diagnostic bands 
derived in the PCR-RFLP analyses shown in chapter (section 3.2) were not due to 
artefacts.
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3.4 Conversion of ApoA-I to ApoA-IM in HepG2 cells
3.4.1 Results
In addition to the recombinant CHO-AI cells, I targeted the human hepatoblastoma cell 
line HepG2 to study gene editing in a cell line with endogenous ApoA-I expression. 
HepG2 cells were “reverse transfected”, i.e. the transfection complexes were added 
directly after trypsinisation and suspension of cells. This “reverse transfection” was 
particularly successful for HepG2 cells as this cell line tends to grow in cell clumps 
rather than a monolayer and prefers tight cell to cell contact. Therefore, the cell surface 
area accessible to transfection complexes is limited if cells are pre-plated, but 
maximised when cells are in suspension during transfection.
One million HepG2 cells per well of a 6 -well plate were transfected with 4 pg of 
huApoA-lM-49NT, huApoA-lM-49T-PTO, huApoA-lM-49NT-PTO or huApoA-IM-Cy5- 
49NT-PTO using a ssODN to Lipofectamine 2000 ratio of 1:2 (w/v). Transfection 
efficiency was monitored and estimated to be 40% in pEGFP and -80%  in Cy5-ssODN 
transfected cells (data not shown). To maximise the percentage of converted cells, 
transfection was repeated 3 and 5 days after the initial transfection.
However, cells treated with huApoA-lM-49NT-PTO showed a high level of cell death 
after the second transfection and therefore were not transfected for a third time. In 
comparison to huApoA-lM-49NT-PTO the unmodified ssODN showed very little 
cytotoxicity, even after repeated administration. As previously discussed (section 3.1.2), 
the unspecific -210 bp band was also present in PCR samples from human cells (Figure 
3-1 la).
Unfortunately, as seen in Figure 3-1 lb  repeat administration did not translate into a 
higher conversion rate when cells were analysed 24 h after the third transfection, i.e. on 
day 6  after the first transfection. The expected bands at 106 and 41 bp are present in all 
samples except AIM. The 147 bp band denoting the presence of the Milano mutation is 
clearly present in lanes 3, 4 and AIM, but not in the control. A faint 147 bp band over 
the background control (Ctr) may be present in lane 2. When the 147 bp band from 
Figure 3-1 lb  lane 3 was sequenced, again a clear C/T double peak could be seen (Figure 
3-1 lc  (D), indicating successful gene targeting. However, when cells from this sample 
where subjected to limiting dilution and clonal expansion, cell lines carrying the Milano 
mutation could not be established (data not shown).
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Figure 3-11 R173C ApoA-1 PCR-RFLP and sequencing in HepG2 ceils
a) PCR products. Ctr: mock-transfected HepG2 cells. Lanes 1-4: Cells transfected with 4 pg of 
huApoA-IM-49NT, huApoA-IM-49T-PTO, huApoA-IM-49NT-PTO and huApoA-IM-Cy5-49NT- 
PTO. AIM: CHO-AIM cells. L: 25 bp ladder.
b) Haell digestion fragments. Ctr: mock-transfected HepG2 cells. Lanes 1-4: Cells transfected 
with 4 pg of huApoA-IM-49NT, huApoA-IM-49T-PTO, huApoA-IM-49NT-PTO and huApoA-IM- 
Cy5-49NT-PTO. AIM: CHO-AIM cells. L: 25 bp ladder.
c) © Sequencing of mock-transfected cells. © HepG2 cells transfected with 4 pg huApoA-IM- 
49NT-PTO. ® CHO-AIM. The bases corresponding to residues Arg173 (CGC; ApoA-I) and Cys173 
(TGC; ApoA-IM) are ringed.
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3.4.2 Discussion
The data presented in this chapter demonstrates successful gene targeting of ApoA-I to 
ApoA-lM with ssODN in HepG2 cells. As with CHO-AI cells, a pronounced strand bias 
for targeting the non-transcribed strand was observed (section 3.2.2). Attempts to isolate 
converted cells did not produce viable colonies of corrected cells, but possible 
explanations for this have already been discussed (section 3.2.2).
Radecke et al. 241 presented evidence that gene editing using unmodified 
oligonucleotides led to stable genotype conversion when phosphorothioate ssODNs did 
not. However, in our hands an unmodified ssODN did not produce detectable levels of 
gene editing even after triple transfection (Figure 3-1 lb  lane 1), whereas a 
phosphorothioate oligonucleotide of the same sequence did. O f course, PCR-RFLP is 
not sensitive enough to pick up correction rates as low as those reported by Radecke and 
colleagues241 (< 1 %) with a direct flow cytometry-based readout and cells containing a 
high number of integrated transgene copies. Furthermore, Radecke et al.241 could not 
detect gene conversion in cells that had only 1 - 2  integrated transgene copies, 
comparable to the situation with the endogenous ApoA-I sequence in HepG2 cells.
The difference in correction efficiency observed in the experiments described here is 
most likely due to the difference in endonuclease resistance between phosphorothioate 
and unmodified ODN. Multiple transfections did seem to increase the correction rate, 
but again problems with quantification of PCR-RFLP diagnostic bands made it 
impossible to determine absolute numbers. Especially worrying in this context was the 
repeatedly demonstrated contamination of the 147 bp band with ApoA-I/ApoA-lM 
heteroduplexes seen in the sequencing results.
The high cytotoxicity associated with repeated Lipofectamine 2000 administration of 
phosphorothioate ssODNs limited the usefulness o f this approach at least for HepG2 
cells. Later experiments with CHO-mEGFP cells demonstrated that repeated targeting 
did not improve gene editing efficiencies (section 5.1).
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3.5 Effects of co-transfection with reporter gene plasmid
3.5.1 Results
As established in the previous experiments, successful gene targeting can be shown in 
both CHO-AI and HepG2 cells several passages after transfection; however, isolation of 
converted cell clones proved difficult. Therefore, ways of selecting for successfully 
targeted cells were investigated.
Co-transfection has been successfully used with two plasmids where GFP expression 
from one plasmid was substituted as a marker to sort for cells expressing the gene of 
interest from the second plasmid. ’ Here, correcting ssODN was co-transfected with 
a pEGFP plasmid in the hope that reporter gene expression would mark cells in which 
plasmid, and potentially ssODN, was efficiently delivered to the nucleus. These cells 
should therefore have a higher percentage of gene-edited cells.
HepG2 cells were transfected with 4 pg ssODN and 1 pg pEGFP-Cl using 
Lipofectamine 2000. Cells were trypsinised 24 h post-transfection and cell sorted for 
EGFP positive and negative cell populations. DNA was extracted from the cells and a 
R173C PCR-RFLP analysis was carried out. However, due to the low number of cells in 
the EGFP positive population (-5,000 EGFP positive cells were recovered) the PCR 
product for this sample had to be re-amplified. For the re-amplification, 2 pi of the first 
PCR mixture was used as template in a second PCR of 20 cycles under the same 
conditions.
The PCR-RFLP analysis (Figure 3-12a) did show clear gene conversion in the unsorted 
population (lane 1), but also for both the EGFP positive (lane 2) and negative 
populations (lane 3). However, PCR-RFLP is not suitable for quantitative assessment of 
conversion efficiency and therefore it is difficult to draw firm conclusions from these 
results. Sequencing of the 147 bp Haell digestion fragment from the unsorted 
population confirmed the nucleotide change from C to T (Figure 3-12b ©). This 
nucleotide change could also be seen in the EGFP positive and negative populations 
(data not shown). Corrected cells persisted for at least 10 d in the unsorted population as 
determined by PCR-RFLP and subsequent sequencing of the 147 bp diagnostic band 
(data not shown).
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Figure 3-12 R173C PCR-RFLP for cells co-transfected with GFP plasmid
a) Ctr: mock-transfected HepG2 cells. Lane 1: Cells transfected with 4 pg of huApoA-IM-49NT 
and 1 pg pEGFP-Cl. Lane 2 and 3: Cells from lane 1 sorted for EGFP positive and negative cells. 
AIM: CHO-AIM cells. The expected bands at 106 and 41 bp are present in all samples except 
AIM. The 147 bp band denoting the presence of the Milano mutation is clearly present in lanes 1-3 
and AIM, but not in the control.
b) © Sequencing of mock-transfected cells. © HepG2 cells transfected with 4 pg huApoA-IM- 
49NT and 1 pg pEGFP. (D CHO-AIM. The bases corresponding to residues Arg173 (CGC; ApoA-I) 
and Cys173 (TGC; ApoA-IM) are ringed.
122
3.5.2 Discussion
Curiously, co-transfection with an EGFP expressing plasmid appeared to increase the 
correction rate, though once more the imprecise nature of quantifying PCR-RFLP bands 
made it impossible to be sure. At the time, the apparent high correction rate was 
attributed to high transfection efficiency and not followed up any further, but Igoucheva 
et al.290 recently reported a similar finding. They demonstrated that the elevated 
correction rate was due to the higher level of activation of the ATM/ATR pathway 
induced by plasmid co-transfection in comparison to ssODN only transfection.
Cell sorting for EGFP positive and negative populations did not appear to enrich for 
corrected cells in the positive population, but on top of the already discussed problems 
with PCR-RFLP band quantification, this analysis was complicated by the re­
amplification step needed for the EGFP positive population. Further experiments to 
quantify this potential increase are shown in section 5.2.
It became clear from these results, that PCR-RFLP analysis was unsuitable for 
determining absolute correction numbers and that a more accurate method was required 
to gain meaningful and usable data. A flow cytometry-based read-out has been widely 
used in conjunction with stably integrated mutated reporter genes ’ and I considered 
a similar system for detection of ApoA-lM in live cells. Unfortunately, I was unable to 
source an antibody capable of distinguishing the wild-type ApoA-I protein from the 
mutated Milano form at that time.
Moreover, ApoA-I is rapidly secreted from liver cells and although Brefeldin A could 
be used to block protein excretion, intracellular antigen staining requires fixation and 
permeabilization of cells. Consequently, I would be unable to recover live cells, 
although such an assay could theoretically be used to analyse gene editing efficiencies 
of ApoA-I to ApoA-IM targeting.
Thus, I decided to change the experimental system from targeting ApoA-I to targeting a 
mutated reporter gene, in the hope that quantitative data gained in such a system could 
in time be applied to ApoA-I gene editing. Prof. Krauss from the Rikshospital in Oslo, 
Norway kindly provided CHO and HEK293 cell lines with the mutated EGFP stably 
integrated. Both these cell lines have been used extensively in their gene editing 
studies. 242’251
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INTRODUCTION
One possible explanation for the problems with isolating viable corrected cell clones
001 ooocould be cytotoxicity associated with the transfection reagent ’ and/or ssODN 
modification293,294 used, which could result in reduced viability or cell death. Therefore, 
I investigated less cytotoxic transfection reagents and oligonucleotide modifications, as 
well as the influence of the number of mismatches between ssODN and target sequence. 
However, to establish the influence of these parameters on gene editing efficiency, 
quantitative experimental data was required. PCR-RFLP and DNA sequencing are 
unsuited for this purpose, as the read-out cannot be accurately quantified (previously 
discussed in section 3.2.2). Fortunately, ingenious model systems using mutated forms 
of enhanced green fluorescent protein (EGFP) have been developed. 182,228,242,245,249
These systems allow the direct cell-based read-out of correction events, as successful 
gene editing is demonstrated by restoration of fluorescence, which can be visualized by 
microscopy or quantified with flow cytometry. Flow cytometry establishes exact 
numbers or percentages of fluorescent cells in mixed populations with a minimum 
sensitivity of around 0.05%. It can examine large numbers of cells and therefore 
distinction of small differences between two or more populations is possible.
Most mutated EGFP systems are based on a premature stop codon in the EGFP gene 
and are thus vulnerable to a low percentage of read-throughs. To solve this problem
'J'JQ
Tran et al. introduced a Tyrosine to Serine mutation at amino acid 6 6  in the central 
chromophore region of EGFP that rendered the protein non-fluorescent, but preserved 
full-length expression. If this mutation is corrected by gene editing the EGFP 
fluorescence is restored. The CHO cell line kindly provided by Prof. Krauss is based on 
this system. These cells have multiple copies of the mutated pEGFP-Cl plasmid stably 
integrated and are therefore called CHO-mEGFP cells. An additional silent mutation at 
Lysine 45 in the EGFP permits exclusion of possible contamination with wild-type 
EGFP plasmid or cells by sequencing.
Figure 4-1 illustrates the differences between wild-type (wtEGFP), mutated (mEGFP) 
and gene-edited (edEGFP) sequences as well as the targeting oligonucleotides used 
here. Gene editing in these CHO-mEGFP cells has been widely studied by Prof. Krauss’ 
group242,251 and strand-bias for the non-transcribed strand was shown. Therefore, all 
targeting ssODNs were complementary to the non-transcribed strand (NT).
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Using these ssODNs, I determined that Lipofectamine 2000 was the optimal 
transfection reagent for oligonucleotide-mediated gene editing in CHO-mEGFP cells. I 
also compared the efficiency of ssODNs with phosphorothioate (PTO) or locked nucleid 
acid (LNA) backbone modifications with unmodified (DNA) ssODN (Figure 4-2). PTO 
ssODNs have been the standard used for oligonucleotide-mediated gene editing in 
recent years, but their cytotoxicity is well-documented.294 According to Andrieu-Soler 
et al.]M LNA-modified ssODNs produce similar correction efficiencies to PTO- 
modified ssODNs, but exhibit reduced cytotoxicity. In my experiments, LNA- were less 
effective than PTO- modified ssODNs. Only DNA ssODNs had very low cytotoxicity, 
but unfortunately also induced very low levels of gene editing.
Andrieu-Soler et al.m  also reported that gene-edited cells treated with LNA-modified 
ssODN expanded into colonies, whereas cells treated with PTO ssODN did not. They 
concluded that LNA modifications were less cytotoxic than PTO ones. On the other 
hand, Radecke et al.241 stated that unmodified ssODNs, especially the shorter ones with 
only 13 or 19 nucleotides, were significantly less toxic than PTO-modified ssODNs. 
Also, Olsen et al, 251 have shown that the use of DNA ssODN leads to ~3 fold higher 
number of colonies than PTO ssODN. Therefore I compared viability of gene-edited 
cells treated with LNA- or PTO-modified ssODNs to unmodified ssODN. I found that 
both backbone modifications reduced viability of gene-edited cells in comparison to 
unmodified ssODN.
Initially, I used oligonucleotides with two mismatches (2A), as these were more 
effective in mediating gene editing than one mismatch ssODNs according to Olsen et 
al.242 However, I needed to create a new restriction endonuclease recognition site for 
validation of oligonucleotide-mediated gene editing (chapter 6 ) and this required three 
mismatch (3 A) ssODNs (Figure 4-lc). In contrast to the published data,242 the mEGFP- 
3A-NT-PTO ssODN performed better than the mEGFP-2A-NT-PTO ssODN in my 
hands.
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Figure 4-1 Schematic of the mEGFP system
a) wtEGFP has a Tyrosine (TAC) at amino acid 66, this has been mutated to a Serine (TCC) in 
mEGFP. All control ssODNs, such as mEGFP-Ctr-NT-PTO, are completely homologous to the 
mEGFP sequence.
b) Targeting ssODNs containing two mismatches (2A), such as mEGFP-2A-NT-PTO, change the 
Serine (TCC) at position 66 in mEGFP to an alternative Tyrosine codon (TAT). Thus, it is possible 
to distinguish wtEGFP and edEGFP (2A).
c) Targeting ssODNs containing three mismatches (3A), such as mEGFP-3A-NT-PTO, change the 
Serine (TCC) at position 66 in mEGFP to an alternative Tyrosine codon (TAT) and additionally 
introduce a silent mutation in the upstream Threonine codon (ACC to ACA). Thus, it is possible to 
distinguish wtEGFP and edEGFP (3A). All 3A ssODNs create a Ndel restriction endonuclease 
recognition site (5’- CA/TATG -3’).
Green boxes denote sequences translating to functional green fluorescence; red letters draw 
attention to differences from the wtEGFP sequence; •  DNA backbone, ■ phosphorothioate (PTO) 
and ■ locked nucleic acid (LNA) backbone modifications of ssODNs. All ssODNs in this figure 
are complementary to the non-transcribed (NT) strand.
mEGFP
ACC 
ACCTCC 
TGGAGG
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I also investigated the best time for sampling gene editing efficiencies. Originally I 
sampled 48 h after transfection, because in my experience optimal accumulation of 
EGFP requires around 36 h. In addition, I estimated that the ssODN would need several 
hours to reach the cell nucleus and for gene editing to take place. However, when I 
studied oligonucleotide localization 3 h after Lipofectamine 2000 transfection, the 
ssODN was already present in the nuclei of the majority of cells and green fluorescent 
cells could be found in this population 24 h later. Therefore, I measured gene editing 
efficiencies over a period of three days. Maximum percentages of green fluorescent 
cells were found at 24 h.
0 = P — S' 0 = P — O' 0 = P — O'
PTO LNA DNA
Figure 4-2 Chemical structure of oligonucleotide backbone modifications
In phosphorothioate (PTO) backbone modifications, sulphur replaces an oxygen anion in the 
linking phosphate group. Locked nucleic acid modifications are bridges connecting the 2' and 4' 
carbons o f the 2-deoxyribose. This bridge "locks" the ribose in the 3'-endo structural conformation.
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4.1 Effect of transfection reagents on gene editing efficiencies
4.1.1 Results
In this experiment I used the CHO-mEGFP cell line to compare the transfection 
reagents Lipofectamine 2000 and jetPEI (a commercially available linear PEI). Three 
wells each were transfected with 4 pg mEGFP-Ctr-NT-PTO or 4 pg mEGFP-2A-NT- 
PTO ssODN as described in section 2.2.1.4. Tissue culture plates containing jetPEI 
transfections were centrifuged for 5 min at 280 g  to enhance cell-reagent contact and 
hence maximize transfection efficiency.236
Cells were trypsinised 48 h post-transfection, pelleted by centrifugation and 
resuspended in PBS. Propidium iodide (PI) was added at 50 pg/ml to permit dead cell 
discrimination. Samples were then examined by flow cytometry and lx l0 5 events were 
acquired for each sample. Cells were gated based on forward scatter (FSC) versus side 
scatter (SSC) and the EGFP fluorescence of each cell was plotted against its PI 
fluorescence on a density plot.
As shown in Figure 4-3 a left panel, cells treated with the fully complementary control 
ssODN (mEGFP-Ctr-NT-PTO) did not express EGFP (x-axis), although some of the 
cells had taken up PI (y-axis). When CHO-mEGFP cells were transfected with the 
targeting ssODN (mEGFP-2A-NT-PTO), a number of cells clearly expressed EGFP 
(Figure 4-3a right panel).
Based on the localization of the cells treated with control ssODN on the density plot, a 
region was drawn around EGFP positive cells (e.g. R1 in Figure 4-3a). The mean and 
standard deviation of the percentages of green fluorescent cells in this region were 
displayed in a column chart (Figure 4-3b). Samples in the same experiment were 
analysed using identical machine and region settings to allow comparison.
Results clearly show that cells transfected with Lipofectamine 2000 exhibit a far higher 
percentage of green fluorescent cells than those transfected with jetPEI. Two-way 
ANOVA with Bonferroni post-tests yielded a P  value of less than 0.001 for 
Lipofectamine 2000 versus jetPEI for cells transfected with mEGFP-2A-NT-PTO.
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Figure 4-3 Lipofectamine 2000 and jetPEI comparison
a) EGFP versus PI density plots of cells transfected with mEGFP-Ctr-NT-PTO (left) and mEGFP- 
2A-NT-PTO (right) using Lipofectamine 2000. Region 1 (R l) was set using the cells transfected 
with mEGFP-Ctr-NT-PTO as negative control.
b) Graph shows the percentage of green fluorescent cells in Rl for Lipofectamine 2000 (Blue) and 
jetPEI (red) for cells transfected with mEGFP-Ctr-NT-PTO (Ctr) and mEGFP-2A-NT-PTO 
(PTO). Numbers represent means and error bars are the standard deviation (SD) of triplicates. 
PcO.OOl (***) as determined by two-way ANOVA with Bonferroni post-tests.
In a similar experiment I compared deacylated LPEI and CDAN/DOPE with 
Lipofectamine 2000. Fully deacylated LPEI has been shown to have increased 
efficiency and less toxicity than the commercial LPEI from which it was derived in 
plasmid transfections. 140 CDAN/DOPE also demonstrated increased down-regulation 
and reduced toxicity compared to Lipofectamine 2000 in siRNA transfections. 148
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Figure 4-4 Lipofectamine 2000, deacylated LPEI and CDAN/DOPE comparison
Graph shows the percentage of green fluorescent cells for Lipofectamine 2000 (Blue; left column), 
deacylated LPEI (middle column) and CDAN/DOPE (yellow; right column) for cells transfected 
with mEGFP-Ctr-NT-PTO (Ctr) and mEGFP-2A-NT-PTO (PTO). Numbers represent means and 
error bars are the SD of triplicates. P 0 .0 0 1  (***) as determined by two-way ANOVA with 
Bonferroni post-tests.
Deacylated LPEI was transfected in the same way as normal LPEI with N/P ratio of 3 
(section 2.2.1.4). CDAN/DOPE transfection was performed as described in section 
2.2.1.4. Cells were prepared for flow cytometry and results evaluated as described 
above.
As seen in Figure 4-4 Lipofectamine 2000 is significantly more effective than either 
deacylated LPEI or CDAN/DOPE. Extensive studies using the biopolymers tri- 
methylated chitosan and atelocollagen for transfection did not lead to any green 
fluorescent cells (data not shown). In both cases two different batches of the reagent 
were tried and for atelocollagen the protocol described by Nakamura et al} 45 was 
followed closely. Optimisation of ssODN electroporation conditions by Wenyan Li, a 
visiting scientist, yielded green fluorescent cells but less than Lipofectamine 2000 and 
electroporation-associated cytotoxicity was higher (data not shown). Thus 
Lipofectamine 2000 was the most effective transfection reagent for gene editing.
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To further evaluate the efficiency of Lipofectamine 2000, I studied the nuclear delivery 
of ssODN with this transfection reagent. A Cy3-tagged mEGFP-2A-NT-PTO ssODN 
was transfected into CHO-mEGFP cells grown on cover slides using Lipofectamine 
2000. Cell nuclei were counterstained by addition of 5 pM Draq5 for 10 min before the 
cover slides were placed upside down on microscopy slides.
Confocal microscopy 3 h post-transfection showed that in more than 90% of cells, the 
majority of ssODN was localized in the nucleus (Figure 4-5 a). When cells were 
permitted to grow for 24 h after transfection, confocal microscopy confirmed the 
presence of EGFP positive cells in this population (Figure 4-5b).
1 0  pm
Figure 4-5 Confocal microscopy of gene-edited cells
CHO-mEGFP cells transfected with Cy3-mEGFP-2A-NT-PTO (pink) were examined (a) 3 h or 
(b) 24 h post-transfection. Cell nuclei were counterstained with Draq5 (blue), EGFP in green.
4.1.2 Discussion
The experiments described in this section clearly demonstrate that flow cytometry is an 
easy and quick way to determine exact gene editing efficiencies in mutated reporter 
gene systems. In contrast to PCR-RFLP it is a direct cell-based read-out and thus the 
possibility of artefacts during analysis can be completely excluded. This system was 
used to evaluate gene editing efficiencies associated with several transfection reagents. 
Lipofectamine 2000 has quickly become the standard transfection reagent used in 
oligonucleotide-mediated gene editing in recent years, as it guarantees nuclear delivery 
of a high proportion of the ssODN and this was completely justified by my data.
LPEI has also been used extensively for oligonucleotide-mediated gene targeting, but 
did not perform nearly as well as Lipofectamine 2000 in my hands. Perhaps polyplex 
formation between the 27 base ssODN and LPEI is not as strong as it is with longer 
DNA sequences. LPEI has been used successfully to transfect 20 - 23 base siRNAs, but
70Swas not as effective as Lipofectamine 2000. Deacylated LPEI was not effective at all 
and CDAN/DOPE did not mediate significant correction above background levels. 
Further optimisation of the lipid to DNA ratio for CDAN/DOPE might yield better 
transfection efficiencies. However, the slower cellular uptake described for 
CDAN/DOPE148 in comparison to Lipofectamine 2000 could result in more degradation 
of the targeting ssODN and thus be the cause of reduced gene editing efficiency. The 
negative results from atelocollagen were particularly disappointing as it has been 
reported to mediate gene editing in -10% of treated HepG2 cells. 145
Confocal microscopy showed that the Cy3-tagged mEGFP-2A-NT-PTO ssODN was 
localized in the nucleus of >90% of cells 3 h after transfection when Lipofectamine 
2000 was used. Green fluorescent cells could be found in this population 24 h later. It is 
interesting that transfection o f ssODN into the nucleus using Lipofectamine 2000 does 
not seem to require cellular division. It has been described that successful plasmid 
transfection is dependent on mitosis and fragmentation of the nuclear membrane, though 
a small percentage of non-dividing cells is also transfected.296 However, the presence of 
oligonucleotide in the nucleus of the majority of unsynchronized CHO-mEGFP cells 
only 3 h after transfection suggests that this is not the case for ssODN transfection. 
Lipofectamine 2000 proved to be the most effective transfection reagent for 
oligonucleotide-mediated gene editing and was therefore used in all further studies.
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4.2 Effect of ssODN backbone modifications on gene editing 
efficiency
4.2.1 Results
In similar experiments, I compared different oligonucleotide backbone modifications. 
The percentages of green fluorescent cells resulting from treatment with PTO- and 
LNA-modified as well as unmodified ssODN were compared. CHO-mEGFP cells were 
transfected with 4 pg of the various ssODNs and prepared for flow cytometry 48 h post­
transfection as described previously.
Cell death associated with mEGFP-2A-NT ssODN transfection was minimal as 
observed under the microscope; unfortunately, correction efficiency was very low too 
(Figure 4-6a). The LNA-modified ssODN resulted in a lower correction efficiency than 
the PTO ssODN (Figure 4-6a). One-way ANOVA with Bonferroni post-tests yielded 
P<0.05 for this difference. All other differences except between mEGFP-Ctr-NT-PTO 
and mEGFP-2A-NT had P<0.001.
Percentages obtained in a second independent experiment varied significantly from the 
first as determined by two-way ANOVA. However, when the percentages from both 
experiments were normalized with the mean of the highest percentage (PTO) set as 
1 0 0 %, it became clear that the differences between the two experiments did not 
invalidate the differences between PTO- and LNA-modified ssODNs (Figure 4-6b). In 
fact, all differences except between mEGFP-Ctr-NT-PTO and mEGFP-2A-NT had 
P<0.001 as determined by one-way ANOVA with Bonferroni post-tests (Table 4-1).
Furthermore, the difference between PTO- and LNA-modified ssODNs was also seen in 
comparisons of three mismatch (3 A) ssODNs (section 4.5.1).
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Figure 4-6 Effect of ssODN backbone modifications on gene editing efficiency
a) Percentage of green fluorescent cells in cells treated with mEGFP-Ctr-NT-PTO (Ctr; black) 
mEGFP-2A-NT-PTO (PTO; blue), mEGFP-2A-NT-LNA (LNA; red) and mEGFP-2A-NT (DNA; 
yellow). Numbers represent means and error bars are the SD of triplicates. P<0.05 (*) as 
determined by one-way ANOVA with Bonferroni post-tests.
b) Normalized percentage of green fluorescent cells in cells treated with mEGFP-Ctr-NT-PTO 
(Ctr; black), mEGFP-2 A-NT-PTO (PTO; blue), mEGFP-2 A-NT-LN A (LNA; red) and mEGFP- 
2A-NT (DNA; yellow). Numbers represent means and error bars are the SD of two independent 
experiments each with triplicates.
ssODN P  value
Ctr vs PTO ***
Ctr vs LNA ***
ssODN P  value
Ctr vs DNA ns
PTO vs LNA ***
ssODN P value
PTO vs DNA ***
LNA vs DNA ***
Table 4-1 Effect of ssODN backbone modifications on gene editing efficiency
Statistical significance of differences between normalized gene editing efficiencies mediated by 
mEGFP-Ctr-NT-PTO (Ctr), mEGFP-2 A-NT-PTO (PTO), mEGFP-2 A-NT-LNA (LNA) and 
mEGFP-2A-NT (DNA) in Figure 4-6b. P  values for differences between ssODNs were determined 
by one-way ANOVA with Bonferroni post-tests. *** PO.OOl; ns P>0.05 grey text.
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4.2.2 Discussion
Contrary to published data184 I found that LNA-modified ssODNs were around 30% less 
effective than PTO-modified ones. Unmodified oligonucleotides had very little activity, 
though their cytotoxicity was very low. These conclusions were confirmed in two 
independent experiments, even if at first sight these experiments gave significantly 
different results in terms of absolute gene editing efficiencies.
After normalization it became clear that the differences between experiments were not 
caused by different results, but rather by unrelated factor(s) that influenced all samples 
in the same experiment. Two possibilities spring to mind: the general condition of the 
transfected cells or differing efficiencies of the Lipofectamine 2000 complex formation.
Whatever the cause, the small standard deviations gained after normalization of only 
two experiments together with data from 3A ssODNs (section 4.5.1) are convincing 
evidence that the observed difference between PTO- and LNA-modified ssODNs is not 
due to experimental artefacts.
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4.3 Effect of ssODN backbone modifications on viability of edited 
cells
4.3.1 Results
CHO-mEGFP cells were transfected as described before and cells were sorted according 
to EGFP status 24 h after transfection as explained in section 2.2.1.9. Single cells were 
seeded in each well of 96-well plates and incubated for 10 d. Wells showing colony 
formation under the microscope were scored as positive and percent viability was 
determined as percent of colony forming wells out of the total number of wells seeded.
Colony formation
Total % viable Viability
Yes No ratio
PTO
EGFP - 75 404 479 15.66
6 :1
EGFP + 47 1852 1899 2.47
LNA
EGFP - 93 387 480 19.38
13:1
EGFP + 26 1785 1811 1.44
DNA
EGFP - 124 356 480 25.83
4:1
EGFP + 31 448 479 6.47
Table 4-2 Effect of ssODN backbone modifications on viability of edited cells
Total numbers (from three independent experiments) of cells treated with mEGFP-3 A-NT-PTO 
(PTO), mEGFP-3A-NT-LNA (LNA) or mEGFP-3A-NT (DNA) that either formed colonies or did 
not after being sorted as EGFP negative or positive. Percent o f viable cells is the proportion of 
colony forming cells out of the total number of cells for each condition. Viability ratio between the 
percentage of EGFP- and EGFP+ viable cells for each backbone modification.
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Table 4-2 summarizes the results from three independent experiments. There is a clear 
reduction in viability between EGFP negative and positive cells treated with either 
LNA- or PTO-modified, as well as DNA ssODNs as demonstrated by the variances in 
viability ratio (13:1 for LNA, 6:1 for PTO and 4:1 for DNA). This reduction is less 
pronounced in cells treated with unmodified oligonucleotide, but is highly statistically 
significant (analysis using contingency tables with Fisher’s exact test; P<0.001) in all 
cases. Interestingly, there is also a decrease in viability of EGFP negative sorted cells of 
LNA or PTO treated cells compared to DNA treated cells.
Notably, only three colonies grown from cells treated with unmodified oligonucleotide 
and originally sorted as EGFP positive showed partial green fluorescence two weeks 
after sorting. Data shown in section 6.2 confirmed successful gene editing in two of 
them.
4.3.2 Discussion
Treatment with any ssODN, whether modified or not, influenced viability of non-edited 
EGFP- cells, presumably because transfection of oligonucleotide per se was cytotoxic to 
some degree. This agrees well with previously reported evidence that single-stranded 
DNA induces phosphorylation of histone 2AX, which is an indicator for activation of 
the ATM damage response pathway.297
However, it is evident that there are additional reductions in viability associated with 
successful gene editing and that these decreases are dependent on the specific nature of 
the oligonucleotide backbone. Thus, both LNA and PTO modifications led to a more 
pronounced reduction in viability of edited cells than the unmodified DNA backbone. 
This should perhaps not come as a surprise. Olsen et al.251 reported that the presence of 
5’ and/or 3’ octyl or hexaethylene glycol blocking groups on the targeting ssODN 
reduced gene editing by up to 80%. Radecke et al.259 confirmed these results using 
ssODNs with non-canonical termini and also showed that targeting oligonucleotides 
were physically integrated into the genome.
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If the oligonucleotide is integrated into the genome while still containing the backbone 
modifications, these abnormalities in the DNA could make it more difficult for affected 
cells to progress through the cell cycle. Perhaps the difference in the viability ratio of 
gene-edited cells treated with LNA (13:1) in comparison to PTO (6:1) reflects the fact 
that the occasional sulphur atom instead of oxygen can be tolerated better than the fairly 
constrained formation of deoxyribose imposed by the LNA modification.
It is also conceivable that the remaining viability in PTO and LNA treated cells is based 
on partial degradation of the ssODNs by endonucleases that would result in a shorter 
remnant consisting of pure DNA. In this case the differences in viability between PTO 
and LNA could be explained by a differential susceptibility to endonucleases. However 
gene-edited cells treated with DNA ssODN also show a significant reduction in 
viability. Thus, the gene editing event itself must play a part in the observed 
cytotoxicity.
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4.4 Effect of the number o f mismatches
4.4.1 Results
For the validation of oligonucleotide-mediated gene editing a new restriction 
endonuclease recognition site had to be created with the targeting ssODNs. However, 
the only feasible restriction site required three changes of the mEGFP sequence. Olsen 
et al.242 have previously evaluated the influence of the number of mismatches on gene 
editing efficiency (Figure 4-7a and Table 4-3) and found that a two mismatch ssODN 
generated the highest percentage of green cells.
When I compared the gene editing efficiency of mEGFP-2A-NT-PTO (2A) with 
mEGFP-3A-NT-PTO (3A), I found that the 3A ssODN was significantly more effective 
(Figure 4-7b and Table 4-3).
Ougo: a d r f e  a1 a  a  2a «3a o4a Ctf 2A 3A
Figure 4-7 Effect of the number of mismatches on gene editing efficiency
a) Figure taken from Olsen et al.242 for comparison.
b) Percent of green fluorescent cells in cells treated with mEGFP-Ctr-NT-PTO (Ctr; black), 
mEGFP-2A-NT-PTO (2A; blue) and mEGFP-3A-NT-PTO (3A; red). Numbers represent means 
and error bars are the SD of two independent experiments each with triplicates. P<0.05 (*) as 
determined by one-way ANOVA with Bonferroni post-tests.
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ssODN sequence 3’ -  5’ % green cells
ac trla TGG GAC TGG AGG CCG CAC GTC ACG AAG 0.00
a la TGG GAC TGG ATG CCG CAC GTC ACG AAG -3.65
a 2 a TGG GAC TGG ATA CCG CAC GTC ACG AAG -4.50
a3a TGG GAC TGC ATG CCG CAC GTC ACG AAG -1.45
a4a TGG GAC TGC ATA CCG CAC GTC ACG AAG -2.90
2A TGG GAC TGG ATA CCG CAC GTC ACG AAG 1.70±0.12
3A TGG GAC TGT ATA CCG CAC GTC ACG AAG 2.75±0.21
Table 4-3 Effect of the number of mismatches on gene editing efficiency
Sequence of ssODNs and resulting percentage o f green fluorescent cells; ac trla , a  la, a2a, a3a 
and a4a used by Olsen et al.?42 2A  and 3A used here. Note that a2a and 2A have the same 
sequence.
4.4.2 Discussion
My experiments demonstrated an effect of the number of mismatches on gene editing 
efficiency. In contrast to data reported by Olsen et al. , 242 the 3A performed better than 
the 2A oligonucleotide. The reason for this is unclear. Although the number and 
position of mismatches was identical in the 3A and a4a ssODNs, the exact sequence 
differed in one nucleotide (Table 4-3). It is noteworthy that in my hands the 2A (=a2a) 
ssODN only yielded 1.70±0.12 (n=2) percent green cells, whereas Olsen’s data were 
around 4.50%.
It is unlikely that this incongruence is based on quality differences between individual 
ssODNs as I used different batches of ssODN for the two independent experiments. 
Perhaps there is a quality difference in ssODNs from different suppliers (Integrated 
DNA Technologies in my case and MWG Biotech or Eurogentec in Olsen’s). It is more 
likely though that there are slight differences between investigators in transfection 
methodology or flow cytometer setup resulting in inconsistent rates of green positive 
cells. These factors, however, would influence all experiments done by the same 
investigator. Thus, relative comparisons between experiments by different investigators 
would be valid.
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It is possible that the single nucleotide sequence difference between the 3A and a4a 
ssODNs could result in differential recognition of the mismatch by the mismatch repair 
system. Dekker et al.260 showed that in MSH2 positive embryonic stem cells 
replacement of a four-nucleotide sequence was more effective than one, two or three 
nucleotide exchanges. However, a slight alteration in positioning and therefore the 
sequence of the four mismatch substitution did not lead to a similar increase.
They also demonstrated that two three-nucleotide substitutions with the same sequence 
resulted in significantly different gene editing efficiencies, even though they were only 
three bases apart, possibly because of the differences in the target sequence. Dekker et 
al.260 were unable to derive rules to determine which sequence substitutions were more 
effective, but their data hint that specific nucleotide differences between target and 
ssODN could be responsible for differential recognition by the mismatch repair system.
However, this differential recognition would not explain the differences in gene editing 
efficiencies between the 2A and a2a ssODNs.
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4.5 Effect o f sam pling time
4.5.1 Results
To investigate the effect of sampling time on gene editing efficiencies, CHO-mEGFP 
cells were transfected as previously described with 4 pg of mEGFP-Ctr-NT-PTO (Ctr), 
mEGFP-3A-NT-PTO (PTO), mEGFP-3A-NT-LNA (LNA) and mEGFP-3A-NT (DNA) 
ssODN. At 24, 48 and 72 h triplicate samples were prepared for flow cytometry. Two 
independent experiments demonstrated significantly different gene editing efficiencies 
for samples from the same time point as determined by two-way ANOVA. Therefore, 
the 24 h PTO sample mean of each experiment (1.06±0.04 and 3.36±0.20 percent 
respectively; +SD of triplicates) was set as 100%; all other sample means were 
normalized to this value (Figure 4-8). The normalized percentages from both 
experiments were compared in a two-way ANOVA with repeated measures and 
Bonferroni post-tests (Table 4-4).
Ctr PTO LNA DNA
Figure 4-8 Effect of sampling time
Normalized percentage of green fluorescent cells in cells treated with mEGFP-Ctr-NT-PTO (Ctr; 
black), mEGFP-3 A-NT-PTO (PTO; blue), mEGFP-3 A-NT-LNA (LNA; red) and mEGFP-3A-NT 
(DNA; yellow) 24, 48 and 72 h after transfection. Numbers represent means and error bars are the 
SD of two independent experiments each with triplicates.
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time P  value
Ctr ns for all time points
DNA ns for all time points
PTO *** for 24 h vs. 48 h
ns for 48 h vs 72 h 
*** for 24 h vs. 72 h
LNA ** for 24 h vs. 48 h
ns for 48 h vs 72 h 
*** for 24 h vs. 72 h
ssODN P  value
Ctr vs PTO *** for all time points
Ctr vs LNA *** for all time points
Ctr vs DNA ns for all time points
PTO vs LNA *** for 24 h * for 48 and 72 h
PTO vs DNA *** for all time points
LNA vs DNA *** for all time points
Table 4-4 Effect of sampling time
Statistical significance of differences between mEGFP-Ctr-NT-PTO (Ctr), mEGFP-3A-NT-PTO 
(PTO), mEGFP-3 A-NT-LNA (LNA) and mEGFP-3A-NT (DNA) 24, 48 and 72 h after 
transfection. P  values for differences between ssODNs and sampling time points were determined 
by two-way ANOVA with repeated measures and Bonferroni post-tests. *** P<0.001; ** PO .O l;
* P<0.05; ns P>0.05 grey text.
As shown in Table 4-4, all differences except between Ctr and DNA have at least 
P<0.05. Maximal percentages of green fluorescent cells were reached at 24 h after 
transfection with PTO ssODN and decreased significantly at 48 h and 72 h compared to 
the first time point. The 3A PTO-modified ssODN again performed significantly better 
than the LNA-modified one, thus confirming previous data from 2A ssODNs. Gene 
editing caused by DNA ssODN was not significantly above control and normalized 
percentages over time were not significantly different.
4.5.2 D iscussion
This experiment showed that the most suitable time point for sampling was 24 h after 
transfection and therefore all further experiments were evaluated at this time point. 
Several possible explanations for decreases in gene editing efficiency after 24 h have 
already been discussed (section 3.2.2) and therefore will not be repeated here. Results 
with DNA ssODN again were not significant due to the low percentages of green 
fluorescent cells derived from treatment with this oligonucleotide. Thus, the results 
highlight the fact that even if viability of PTO- and LNA-treated gene-edited cells is 
reduced, the higher gene editing efficiencies associated with modified ssODNs are 
required to examine the influence of small differences in treatment conditions.
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CHAPTER 5: TOWARDS 
INCREASING GENE EDITING 
EFFICIENCY AND SELECTING 
EDITED CELLS
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5.1 Repeated targeting
5.1.1 Introduction
Repeated targeting of the same population has been reported to enhance chromosomal 
gene editing efficiencies with LNA ssODN in HEK293T cells. 184 According to Andrieu-
184Soler et al. three consecutive transfections at 24 h intervals (t=0, 1 and 2 d) increased 
the percent of green fluorescent cells compared to a single (t=0 ) and two successive (t= 0  
and 1 d) control transfections when measured 3 days after the last transfection (t=5 d). 
However, as I have shown in the previous chapter (section 4.5.1), the fraction of green 
fluorescent cells decreases significantly over as little as 24 h.
Consequently, the increase seen by Andrieu-Soler et al.m  with triple transfection could 
simply be due to the different time delays between the single (5 d delay), double (4 d 
delay) and triple (3 d delay) transfections and measurement. Thus, I evaluated whether 
triple transfection would increase the percentage of green fluorescent cells when single 
and double control transfections with identical time delays between targeting and 
measurement were included in the experiment. Consistent with my previous tentative 
data with HepG2 cells (section 3.4.1), I found that repeated targeting did not increase 
gene editing efficiencies in CHO-mEGFP cells under these circumstances.
5.1.2 Results
CHO-mEGFP cells were transfected three times with mEGFP-2A-NT-PTO (Figure 5-la 
sample C) or mEGFP-2 A-NT ssODN (Figure 5-lb  sample C) as previously described at 
t=0, 2 and 5 d. Samples with single transfections at t=0 (E) or t=5 d (A) as well as 
double transfections at t=0 and 2 d (D) or t=2 and 5 d (B) were included as gene editing 
efficiency controls. The corresponding mEGFP-Ctr-NT-PTO and mEGFP-Ctr-NT 
ssODNs were also transfected and used to set gates for flow cytometric analysis. Cells 
were harvested and analysed 1 d after the last transfection (i.e. t= 6  d).
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Figure 5-1 Repeated targeting
Flow cytometry results o f CHO-mEGFP cells transfected with (a) mEGFP-2A-NT-PTO or (b) 
mEGFP-2 A-NT at the time-points indicated with an X. Numbers represent means and error bars 
are SD of triplicates.
Bonferroni post-tests a) P value
A vs B ***
A vs C ***
A vs E ***
B vs C **
B vs D ***
C vs D *♦
C vs E ***
Bonferroni post-tests b) P value
A vs B *
A vs C *
A vs E ***
B vs C ns
B vs D ns
C v s D ns
C v s E ns
Table 5-1 Repeated targeting
Statistical significance of differences between single, double and triple transfected samples. P 
values for differences between samples were determined by one-way ANOVA and Bonferroni 
post-tests. *** PO.OOl; ** P<0.01; * /*<0.05; ns .P>0.05 grey text.
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As shown in Figure 5-la, a single transfection 24 h before analysis (A) results in 0.45% 
green fluorescent cells, whereas double (B) and triple (C) transfections with no 
difference in the time delay between transfection and analysis result in 0 .2 2 % and 
0.13% respectively. However, if there are differences in the delay, triple transfection 
(0.13%; C) yields more green fluorescent cells than double (0.06%; D) and single 
(0.02%; E) transfections. Thus it might appear as if triple transfection (C) is more 
effective when compared to D and E only.
However, comparison of the triple transfection (0.13%; C) to A and B shows that the 
single transfection at t=5 d (0.45%; A) and double transfection at t=2 and 5 d (0.22%; 
B) are actually more effective than C. The P  values presented in Table 5-1 demonstrate 
that at least for the PTO ssODN, these differences in gene editing efficiencies between 
samples are highly significant. Similar results were obtained with the mEGFP-2A-NT 
ssODN, although gene editing efficiencies were very low. Consequently, differences did 
not reach statistical significance in all comparisons, though A (0.023%) vs C (0.007%) 
was still significant (PO.05).
5.1.3 Discussion
Similar to data reported by Andrieu-Soler et a / . , 184 I found that triple transfection results 
in higher gene editing efficiencies than double or single transfection if the time delay 
between transfection and analysis is different. This was the case even though the cells I 
used here (CHO-mEGFP) are different from the cells used by Andrieu-Soler (HEK293T 
with blue fluorescent protein). However, when the delay is the same, single transfection 
is more effective than either double or triple transfection. Thus, it is clear that the 
apparent increase in gene editing efficiency through triple transfection seen by Andrieu- 
Soler et a l m  was due to an experimental artefact.
Furthermore, the published data were from one experiment only, where the single 
transfection gave comparable gene editing efficiencies to previous experiments and the 
triple transfection gave a 2.5 times higher outcome. This discrepancy is easily explained 
by factors amply demonstrated in previous chapters o f this thesis; even when every 
effort is made to standardize cell treatment and transfection method, significant 
differences in gene editing efficiencies between repeat experiments happen.
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In my opinion this does not reflect the fact that oligonucleotide-mediated gene editing 
efficiencies per se are widely variable, but rather that many factors cannot conveniently 
be controlled for when working with cell cultures. Factors such as the general state of 
the cells in culture or the efficiency of complex formation between transfection reagent 
and DNA can have a major influence on results. Even though these factors can be 
investigated in detail if required, the actual time and expenditure involved precludes this 
option in practice. Thus, it is imperative to include accurate experimental controls, 
interpret resulting data carefully and repeat experiments at least once.
Although the data represented here are also based on only one experiment each for 
mEGFP-2 A-NT-PTO and mEGFP-2 A-NT, the fact that two different ssODNs gave 
similar results is more convincing than a simple repeat would be. Thus, triple 
transfection does not increase gene editing efficiencies compared to single transfection 
in CHO-mEGFP cells. This observation seems counterintuitive. Repeated transfection 
should in theory enrich for gene-edited cells, as the large majority of non-edited cells 
left over after the first transfection should then be targetable in the second and third 
transfections. Two main possibilities could explain why this is not the case.
Firstly, only a certain percentage of the whole population might be susceptible to gene 
editing. Considering that nearly all CHO-mEGFP cells show large amounts of 
fluorescently-labelled ssODN in the nucleus with Lipofectamine 2000 transfection (see 
section 4.1.1), but less than 2.5% of cells are gene-edited, this could well be the case. 
However, results presented in a later chapter (section 7.2.1) demonstrate that a much 
higher percentage of CHO-mEGFP cells can be gene-edited under certain 
circumstances. Thus, this explanation is unlikely.
Secondly, and the more likely explanation, is cytotoxicity associated with repeated 
administration of ssODN/Lipofectamine 2000 complexes. This explanation is certainly 
supported by routine visual observations o f cells after transfection, as well as data from 
propidium iodide staining not shown here. Furthermore, when CHO-mEGFP cells were 
transfected with siRNA, followed by ssODN 24 h later using Lipofectamine 2000, gene 
editing efficiency decreased significantly even with control siRNA (James Booth and 
Ioannis Papaioannou, personal communication).
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5.2 Plasmid co-transfection
5.2.1 Introduction
Another attempt to improve gene editing efficiencies, and perhaps enrich for edited 
cells, was based on a report by Igoucheva et al.290 that co-transfection of heterologous 
plasmid with targeting ssODN led to a 5-fold increase over targeting ssODN alone. 
Instead of a random plasmid, I chose to use a red fluorescent protein (RFP) expressing 
plasmid. I hoped that I would be able to use RFP expression to enrich for cells that had 
received a high amount of not only plasmid but ssODN as well.
Such enrichment is possible for co-transfections of two plasmids if one of the plasmids 
expresses a fluorescent protein.288,289 Also, dose-response has been clearly established 
for oligonucleotide-mediated gene editing. 184,245 Thus, I theorized that cells which 
expressed detectable RFP would be enriched in gene-edited cells. However, my results 
showed that this was not the case. Interestingly there was a slight but significant 
increase in gene editing efficiency with co-transfection compared to ssODN transfection 
alone, even though I was unable to identify cells that were both RFP and EGFP positive.
5.2.2 Results
CHO-mEGFP cells were transfected with 3 pg of mEGFP-3A-NT-PTO together with 
decreasing amounts (2, 1 and 0.5 pg) of pRFP (Figure 5-2; samples B, C and D). 
Control samples included cells treated with 5 pg mEGFP-Ctr-NT-PTO (A), 3 pg 
mEGFP-3A-NT-PTO (E) or 2 pg pRFP (F). A ssODN with no sequence homology to 
the CHO-mEGFP genome (huApoA-lM-49NT-PTO; Scr) was added where necessary to 
keep the total amount of transfected DNA identical between samples.
Cells were transfected as described before with a DNA to Lipofectamine 2000 ratio of 
1:2, though the total amount of transfected DNA was 5 pg, not 4 pg as usual with 
ssODN transfection alone. The total amount of transfected DNA was limited by the fact 
that Lipofectamine 2000 was highly cytotoxic at more than 10 pi per well.
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Figure 5-2 Effect o f plasmid co-transfection on gene editing efficiency
a) Samples transfected with the indicated amounts of pRFP, mEGFP-Ctr-NT-PTO (Ctr), mEGFP- 
3A-NT-PTO (3A) and huApoA-IM-49NT-PTO (Scr). Numbers represent means and error bars are 
the SD of triplicates.
b) Normalized percentage of green fluorescent cells achieved by setting the means of sample B in 
two independent experiments as 100% and normalizing all other samples in that experiment to this 
value. Numbers represent means and error bars are the SD of two independent experiments with 
triplicates each.
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Bonferroni post-tests b) P  value
B vs. C ns
B vs. D ns
B vs. E *
C vs. D ns
C vs. E ns
D vs. E ns
Bonferroni post-tests a) P  value
B vs. C ***
B vs. D ***
B vs. E ***
C vs. D **
C vs. E ***
D vs. E ***
Table 5-2 Effect of plasmid co-transfection on gene editing efficiency
Statistical significance of differences between samples in Figure 5-2a and b. P values for 
differences between samples were determined by one-way ANOVA and Bonferroni post-tests. *** 
P<0.001; ** .P<0.01; * P<0.05; ns P>0.05 grey text.
Cells were trypsinised and analysed 24 h after transfection. Propidium iodide could not 
be employed for dead cell discrimination in this experiment because its emission 
spectrum would overlap with RFP. Cells transfected with mEGFP-Ctr-NT-PTO (A) 
were used to set a forward scatter (FSC-H) versus side scatter (SSC-H) gate (Rl), which 
excluded most of the dead cells independent of propidium iodide staining (Figure 5-3 
left panel). One sample treated with mEGFP-3A-NT-PTO but no pRFP (E), and another 
sample treated with pRFP but no mEGFP-3A-NT-PTO (F), were used as the EGFP and 
RFP positive controls for autocompensation with WinList 6.0 (Figure 5-3 right panel). 
Figure 5-3 shows example data from one of the triplicates for each sample.
As shown in Figure 5-2a and Table 5-2, co-transfection with plasmid and targeting 
ssODN did significantly increase the gene editing efficiency over transfection with 
ssODN alone (1.36, 0.89 and 0.73% compared to 0.45%; P<0.001 for all pairs). This 
increase in gene editing efficiencies was dose-dependent as the percentage of green 
fluorescent cells was also significantly different between the samples with decreasing 
amounts of plasmid (samples B, C and D; Table 5-2). However, percentages of green 
fluorescent cells in a second independent experiment were significantly different as 
determined by two-way ANOVA.
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Figure 5-3 Flow cytometry plots of plasmid co-transfection
The FSC versus SSC plot of a cells transfected with mEGFP-Ctr-NT-PTO (sample A) was used to 
set R1 (left panel). Cells were gated based on R1 and EGFP fluorescence was plotted against RFP 
(right panel). EGFP+ cells appear in R2, RFP+ in R4 and double positive cells in R3. Cells treated 
with 3 pg mEGFP-3A-NT-PTO and 2 pg pRFP (B), 3 pg mEGFP-3A-NT-PTO (E) or 2 pg pRFP 
(F).
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Therefore, samples in each experiment were normalized with the mean of that 
experiment’s sample B (1.36±0.09 and 0.71 ±0.05) set as 100% and statistical 
significance of differences between samples was determined by one-way ANOVA with 
Bonferroni post-tests. Under these circumstances, only the co-transfection with the 
highest quantity of plasmid remained significant compared to transfection with ssODN 
alone (100% versus 47.5%; P<0.05; Figure 5-2b). Thus, co-transfection doubled the 
percentage of green fluorescent cells compared to transfection with ssODN alone.
However, the EGFP versus REP cytometry plots did not show a distinct double positive 
cell population (Figure 5-3; cells in R3) in the sample treated with both pRFP and 
ssODN (sample B), although there are clearly defined EGFP and RFP positive cell 
populations (1.44% in R2 and 5.16% in R4 respectively). Considering that these 
percentages represent 1168 EGFP and 4190 RFP positive cells, there should be 60 
double positive cells even if plasmid transfection and gene editing are independent 
events. This number is derived by calculating 1.44% of 4190 or 5.16% of 1168 cells.
5.2.3 Discussion
The results presented in this chapter were rather surprising. It appeared that even though 
I did not observe cells expressing both EGFP and RFP, co-transfection with pRFP did 
increase gene editing efficiency. The former suggests that transfection of plasmid and 
ssODN were mutually exclusive events, but the latter implies the exact opposite. It is 
difficult to understand how pRFP co-transfection could influence gene-editing 
efficiency when there were no detectable traces of RFP expression in GFP positive 
cells.
One could postulate that successfully gene-edited cells express such low amounts of 
RFP that they were undetectable or vice versa, but this would be pure speculation. In 
theory, dimly double positive cells could be hidden by the background fluorescence of 
the non-edited and non-transfected cells. It is difficult to distinguish such weak positive 
cells from background fluorescence reliably with flow cytometry, though it could be 
done with RT-PCR. That, however, would require cell lysis and the goal of this 
experiment was to select or at least enrich for gene-edited live cells.
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A possible explanation for the conundrum of increased gene-editing efficiency but no 
double positive cells could be that the increasing amounts of PTO-modified residues 
(the amount of huApoA-IM-49NT-PTO ssODN increased with the reduction in pRFP) 
led to an increase in cytotoxicity. If this was the case, the reduction in gene editing 
efficiency in samples with less or no pRFP would actually be due to an increase in 
cytotoxicity in those samples, not a real difference in gene editing. More experiments 
with an unmodified ssODN as the scrambled control would be needed to investigate this 
possibility.
Noteworthy is also that the limitation on the maximum amount of transfected DNA 
imposed by the cytotoxicity of Lipofectamine 2000 meant that l/4th less ssODN than 
usual was transfected. Without further experiments incorporating transfection of 4 or 
even 5 pg ssODN as gene-editing efficiency controls, no conclusions can be drawn 
about which transfection condition would give the highest efficiency.
Thus, the main point to take from these results is that plasmid co-transfection cannot be 
used to enrich for gene-edited cells.
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5.3 Selecting G2/M arrested cells by sorting
5.3.1 Introduction
A further attempt to enrich for gene-edited cells was based on data by Olsen et a l.242 
which showed that these cells accumulate in the G2/M phase of the cell cycle. Most of 
the gene-edited cells were terminally arrested, but a small percentage proceeded to form 
viable colonies. Considering the evidence that the targeting oligonucleotide is 
physically integrated into the genome of gene-edited cells259 it is likely that colony- 
forming edited cells escape from this G2/M arrest rather than not entering arrest at all.
Therefore, I thought that if I transfected synchronized CHO-mEGFP cells with ssODN 
and released the cells to proceed through the cell cycle, there would be a time point 
where all normally cycling cells would have gone through the G2/M stage. Any cells 
remaining in the G2/M phase at that time would then be enriched for gene-edited 
arrested cells.
Although technically challenging this experiment was feasible in my opinion. Cell- 
permeable DNA stains that allow flow cytometric cell cycle analysis without the need to 
fix cells are available. Such DNA stains bind stoichiometrically to DNA, so flow 
cytometric cell cycle analysis generates distinctive histograms: a high peak consisting of 
G0/G1 phase cells (one set of paired chromosomes per cell), a smaller peak for the 
G2/M phase (two sets o f paired chromosomes per cell, prior to cell division) and a 
spread between these peaks with S phase cells (DNA synthesis with variable amount of 
DNA). Cell cycle synchronization and cell sorting are also widely employed in cell 
biology. Thus, a combination of these three techniques should be possible.
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5.3.2 Results
Unfortunately, all DNA stains are cytotoxic to various degrees, but after researching the 
available options I settled upon Hoechst 33342. In preliminary experiments, I titrated 
the Hoechst 33342 to minimize cytotoxicity (data not shown). I found that good 
histogram data could be achieved at a minimum concentration of 5 pg per ml and lx l0 6 
cells. Even though the stain induced growth inhibition lasting 24-48 h at this 
concentration, the majority of cells recovered without difficulty (data not shown).
CHO-mEGFP cells were synchronized using 48 h serum starvation and subsequent 
incubation with 100 pM mimosine as described in section 2.2.1.5. This synchronization 
method was chosen because Dr. Petter Olsen found that it was optimal for inducing cell 
cycle arrest in CHO-mEGFP cells (personal communication). Immediately after release 
from the mimosine induced G1 block, cells were transfected with mEGFP-2A-NT-PTO 
as described before.
At 13 h after release from the cell cycle block, when non-arrested cells had proceeded 
through the G2/M phase according to Olsen et al.,242 5 pg per ml and lxlO6 cells 
Hoechst 33342 was added and lxlO 5 cells each were sorted for the G0/G1 and G2/M 
phase (Figure 5-4a). Unsynchronized control cells were also treated with mEGFP-2A- 
NT-PTO and sorted (Figure 5-4b). Cells were gated based on FSC versus SSC for 
viability and FSC-area versus FSC-width for doublet discrimination. Cells were sorted 
directly into full-growth medium containing 10% FBS and plated at lx l0 5 cells per well 
of a 6 -well plate.
Unfortunately, 24 h after sorting total cell death was observed in the synchronized 
samples, whereas the majority of non-synchronized cells recovered after 48 h (data not 
shown). Cells that were synchronized and transfected but not treated with the DNA stain 
did show moderate cell death.
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Figure 5-4 Sorting for G2/M arrested cells
Cells synchronized with serum starvation and 100 pM mimosine (a) or unsynchronized cells (b) 
transfected with mEGFP-2A-NT-PTO. G1 and G2 denote gates set for cells in the G0/G1 and 
G2/M cell cycle phases.
5.3.3 D iscussion
I concluded that the cytotoxicity of the synchronization treatment, combined with the 
toxicity of the DNA stain required for cell cycle analysis, was responsible for the total 
cell death observed in the synchronized and sorted cells. Perhaps a less toxic 
combination of synchronization method and DNA stain would lead to the recovery of 
live cells. Encouraging results show that the newly-developed Vybrant DyeCycle stains 
can be used to sort according to cell cycle though they do cause some growth 
retardation. However, the cells were not synchronized, so it is difficult to predict if 
these stains would be less toxic in combination with synchronization.
Depending on the time the stains remain attached to the DNA it might be possible to 
stain unsynchronized cells with a DNA-specific dye and then sort for cells in the G1 
phase. These “pseudo-synchronized” cells could then be transfected with targeting 
oligonucleotide and sorted again for cells arrested in the G2/M phase at a time when 
normally growing cells have passed the G2/M checkpoint. Thus, this approach might 
still be practicable to enrich for edited cells, if the technical problems can be overcome.
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5.4 FRET between genomic DNA and ssODN
5.4.1 Introduction
As discussed above, dose response curves have previously been described for 
oligonucleotide-mediated gene editing, 184 however in these studies only the 
concentration during transfection was taken into consideration. As the oligonucleotide 
has to reach the nucleus in order to function in gene editing and undefined amounts of 
complex are lost during transfection, this is not a very accurate measurement of 
functional reagent at the site of activity.
Recently, Murphy et al.244 demonstrated that when cells were sorted according to the 
successfully transfected amount of Cy5-labelled oligonucleotide, the cells with higher 
ssODN amounts had a higher probability of correction. However, flow cytometry can 
only determine if and how much Cy5-ssODN is present in each cell, but not where in 
the cell it is located. Again this is not an accurate measurement of functional reagent at 
the site of activity.
In this experiment I attempted to employ fluorescence resonance energy transfer 
(FRET) between Cy5-labelled ssODN and Cy3-labelled genomic DNA to gain a more 
accurate measurement of the amount of close spatial interaction between the targeting 
oligonucleotide and the genomic DNA. From the previously published data I predicted 
that I would be able to enrich for cells most likely to be gene-edited by this method, 
hopefully to a higher degree than Murphy et a l244 achieved.
The first step was to label genomic DNA with Cy3-dCTP. Labelling genomic DNA 
with fluorescent nucleotides is a fairly standard method in chromosome studies, 299 but 
usually involves microinjection (limiting the number of labelled cells), cell 
permeabilization with glass-beads (not overly successful according to literature) or a 
“micro-scratch” technique (which also limits cell numbers). However, another 
publication reported successful use of electroporation to transfect a biotin-labelled 
dUTP .300
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5.4.2 R esults
Therefore, I electroporated 3x l05 CHO-mEGFP cells with 20 pM of Cy3-dCTP and 
seeded the cells into two wells of a 6-well plate. Another 1.5xl05 cells were not 
electroporated, but 20 pM Cy3-dCTP was added before seeding (section 2.2.1.6). The 
cells were examined under the fluorescence microscope 2 h after electroporation, or at 
the start o f incubation with Cy3-dCTP. As seen in Figure 5-5a more than 75% of 
electroporated cells had taken up the labelled nucleotide. There was no accumulation of 
fluorescence in the cells incubated, but not electroporated, with Cy3-dCTP up to 24 h 
after the start o f the experiment (data not shown).
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Figure 5-5 Cy3-dCTP electroporated and Cy5-ssODN transfected cells
a) CHO-mEGFP cells electroporated with Cy3-dCTP; left panel phase contrast, right panel Cy3.
b) CHO-mEGFP cells from a) transfected with Cy5-ssODN; left panel phase contrast, right panel 
Cy5.
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The electroporated cells were transfected using Lipofectamine 2000 and Cy5-huAIM- 
49NT-PTO ssODN 24 h later to allow time for the Cy3-dCTP to be integrated into the 
genomic DNA. Fluorescence microscope observation 24 h after the lipofection showed 
that the Cy5-ssODN was easily transfected (Figure 5-5b), however the Cy3 signal was 
no longer detectable (data not shown).
Therefore, I attempted to transfect Cy3-dCTP (0.2 pg) at the same time as Cy5-ssODN 
(2 pg) with 4 pi Lipofectamine 2000. Cells transfected with Cy3-dCTP only and Cy5- 
ssODN only were used as fluorescence controls. The Cy5-ssODN/Cy3-dCTP solution 
and the Lipofectamine 2000 were diluted in 125 pi OptiMEM each, mixed and added to 
one well of a 12-well plate containing lxlO 5 cells in 500 pi antibiotic-free medium. 
Cells were washed into fresh medium 1.5 h after the start of transfection and observed 
under the microscope 1 h later. Unfortunately, no signal could be detected in the Cy3 
channel in any of the samples, not even in the Cy3-dCTP only control. There was a 
strong signal in the Cy5 channel in the Cy5-ssODN only and Cy5-ssODN/Cy3-dCTP 
transfected samples (data not shown).
In another effort to transfer both the Cy3-dCTP and the Cy5-ssODN into cells within a 
reasonable timespan, I used the Influx pinocytic cell-loading reagent to load 0.2 pg 
Cy3-dCTP into lxlO6 cells (section 2.2.1.6). This reagent has been used to load Alexa 
Fluor hydrazides and Texas Red dextran into cells. Observation under the microscope 
showed that immediately after loading, up to 75% of cells had taken up the Cy3-dCTP. 
The staining pattern 14 h after loading was congruent with that observed after 
fluorescent ssODN transfection. Confocal microscopy of ssODN transfected cells has 
previously shown that this pattern is characteristic for staining of the nucleus (section 
4.1.1).
Cells were then transfected with 4 pg mEGFP-Cy3-3A-NT-PTO oligonucleotide using 
Lipofectamine 2000. The incubation time with transfection complex was reduced to 45 
min, as cells appeared stressed (Figure 5-6a). One hour after the end of transfection (or t 
= 16 h after the start of the experiment) cells were examined for both Cy3 and Cy5 
signals Figure 5-6b). Another 24 h later (t = 40 h) gene-edited EGFP positive cells 
could also be seen (Figure 5-6 c).
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Several attempts to study cells treated in this manner on a flow cytometer at t = 16 h did 
not result in usable data as the success of the Cy3-dCTP loading seemed to be rather 
variable and excess Cy5 signal interfered with detection of any possible FRET. In some 
experiments there were very few surviving cells after loading and lipofection.
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Figure 5-6 Cy3-dCTP loaded and Cy5-ssODN transfected cells
a) CHO-mEGFP cells loaded with Cy3-dCTP 14 h after start o f experiment, b) Same cells 1 h 
after transfection with Cy5-ssODN.
c) Same cells 24 h after transfection with Cy5-ssODN when gene-edited EGFP positive cells were 
visible.
C
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5.4.3 Discussion
Here, I attempted to employ FRET between Cy3-dCTP, which had been integrated into 
genomic DNA, and Cy5-ssODN to select for cells that have a high amount of spatially 
close interaction leading to FRET between the partners. Although I managed to transfer 
both the labelled nucleotide and targeting ssODN into the cells after some optimization, 
I could not detect any FRET signal on the flow cytometer. Perhaps further optimization 
of the amount of Cy3-dCTP loaded into cells or of the exact timing of loading and 
transfection could improve results.
There are several points to take from these results. It appears that either Lipofectamine 
2000 is not able to transfect Cy3-dCTP into cells or that the amount of Cy3-dCTP (0.2 
pg) was not high enough for detectable fluorescence. The latter seems unlikely though, 
as 2 pg Cy5-ssODN resulted in strong fluorescence. Considering that the ssODN was 49 
bp long and contained one Cy5-dNTP per molecule, the transfected amount of Cy5- 
ssODN had about 5 times less fluorescent entities than the amount of Cy3-dCTP.
The amount of Cy3-dCTP (0.2 pg) loaded into the cells with the Influx pinocytic 
reagent also seemed adequate for fluorescence microscopy. However, there is a 
difference in sensitivity between microscopy and flow cytometry as the former permits 
longer exposure times, whereas the latter relies on higher laser excitation power, but 
very short exposure. It might be worthwhile to examine possible FRET under the 
confocal microscope before attempting to transfer to flow cytometry.
The main disadvantage of using confocal microscopy is that it is impossible to recover a 
reasonable number of live cells from a mixed population with this method, but at least it 
would establish if FRET detection of the interaction between targeting ssODN and 
genomic DNA is possible per se. Even if it is possible to detect such interaction by 
confocal microscopy it might be impossible to use it for sorting cells with flow 
cytometry because of the technical difficulties involved.
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CHAPTER 6: VALIDATION OF 
OLIGONUCLEOTIDE-MEDIATED 
GENE EDITING
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6.1 Introduction
In response to the chimeraplasty controversy (section 1.4.5.2 and 1.4.5.3), 
Albuquerque-Silva et al?21 proposed four experimental criteria for rigorous validation. 
First, the targeting oligonucleotide must introduce a rare mutant genotype to rule out 
spontaneous reversion events. Second, this genotype should not exist in cells within the 
laboratory to prevent cross-contamination artifacts. Third, mutated clones must be 
studied individually to exclude PCR and sequencing artifacts caused by large molar 
amounts o f targeting oligonucleotides. Fourth, editing efficiency must be confirmed at 
the protein level in pooled cells at time points that eliminate artefacts of selection and 
expansion of rare spontaneous mutations.
In this chapter, I set out to validate oligonucleotide-mediated gene editing as a viable 
technology with experiments fulfilling these requirements. I used the previously 
described CHO-mEGFP cells (chapter 4) as they allow easy selection of green 
fluorescent single cells which presumably are gene-edited. However, selection based 
solely on restored fluorescence cannot exclude spontaneous reversion events.
Consequently, I designed a targeting ssODN that introduces three specific base changes. 
Two of the nucleotide changes alter the Serine at position 6 6  in the mEGFP sequence 
(TCC) to a Tyrosine triplet (TAT) different from the codon in wtEGFP (TAC).The third 
creates a synonymous Threonine codon in the upstream position (ACA instead of ACC; 
Figure 6-1). In addition to creating a rare mutant genotype, my ssODN design generates 
a novel Ndel restriction endonuclease site in the target sequence, which allows 
successful gene-editing to be distinguished from reversion by Southern blotting. Thus, 
my experiments fulfilled Albuquerque-Silva’s first criterium.
No cells or plasmids containing these sequences existed in the laboratory (or, to my 
knowledge, worldwide), thus obviating cross-contamination artefacts (Albuquerque- 
Silva’s second criteria). I also interpreted the third requirement conservatively and 
avoided the potential for PCR and sequencing artefacts caused by large molar amounts 
o f targeting oligonucleotides by using flow cytometry for detection and quantification.
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The fourth condition states that editing efficiency must be confirmed at the protein level 
in pooled cells at time points that eliminate artefacts of selection and expansion of rare 
spontaneous mutations. Therefore, I transfected the CHO-mEGFP cells with targeting 
ssODN and isolated single green fluorescent cells 24 h later by fluorescence-activated 
cell sorting.
I confirmed the presence of the three specific nucleotide changes in the genomic DNA 
of two independently selected clones by Southern blotting. Figure 6-1 shows a 
schematic of the expected Southern blot band sizes depending on which enzyme 
combination was used for digestion of the genomic DNA and which probe was 
hybridized to the resulting DNA fragments. It is important to remember that the CHO- 
mEGFP cells used here contain multiple copies o f the mEGFP gene and that it is 
unlikely that more than one or two of the mEGFP copies have been gene-edited. Thus, 
the mEGFP Southern blot bands from edited clones will not be noticeably reduced in 
intensity compared to the parental CHO-mEGFP cells, though there should be 
additional bands demonstrating the presence of at least one edited EGFP (edEGFP) 
copy.
The predicted band sizes when edited clones are hybridized with Probe A are 576 bp for 
edEGFP digested with Ndel and Mfel (0 ) , Ndel and Dral (0 )  or Ndel and Xbal (0 ). 
Band sizes for the non-edited mEGFP alleles should be 1271 bp (©), 1223 bp (0 )  and 
1168bp ( 0 )  respectively. For edited clones hybridized with Probe B, the expected band 
sizes are 695 bp (©), 647 bp (0 )  and 592 bp ( 0 )  for edEGFP, whereas the band sizes 
for mEGFP alleles are the same as with Probe A. Hybridization with both Probe A and 
Probe B will result in an amalgamated pattern of the bands, so that edEGFP will be 
denoted by a 576 bp band in all three enzyme combinations as well as 695 bp (©), 647 
bp ( 0 )  and 592 bp ( 0 )  bands depending on which downstream restriction enzyme was 
used in combination with Ndel. The non-edited mEGFP alleles will show 1271 bp (©), 
1223 bp ( 0 )  and 1168bp (0 )  bands respectively.
Sequencing of edited EGFP (edEGFP) gene alleles recovered from these clones also 
showed the specific nucleotide alterations. Thus, I have validated oligonucleotide- 
mediated gene editing as a viable technology for introducing up to three nucleotide 
changes in the genomic DNA of mammalian cells.
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Figure 6-1 Schematic for validation of gene editing by Southern blotting
Mutated EGFP contains a Tyrosine (TAC) to Serine (TCC) substitution at amino acid 66, which 
destroys the central chromophore region and renders the protein non-fluorescent. The control 
ssODN is homologous to the mEGFP sequence, whereas the 3 A ssODN contains three mismatches 
(red letters) that change the Serine (TCC) triplet back to an alternative Tyrosine codon (TAT) and 
add a silent mutation in the upstream Threonine codon (ACC to ACA).
Thus, green fluorescence is re-established (gray shading) and a novel Ndel restriction 
endonuclease recognition site is created (black boxes). As CHO-mEGFP cells contain multiple 
transgene copies, both edited EGFP (edEGFP) and mEGFP alleles will be present in gene-edited 
clones. Digestion with Ndel and the downstream enzymes Mfel (©), Dral (©) and Xbal (©) is 
predicted to yield diagnostic bands of the indicated sizes.
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6.2 Results
I selected two green fluorescent mEGFP clones (11-B10 and 20-A11) from the colonies 
I obtained previously when evaluating viability of cells treated with modified or 
unmodified ssODN (section 4.3.1). Both cell clones were derived from cells treated 
with the unmodified ssODN and grown for more than 4 weeks after selection before I 
extracted genomic DNA as described in section 2.2.2.1. Per lane, 15 pg genomic DNA 
was double digested with Ndel and the downstream enzymes Mfel (©), Dral ((D ) or 
Xbal ((D ) as explained in section 2.2.2.4.
Samples were concentrated and loaded onto a 1.5% TAE-agarose gel as well as 2 pg of 
100 bp DNA ladder (section 222.1). After gel electrophoresis, the gel was 
photographed together with a fluorescent ruler and Southern blotting was performed as 
detailed in section 2.2.2.10. The blotting membrane was hybridized with Probe B, 
which binds downstream of the newly generated Ndel site and will result in diagnostic 
bands of varying length depending on the enzyme combination (see Figure 6-1 for 
details).
Pre-flashed Kodak Biomax-MS film was exposed to the membrane for 2 - 24 h at -70 
°C. The size of bands on the blot was established by marking the distance that marker 
bands had migrated from the wells according to the gel-photograph. Thus, the size of 
diagnostic bands could be ascertained.
As can be seen in Figure 6-2, both independent clones (11-B10 and 20-A 11) did show 
the expected diagnostic bands when digested genomic DNA was hybridized with Probe 
B, while untreated CHO-mEGFP cells digested with the same enzyme combinations did 
not. The 695 bp (©), 647 bp (©) and 592 bp ((D ) bands characteristic for the edEGFP 
allele were clearly present in the genomic DNA from clone 11-B10 (Figure 6-2a). The 
bands were also present in digested genomic DNA from clone 20-A ll (Figure 6-2b), 
though this blot lacked samples digested with Ndel and Xbal ((D ).
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a CHO-mEGFP 11-B10 b  CHO-mEGFP 20-A11
Figure 6-2 Southern blots of gene-edited clones 11-B10 and 20-A ll
Southern blots o f untreated CHO-mEGFP cells and independently derived clones 11 -BIO (a) and 
20-A11 (b) hybridized with Probe B. Labelling on the left marks the location of marker bands and 
on the right the position of diagnostic bands: 695 (©), 647 bp ((D) and 592 bp ((D) are 
characteristic for edEGFP; 1271 (©), 1223 (©) and 1168bp ((D) for mEGFP. See also Figure 6-1.
To confirm these results, a second set of Southern blots was performed on both clones. 
This time, the 11-BIO Southern blot was hybridized with both Probe B and Probe A, 
which binds upstream of the newly generated Ndel site, but downstream of an 
established Ndel site. Thus, hybridization with Probe A will result in diagnostic bands 
o f the same length in all enzyme combinations (see Figure 6-1 for details).
As shown in (Figure 6-3a) hybridization of digested 11-B10 genomic DNA with Probe 
A and Probe B resulted in clearly visible 576 bp diagnostic bands in all digestion 
samples as well as 695 bp, 647 bp and 592 bp diagnostic bands in digestions ©, © and 
© respectively.
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CHO-mEGFP 11-B10 b  CHO-mEGFP 20-A11
Figure 6-3 Southern blots of gene-edited clones 11-B10 and 20-A ll
Southern blots o f untreated CHO-mEGFP cells and independently derived clones 11-BIO (a) and 
20-A11 (b) hybridized with Probe A and B (a) or Probe A only (b). Labelling on the left marks the 
location of marker bands and on the right the position of diagnostic bands: 576 bp (Probe A), 695 
bp (©), 647 bp (© ) and 592 bp ((D) (Probe B) are characteristic for edEGFP; 1271 (©), 1223 (©) 
and 1168bp (CD) for mEGFP. See also Figure 6-1.
A Southern blot of clone 20-A11 hybridized with Probe A (Figure 6-3b) also displayed 
the diagnostic 576 bp band, but not in untreated CHO-mEGFP cells digested with the 
same restriction enzymes. However, two unspecific bands with sizes of around 530 bp 
and 480 bp (© and © respectively) were visible in clone 20-A ll as well as the CHO- 
mEGFP control cells.
As expected, 1271 bp (©), 1223 bp ((D) and 1168bp ((D) bands characteristic for the 
presence of mEGFP alleles were evident in both gene-edited and untreated CHO- 
mEGFP cells (Figure 6-2 and Figure 6-3). There was no discernible reduction in the 
intensities of these bands in the gene-edited clones, even when X-Ray film exposure 
times were optimized to reduce saturation of these particular bands (data not shown).
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Notably, all Southern blots demonstrated identical patterns of non-diagnostic higher 
molecular weight bands in samples from parental CHO-mEGFP cells and gene-edited 
clones, when these were digested with the same enzyme combination and hybridized 
with the same probes (Figure 6-2 and Figure 6-3).
To corroborate the findings from Southern blotting, edited EGFP allele(s) were 
recovered from the genomic DNA of clone 11-B10 by PCR and cloned into a plasmid 
as described in section 2.2.2.11. Sequencing (section 2.2.2.12) of the inserts 
demonstrated the presence of the three specific nucleotide changes (Figure 6-4a), while 
non-edited alleles showed the mEGFP genotype (Figure 6-4b).
Alignment o f the sequence traces from edited alleles revealed that in one of the bacterial 
clones there was an additional mutation (GGC Glycine instead of AGC Serine) in the 
nucleotide after the 27 bp sequence stretch targeted by the editing ssODN, i.e. 5’ 
proximal to the start o f the targeting ssODN (data not shown). However, other bacterial 
clones containing edited alleles did not show this mutation.
edEGFP
A C A T A T  G G C
Thr Tyr Gly
mEGFP
A C C T C C G G C
Thr Ser Gly
Figure 6-4 Sequencing of edEGFP and mEGFP alleles
Sequence traces of edEGFP (a) and mEGFP (b) alleles recovered from clone 11 -B10. Nucleotide 
differences between alleles are highlighted with grey shading.
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6.3 Discussion
In this chapter I have established without doubt that oligonucleotide-mediated gene 
editing does introduce specific nucleotide changes into the genomic DNA of 
mammalian cells. Southern blots of two independently derived clones (11-B10 and 20- 
A l l )  using probes from either side of the nucleotide alterations showed bands of the 
predicted sizes in every case. All three nucleotide changes were required for the 
generation of the Ndel site, so the Southern blotting results alone demonstrate that these 
changes were introduced into the genome.
Furthermore, comparison of the higher molecular weight non-diagnostic bands on all 
Southern blots verified that the gene-edited clones 11-BIO and 20-All are isogenic 
derivatives of the parental CHO-mEGFP cells. Notably, the intensities of the mEGFP 
diagnostic bands did not change in the gene-edited clones confirming the assumption 
that only one or two alleles of the multiple mEGFP copies had been gene-edited.
My experiments fully conformed to the four criteria postulated by Albuquerque-Silva et 
al, : 227
(1) Conversion to a rare mutant genotype to exclude spontaneous reversion events. In 
my experiments, the targeting ssODN introduced three specific nucleotide changes and 
hence completely excluded the possibility of spontaneous events.
(2) Absence o f the specific mutation in cell lines or plasmids used in the laboratory to 
avoid contamination artefacts. Before undertaking these experiments, the novel EGFP 
variant did not exist in the laboratory in any form except as the editing oligonucleotides.
(3) Analysis o f  isogenic edited clones to prevent artefacts caused by the presence o f  
residual oligonucleotide in genomic DNA that could generate false positives with PCR- 
based detection. My initial analysis of clones avoided PCR altogether, relying on 
phenotypic separation by flow cytometry and Southern blotting.
(4) Quantitative analysis at the protein level at time points that exclude artefacts o f  
selection and expansion o f  rare spontaneous mutations. I used flow cytometric analysis 
of editing efficiencies at very early time points, before any selection could operate.
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In this way, I eliminated all possible scenarios suggesting that my results could be 
derived from artefacts and therefore incorporation of the three specific nucleotide 
sequence alterations cannot be explained other than by editing. Radecke et a l 2AX have 
previously shown the presence of a novel restriction site in edited cells by Southern 
blotting. However, restoration of fluorescence in their system could, in principle, have 
resulted from a spontaneous event because only a single nucleotide change was 
generated.
The presence of the three specific nucleotide changes in edited clones was also 
substantiated by sequencing of PCR products recovered as bacterial plasmids. As the 
clones were derived from single cells and cultured for over 4 weeks after the initial 
transfection with targeting ssODN, no targeting ssODN could have remained in the 
cells. Thus, the sequencing results presented here cannot have been due to a PCR 
artefact caused by the gene editing oligonucleotide.
However, comparison of the sequence traces from different bacterial colonies derived 
from clone 11-BIO showed that there was an additional mutation in one of them. All 
other sequence traces did not show extra nucleotide changes. This could suggest that 11- 
B10 contains two gene-edited EGFP alleles, one with the additional mutation and one 
without it. More likely though, this change was introduced during PCR amplification of 
the EGFP gene from genomic DNA, even though the proof-reading polymerase Pfii 
Turbo was used.
These results highlight the fact that research has not yet answered the question of how 
accurate oligonucleotide-mediated gene editing is in introducing only the intended and 
not additional nucleotide changes. If three nucleotide changes can be made in the 
genomic DNA, target sequence selection will have to take into account closely 
matching sequences from members of the same gene family or even different families if 
the target sequence is in a highly conserved domain.
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CHAPTER 7: GENE EDITING 
LEADS TO A STABLE GENOTYPE 
AND IS POSITIVELY ASSOCIATED 
WITH EXPRESSION
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7.1 The genetic changes are stable but EGFP expression is not
7.1.1 Introduction
During the experiments described in the previous chapter, I observed that only a low 
percentage of cells in the gene-edited clones 11-BIO and 20-A ll exhibited green 
fluorescence and that this percentage progressively declined over time in culture. 
Although these cell lines were established from sorted single cells, the possibility 
existed that each clone was derived from more than one cell. However, when I isolated 
green fluorescent and non-fluorescent sub-clones of 1 1 -BIO, again by single cell 
sorting, every single one of the resulting sub-clones including all the clones derived 
from EGFP negative cells contained green fluorescent cells in varying proportions. The 
percentages o f green fluorescent cells in these sub-clones also declined over time in 
culture, yet Southern blot analysis of two sub-clones derived from non-fluorescent cells 
confirmed the continued presence of the three specific sequence changes.
This behaviour suggested epigenetic modulation of expression. To investigate this, I 
treated a number of 1 1 -BIO sub-clones with the histone deacetylase inhibitor sodium 
butyrate and the cytosine analogue 5-aza-2’-deoxycytidine which prevents DNA 
methylation. Both reagents have been shown to raise transgene expression from silenced 
CMV promoters301 and, indeed, percentages of green fluorescent cells were significantly 
increased after such treatment.
This raised the question whether the epigenetic down-regulation was specific to the 
gene-edited copy or if  all copies of the EGFP gene, including the uncorrected ones, 
were similarly affected. Silencing of integrated transgenes is a well-known 
phenomenon, 84,302 but if the targeting oligonucleotide is indeed integrated into the 
genomic sequence, the gene editing event itself could potentially result in down- 
regulation of the target gene. However, intracellular staining with an antibody 
recognizing both the mutated and edited EGFP revealed that all cells in which EGFP 
protein was detectable by antibody staining were also green fluorescent, and that the 
levels of green fluorescence and EGFP protein were directly proportional to each other. 
Surprisingly, the majority of cells in the corrected (sub-)clones did not detectably 
express any form of EGFP.
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Therefore, I investigated the stability of mEGFP expression in the parental CHO- 
mEGFP cells. Notably, I found that even in the earliest passage cells available to me 
(passage 4 after the initial freeze) only 20% of cells actively expressed mEGFP and that 
this percentage also rapidly decreased over time in culture, despite the fact that these 
cells were isogenic. Thus, the epigenetic down-regulation was a result of the transgene 
reporter gene system and was not due to the gene editing event.
7.1.2 Results
7.1.2.1 Green fluorescent cells are lost from the population of gene-edited cells
The gene-edited cell lines 11-BIO and 20-A ll were regularly observed under the 
fluorescence microscope for several weeks after selection to examine viability and cell 
density. I found that less than 30% of cells from 11-B10 (Figure 7-la) and less than 5% 
from 20-A ll (Figure 7-lb) demonstrated green fluorescence and that this percentage 
decreased rapidly over time in culture. Also, the intensity of fluorescence was variable 
between green cells o f the same clone and small colonies of fluorescent cells developed 
after sub-culturing (Figure 7-lc).
Even though both clones were supposedly derived from single sorted cells and doublet 
discrimination had been employed during sorting, it was possible that the clones were 
derived from more than one cell. Thus, I re-cloned 11-B10, again by single cell sorting, 
and isolated both fluorescent and non-fluorescent cells. Remarkably, every single sub­
clone derived from these cells contained green fluorescent cells on expansion, including 
over 60 sub-clones derived from cells identified by FACS as EGFP-negative (Figure 
7-2a; and data not shown).
The proportion of fluorescent cells in sub-clones was variable, but generally higher in 
those derived from EGFP-positive cells (Figure 7-2b; and data not shown), although this 
progressively fell to the low levels of negative-sorted cells over time in culture.
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Phase EGFP
Figure 7-1 Fluorescence microscope pictures of gene-edited clones
The gene-edited clones 11-B10 (a) and 20-A 11 (b) 10 d after selection. Clone 11-B10 30 d after 
selection (c).
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Figure 7-2 Fluorescence m icroscope pictures o f  11-B10 sub-clones
Sub-clones o f gene-edited clone 11 -B 10 derived from single cells that were non-fluorescent (a) or 
that were strongly green fluorescent (b) at the time of sorting. Phase contrast and EGFP 
fluorescence pictures o f the same area were captured and then overlaid with LuciaG software.
As part o f the sort, I also collected 5xl04 cells each of EGFP-negative, low positive or 
bright positive cells. According to post-sort observation under the microscope, sorting 
purity was higher than 95% (data not shown). Yet when I compared these sorted cell 
pools to the parental 1 1  -B 1 0  clone using flow cytometry 1 2  d later, only small 
differences in the percentage of green fluorescent cells remained. For this experiment, 
EGFP-negative cells, low positive and bright positive, as well as parental 11 -B 10 cells, 
were trypsinised as usual and treated with propidium iodide for dead cell discrimination. 
For each sample lxlO 5 cells were acquired on a flow cytometer, gated based on FSC vs 
SSC as well as PI and plotted according to their EGFP fluorescence.
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EGFP
Figure 7-3 Percentage o f green fluorescent cells in 11-B10 its subpopulations
Histogram overlay o f unsorted 11 -BIO (red fill) with negative (green), medium positive (blue) and 
bright positive (yellow) sorted pooled cells. Cells in region Ml are EGFP-positive.
The resulting histograms for negative, medium positive and bright positive cells were 
overlaid onto a histogram of unsorted 11-B10 cells using WinMDI 2.8 software. CHO- 
mEGFP cells were used as a negative control and region M l was set accordingly to 
quantify the percentages of EGFP-positive cells. As shown in Figure 7-3, only small 
differences are apparent between the parental and sorted sub-populations. Thus, 20.19% 
of unsorted 11-B10 cells showed green fluorescence compared to 16.77%, 22.80% and 
26.94% of cells in the negative, low positive and bright positive sorted cell pools, 
respectively.
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7.1.2.2 This loss is due to instability of the phenotype not the genotype
To corroborate that the green fluorescence in the 11-BIO sub-clones was due to the 
continued presence o f the three specific nucleotide alterations of the edEGFP variant, I 
performed a Southern blot on selected sub-clones as previously described (section 6.2). 
Genomic DNA was extracted from the sub-clones 3-C8, 3 -E l2 and untreated CHO- 
mEGFP cells and digested with Ndel and Mfel ( 0 )  or Ndel and Dral (0 ) . Both sub­
clones were derived from cells identified as EGFP-positive during sorting.
3-C 8 3-E 12  CH O -m EG FP
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69 5  bp  — 
647 bp  -
Figure 7-4 Southern blot of 11-B10 sub-clones 3-C8 and 3-E12
Southern blot of untreated CHO-mEGFP cells and sub-clones 3-C8 and 3-E l2 hybridized with 
Probe B. Predicted edEGFP band sizes: 695 (©) and 647 bp (©); mEGFP band sizes: 1271 (©) 
and 1223 (©). See also Figure Figure 6-1.
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After blotting and hybridization with Probe B, clone 3-C8 displayed the 695 bp band 
characteristic for the presence of at least one edEGFP allele when digested with Ndel 
and Mfel (Figure 7-4). Digestion of DNA from clone 3-E12 with Ndel and Dral 
resulted in the expected edEGFP diagnostic band at 647 bp. The clones also showed the 
1271 or 1223 bp bands typical of mEGFP alleles after digestion with Ndel and Mfel 
(©) or Ndel and Dral ((D ). The CHO-mEGFP control samples showed the mEGFP, but 
not the edEGFP diagnostic bands (Figure 7-4). The patterns of non-diagnostic bands 
with higher molecular weight were similar in the sub-clones and CHO-mEGFP cells 
confirming the isogenic descent of the sub-clones.
In light of these results, it seemed that the loss of green fluorescent cells from the 
populations of the (sub-)clones was not due to instability of the introduced genomic 
alterations, but instability of EGFP expression as a result of epigenetic down-regulation. 
Therefore, I treated several sub-clones of 11-BIO with reagents that enhance transgene 
expression. I selected four sub-clones derived from EGFP-negative (1-E8, 4-D4, 4-F4 
and 4-G4) or EGFP-positive cells (3-A2, 3-B7, 3-El2 and 3-H1) and incubated them 
with 2 mM of sodium butyrate and 4 pM 5-aza-2’-deoxycytidine (Aza-dC) for 48 h. 
Sodium butyrate is a histone deacetylase inhibitor and Aza-dC a cytidine analogue that 
inhibits DNA methylation; both have been shown to increase transgene expression.301
After incubation, cells were allowed to recover for 24 h in fresh growth medium. In 
addition to the treated samples, untreated control samples from each sub-clone were 
prepared for flow cytometry as described before. Also, treated and untreated CHO- 
mEGFP cells were included as negative control for EGFP fluorescence. For each 
sample lx l0 5 cells were acquired and plotted according to their EGFP fluorescence. 
The resulting histograms of untreated and treated samples from each sub-clone were 
overlaid using WinMDI (Figure 7-5) and region M l was set to quantify the percentage 
of EGFP-positive cells using the treated CHO-mEGFP negative control.
As shown in Figure 7-5, incubation with sodium butyrate and Aza-dC has a significant 
effect on the percentage of cells expressing detectable levels of EGFP fluorescence. For 
example, in clone 1-E8 only 1.41% of untreated cells, but 22.56% of treated cells are 
green fluorescent, a 15-fold increase.
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Figure 7-5 11-B10 sub-clones treated with sodium butyrate and Aza-dC
Eight sub-clones of the gene-edited clone 11-BIO derived from single cells that were non- 
fluorescent (1-E8, 4-D4, 4-F4 and 4-G4) or cells that were strongly green fluorescent (3-A2, 3-B7, 
3-El 2 and 3-H1) at the time of sorting were either untreated (red fill) or treated with 2 mM sodium 
butyrate and 4 pM Aza-dC (black line). Numbers represent the percentage of untreated (red) or 
treated (black) cells in region M l. Data are representative of two independent experiments.
In the other sub-clones that were derived from EGFP-negative cells, percentages of 
green cells increased about 10-fold upon treatment. Increases in the sub-clones derived 
from EGFP-positive cells were generally lower (4-fold for 3-A2, 2-fold for 3-B7 and 5- 
fold for 3-H1), though clone 3 -E l2 also showed a 10-fold rise.
However, region M l had to be repositioned for clone 3-B7 as the majority o f cells in 
this sub-clone was very strongly EGFP-positive even before treatment. Indeed, 
incubation with sodium butyrate and Aza-dC resulted in such high EGFP expression in 
this sub-clone that the majority o f cells exceeded the detection range of the flow 
cytometer under the acquisition settings used for the other sub-clones.
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7.1.2.3 EGFP down-regulation is not specific to the gene-edited copy
These results demonstrated that the loss of green fluorescent cells from the populations 
of gene-edited clones was due to instability of the phenotype, whereas the genotype was 
stable. Although gene silencing is a well-established phenomenon in mammalian 
transgene systems the possibility existed that the silencing was specific to the edited 
EGFP allele, i.e. that the gene editing event itself had induced the silencing.
To clarify this question, I fixed and permeabilized cells from the gene-edited clone 11- 
B 1 0  and several of the 1 1 -B 1 0  sub-clones and then stained with a rabbit polyclonal anti- 
EGFP antibody as described in 2.2.1.8. This antibody detects both the mutated (non- 
fluorescent) and edited (fluorescent) EGFP forms. To avoid any possible compensation 
artefacts, the antibody was labelled with Alexa Fluor 647 as this fluorophore’s 
excitation and emission spectra do not overlap with those of EGFP.
CHO-mEGFP cells were used as single stain positive control as they express EGFP, but 
are not green fluorescent. Fixed and permeabilized cells from the gene-edited, and 
therefore green fluorescent, sub-clone 3-B7 were stained with an isotype control 
antibody (rabbit polyclonal anti-human C reactive protein antibody) labelled with Alexa 
Fluor 647 for use as the second single stain positive control. CHO-K1 cells, the parental 
line of CHO-mEGFP cells, stained with the anti-EGFP antibody were used as the 
double negative control because they do not express EGFP nor are they green 
fluorescent.
For each sample, 2xl04 events were acquired on the flow cytometer, gated based on 
FSC versus SSC and the green fluorescence from expression of the edEGFP allele(s) 
was plotted against the EGFP (mEGFP and edEGFP) expression detected with the 
Alexa Fluor 647 labelled pan-EGFP antibody. The double-negative CHO-K1 cells 
together with the single stain positive CHO-mEGFP and 3-B7 isotype controls were 
used to determine the respective regions on the green fluorescence versus EGFP 
expression plots (Figure 7-6).
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Figure 7-6 Correlation of fluorescence and EGFP expression in edited (sub-)clones
Density plots of green fluorescence from edEGFP expression (x-axis) versus intracellular staining 
with an Alexa Fluor 647 labelled pan-antiEGFP antibody recognizing both mEGFP and edEGFP 
(y-axis). CHO-K1 cells were used as a control to determine non-expressing cells; CHO-mEGFP 
and the 3-B7 sample stained with isotype antibody were used as single stain positive controls. 
Clone 11-BIO was confirmed to be gene-edited and its subclones 1-E8 and 3-B7 were derived 
from non-fluorescent and strongly green fluorescent single cells respectively (see Figure 7-2). Data 
are representative o f three independent repeats.
Surprisingly, when comparing the EGFP expression in CHO-mEGFP cells with CHO- 
K1 cells, I found that >85% of CHO-mEGFP cells did not express mEGFP at all. 
Similarly, 96.05% and 95.47% of cells in the gene-edited clone 11 -BIO and its sub­
clone 1-E8 did not express any form o f EGFP, be it fluorescent edEGFP or non- 
fluorescent mEGFP. This percentage remained relatively stable for 11-BIO 
(94.93±0.87%, n=3), but had increased from 90.48% in a previous independent repeat to 
96.54% in a subsequent repeat for clone 1-E8. The percentage o f non-expressing cells in 
the gene-edited sub-clone 3-B7 was 46.62% in this particular experiment, but had risen 
from 26.55% to 69.15% during the three experiments.
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Similar to the CHO-mEGFP control, cells expressing non-fluorescent mEGFP, but not 
fluorescent edEGFP would appear in region R2. Notably though, all cells in the gene- 
edited (sub-)clones 11-BIO, 1-E8 and 3-B7 that actually expressed EGFP were also 
green fluorescent (Figure 7-6 region R3). Indeed, there was a very tight correlation 
between overall EGFP expression and EGFP fluorescence in all three of the gene-edited 
(sub-) clones, but particularly striking in 3-B7, where 53.24% of cells were located in 
region R3.
From these results I concluded that the epigenetic down-regulation responsible for the 
loss of green fluorescent cells from the populations of gene-edited EGFP (sub-)clones 
was not specific to the gene-edited EGFP allele(s). The low percentage of expressing 
cells in the parental CHO-mEGFP control suggested that it was an artefact of the 
multiple-copy transgene array. To confirm this, I investigated the extent of the down- 
regulation in the parental CHO-mEGFP cells in more detail by comparing the mEGFP 
expression in cells that were cultured for a short time only with cells cultured for longer 
times.
CHO-mEGFP cells from passage number 4, 10 and 18 were stained with the Alexa 
Fluor 647 labelled pan-EGFP antibody, lxlO 5 events were acquired per sample and 
analysed as described above. CHO-K1 cells were again used as the non-expressing 
control and regions were set accordingly (Figure 7-7). The flow cytometric analysis 
showed a rather rapid decline in the percentage of expressing cells over time: from 
20.08% in passage 4 to 10.31% by passage 10 and 6.78% by passage 18. These data are 
derived from three different defrosted aliquots of the parental CHO-mEGFP cells and 
were also confirmed in independent experiments. Thus, transgene expression was 
already unstable in the parental CHO-mEGFP cells.
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Figure 7-7 mEGFP expression in CHO-mEGFP cells over time in culture
Density plots of green fluorescence (x-axis) versus intracellular staining with an Alexa Fluor 647 
labelled pan-antiEGFP antibody (y-axis). CHO-K1 cells were used as a control to determine non­
expressing cells; mEGFP expression in CHO-mEGFP cells from passage 4, 10 and 18. Data are 
representative of two independent repeats.
7.1.3 Discussion
Here, I systematically investigated possible explanations for the loss of green 
fluorescent cells from the populations of gene-edited (sub-)clones that I observed during 
isolation of the gene-edited clones described in the previous chapter. At first, the most 
likely explanation seemed that the edited clones 11-B10 and 20-A11 were both derived 
from more than one cell.
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In this case, decreasing percentages of green fluorescent cells in the populations could 
be the result of a slight growth advantage for cells expressing non-fluorescent mEGFP 
compared to fluorescent edEGFP. It has been reported that wild-type EGFP can be toxic 
in mammalian cells303 and this is probably due to the production of free oxygen radicals 
as a result of fluorescent excitation. 304 Thus, expression of the fluorescent edEGFP 
variant could also lead to reduced cell viability compared to cells expressing non- 
fluorescent mEGFP.
However, to ensure that my gene-edited clones were derived from single cells, I sub­
cloned clone 11-B10, again by single cell sorting. This sub-cloning demonstrated that a 
certain percentage of cells in every single sub-clone of the edited clone 1 1 -BIO were 
green fluorescent, even though a large number of the sub-clones were derived from cells 
identified as EGFP-negative during sorting. These results suggested that every cell in 
the 11-BIO clone contained the edEGFP genotype even if no green fluorescence was 
expressed. Thus, the loss of green fluorescent cells from the population appeared to be 
due to instability of the phenotype and not the genotype.
Southern blot analysis of two 11 -BIO sub-clones also showed that the specific sequence 
changes were still present in theses clones, more than 1 0  weeks of culture and two 
rounds of cloning after the original selection. However, because the CHO-mEGFP cells 
and their sub-clones contain multiple mEGFP copies and only one or two of these may 
be edited, Southern blotting alone could not completely exclude the possibility that 11- 
B 1 0  and its sub-clones are mixed populations of edited and non-edited cells.
On the other hand, recovery of fluorescent EGFP expression in a significant proportion 
of cells in the sub-clones after treatment with sodium butyrate and Aza-dC established 
that the edited genotype was still present even in non-fluorescent cells. Therefore, 11- 
B10 and its sub-clones were not derived from more than one cell. In fact, this 
experiment demonstrated that epigenetic down-regulation was responsible for the loss 
of green fluorescent cells from the population of gene-edited clones. These results show 
that the genotype is stable, but the phenotype is not.
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Although epigenetic down-regulation of transgene expression is a well-known 
phenomenon in transgenic mice84 and mammalian cells, 302,305 I had to exclude the 
possibility that the gene editing event itself was responsible for the loss of fluorescent 
cells from the populations of gene-edited (sub-)clones. There is convincing evidence 
that the targeting oligonucleotide is physically integrated into the genome of edited 
cells259 and, analogous to what happens after transgene integration the integration event 
itself could potentially cause specific down-regulation of the edited allele or general 
down-regulation of all EGFP alleles.
However, labelling of the gene-edited (sub-)clones with an EGFP antibody resulted in a 
clearly defined population expressing both non-fluorescent mEGFP and fluorescent 
edEGFP, while there were no cells expressing non-fluorescent EGFP only. Thus, the 
down-regulation was not specific to the gene-edited allele. Also, the direct 
proportionality of EGFP expression and green fluorescence seen in the gene-edited 
clone 1 1 -BIO and its sub-clones suggests that the epigenetic modulation of expression 
of the different copies of the EGFP gene was coordinated. Further experiments 
demonstrated that the epigenetic down-regulation was already present in the parental 
CHO-mEGFP cells. Again, this established that gene editing itself was not the cause of 
the down-regulation.
In summary, oligonucleotide-mediated gene editing leads to a stable genotype and does 
not induce epigenetic down-regulation of the targeted gene. The unstable phenotype is 
an artefact of the EGFP transgene system and, at least in this system, a large majority of 
cells do not express the transgene. These results not only have implications for my 
research, but also for gene editing in general.
In my system, the lack of target gene expression in 80% of the cell population means 
that any editing in those cells would have been undetectable using the phenotypic assay. 
Thus, if any gene editing has occurred in that population, I have underestimated the 
efficiency. I also found that expression was unstable in viable edited cells.
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These data suggest that calculating viability of gene-edited cells in pools of treated cells 
may result in underestimates unless corrected for instability of expression. To my 
knowledge, all published data in regards to viability of gene-edited clones resulted from 
exactly such experiments. In particular, viability data published by Olsen et a / . 242,251 are 
based on the exact same system. Indeed, data from measuring viability of single gene- 
edited cells presented in a previous chapter (section 4.3.1) suggested a much higher 
viability (15.77% for cells treated with PTO-modified ssODN and 25.05% with 
unmodified ssODN) than that reported by Olsen et al.25] (2% and 6 % respectively).
Also, the observation by Olsen et al.242 that the intensity of green fluorescence varied 
between the two daughter cells of gene-edited cells can no longer be taken as supporting 
evidence that gene editing occurs predominantly in the S or G2/M phase. However, this 
does not invalidate other data presented in the same paper demonstrating that 
transfection with targeting ssODN immediately after release from G1 arrest results in 
significantly higher gene editing efficiencies.
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7.2 Gene editing detection is dependent on and positively associated 
with target gene expression
7.2.1 Results
Considering that successful gene editing as signified by green fluorescence would be 
undetectable in the 80% of cells not expressing any EGFP, I wondered what the gene 
editing efficiency would be if only EGFP-expressing cells were evaluated. Therefore, I 
transfected CHO-mEGFP cells with 4 pg of mEGFP-3A-NT-PTO ssODN as previously 
described and then looked at the percentage of green fluorescent cells compared to 
EGFP expression 24 h later. EGFP expression levels were determined by intracellular 
staining with a pan-EGFP antibody recognizing both the non-fluorescent mEGFP and 
fluorescent edEGFP variants (section 2.2.1.8).
For each sample, 3xl05 events were acquired on the flow cytometer, gated based on 
FSC versus SSC and EGFP fluorescence was plotted against total EGFP expression 
(Figure 7-8a). CHO-mEGFP cells transfected with 4 pg of mEGFP-Ctr-NT-PTO were 
used as negative control to determine positive green fluorescence (i.e. where to set 
region Rl). In this way, I determined that 2.53% of cells in the population were green 
fluorescent and, therefore, gene-edited.
I then gated out cells that did not express any EGFP (Figure 7-8b) using non-expressing 
CHO-K1 cells transfected with the targeting ssODN as double negative control, as I 
would be unable to determine if those cells were gene-edited or not. I found that in the 
EGFP expressing subpopulation (Figure 7-8b, cells in region R2; 23.78% of the total 
population) derived in this manner, 10.39% of cells were green fluorescent. As 
expected, higher expressing cells were also stronger green fluorescent, but notably an 
elevated percentage of high expressing cells appeared to be gene-edited compared to 
low expressing cells.
To more accurately quantify this observation, I divided the EGFP expressing 
subpopulation into ten regions, each containing 10% of the cells (Figure 7-8c, regions 
R3-R12). The regions were set according to the level of total EGFP expression in those 
cells, so that R3 was the decile with the lowest expressing cells and R12 the decile with 
the highest expressing cells.
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Figure 7-8 Percentage of edited cells and EGFP expression in CHO-mEGFP cells
a) Density plot o f CHO-mEGFP cells treated with mEGFP-3A-NT-PTO 24 h after transfection. 
Green fluorescent gene-edited cells are located in region R l.
b) Non-expressing cells as determined by parental CHO-K1 control cells treated with targeting 
ssODN are gated out o f the density plot, so only EGFP expressing cells are in region R2.
c) Cells were then divided into deciles o f EGFP expressing cells (regions R3-R12) and the 
percentage of green fluorescent cells in each decile was determined (cells that were also in Rl).
d) These percentages were plotted against the geometric mean fluorescent intensity (MFI) of the 
pan-EGFP antibody staining in each decile. CHO-mEGFP cells treated with mEGFP-3A-NT-PTO 
(■) or mEGFP-Ctr-NT-PTO ssODN (A); one-phase exponential association curves o f the data in 
the respective colours. Data are representative of three independent experiments.
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Then the percentage of gene-edited cells in each decile was calculated by determining 
how many cells in each of the regions R3-R12 were also in region R2 (Figure 7-8c). I 
found that 21.80% of cells in the decile containing the highest EGFP-expressing cells 
(region R12) were green fluorescent. This result was confirmed in a further two 
independent experiments and on average 23.09±1.16% (n=3) of the highest expressing 
cells were green fluorescent. However, these results were all achieved with early 
passage CHO-mEGFP cells (passage 4, 9 and 10). Later passage cells were somewhat 
lower at 18.75%, 17.13% and 15.86% (for passage 15, 18 and 23 respectively).
I then plotted the percentage of green fluorescent cells in each decile against the EGFP 
expression as signified by the geometric mean fluorescence intensity (MFI) of the pan- 
EGFP antibody staining in that decile (Figure 7-8d). The data points suggested a strong 
positive association between total EGFP expression and the percentage of gene-edited 
cells. Indeed, curve fitting of data from cells treated with the targeting ssODN yielded 
R2=0.99 for one-phase exponential association. Again, this value held true in 
independent repeats, with R2=0.98±0.02 (n=3). The data points from region R3 were 
excluded in all cases.
To see if these results held true for human as well as rodent cell lines, I performed 
similar experiments in the HEK293T-mEGFP cells, which were also received from 
Prof. Krauss, and in a HepG2-mEGFP cell line I had produced myself (section 
2.2.1.10). Cells were transfected with 4 pg mEGFP-3A-NT-PTO or mEGFP-Ctr-NT- 
PTO as described in section 2.2.1.4. After intracellular staining with the pan-EGFP 
antibody recognizing the mEGFP and edEGFP variants (section 2.2.1.8), 8xl05 events 
were acquired on the flow cytometer.
Events were gated based on FSC versus SSC and EGFP fluorescence was plotted 
against total EGFP expression (Figure 7-9a, b). HEK293T-mEGFP and HepG2-mEGFP 
cells transfected with the control ssODN were used as negative control to determine 
positive green fluorescence (i.e. where to set region R l). Staining with the pan-EGFP 
antibody showed that, in comparison to the CHO-mEGFP cells, a higher percentage of 
cells in these cell lines actually expressed mEGFP.
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Figure 7-9 Percentage of edited cells and EGFP expression in HEK293T- and HepG2- 
mEGFP cells
Density plot of HEK293T-mEGFP (a) and HepG2-mEGFP cells (b) 24 h after treatment with 
targeting ssODN. Green fluorescent gene-edited cells are located in region R l. Non-expressing 
cells as determined by the parental HEK293T or HepG2 control cells treated with targeting ssODN 
were gated out o f the respective density plots. Cells were divided into quintiles, each containing 
20% of EGFP expressing cells (regions R2-R6) and the percentage of green fluorescent cells was 
determined (cells that were also in Rl). These percentages were plotted against the MFI of the 
pan-EGFP antibody staining in each quintile o f HEK293T-mEGFP (c) or HepG2-mEGFP (d) cells 
treated with targeting ssODN (■) or control ssODN (A ); one-phase exponential association 
curves of the data in the respective colours. Data are representative of two independent 
experiments each.
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In the HEK293T-mEGFP cells 46.49%±1.85 (n=2) of cells expressed EGFP and in the 
HepG2-mEGFP cells 54.85%±13.62 (n=2). I also found that 0.49% (or 0.19% in a 
repeat experiment) of the HEK293T-mEGFP cells treated with targeting ssODN showed 
green fluorescence. When the non-expressing cells were gated out based on parental 
HEK293T cells treated with targeting ssODN, 1.02% (0.42% respectively) of cells were 
green fluorescent (Figure 7-9a; cells in Rl).
In the HepG2-mEGFP cells, 0.11% (or 0.15% in a repeat experiment) green fluorescent 
cells in the total population translated to 0.15% (0.36% respectively) in the expressing 
subpopulation (Figure 7-9b; cells in Rl). Parental HepG2 cells treated with targeting 
ssODN were used as non-expressing negative control cells. As in the CHO-mEGFP 
cells, there appeared to be a positive association between the level of EGFP expression 
and percentage of gene-edited cells. Therefore, I analyzed the results as described above 
for CHO-mEGFP cells (Figure 7-9).
However, EGFP expression levels were more tightly regulated in the HEK293T- 
mEGFP and HepG2-mEGFP cells, such that the highest expression levels in these cell 
lines were considerably lower than in the CHO-mEGFP cells (Table 7-1). Since the MFI 
of specific populations varies depending on acquisition settings, the MFI ratio between 
the 2 0 % highest and lowest expressing cells in each cell line is a more accurate 
measurement of the expression differences. As shown in Table 7-1, CHO-mEGFP cells 
have a 4-fold higher MFI ratio (18.14±1.81; n=3) than either HEK293T-mEGFP 
(4.48±0.19; n=2) or HepG2-mEGFP cells (4.40±1.03; n=2).
Because of the tight regulation of EGFP expression in HEK293T- and HepG2-mEGFP 
cells, it was not practicable to divide these cells into deciles for further analysis. Instead 
they were separated into five regions containing 20% of the cells each (quintiles). The 
regions were set according to the level of total EGFP expression in the cells, so that 
region R2 was the quintile with the lowest expressing cells while region R6  contained 
the highest expressing cells (Figure 7-9a, b).
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MFI of the top and bottom quintile of 
EGFP-expressing cells in each experiment MFI ratio
CHO-mEGFP 470.47/26.11; 373.40/23.35; 128.45/6.29 18.1411.81
HEK293T-mEGFP 68.92/14.76; 38.61/9.00 4.4810.19
HepG2-mEGFP 64.59/11.90; 33.76/10.03 4.4011.03
Table 7-1 MFI ratio of the top and bottom quintiles of EGFP-expressing cells
To calculate the MFI ratio, the MFI of the highest 20% and lowest 20% expressing CHO-, 
HEK293T- and HepG2-mEGFP cells were divided. Then the mean average±standard deviation 
was determined for the values from the respective independent experiments for each cell line.
When the percentage of green fluorescent cells in each quintile was plotted against the 
MFI of the pan-EGFP antibody staining of the same quintile, again there was a direct 
positive association between them. Thus, in HEK293T-mEGFP cells 1.61% (or 0.45% 
in the repeat experiment) of cells in the highest expressing quintile were green 
fluorescent. In HepG2-mEGFP cells, the percentage was 0.20% (or 0.24% in the repeat 
experiment). Curve fitting of data from cells treated with the targeting ssODN yielded 
R2=0.97±0.02 (n=2) for HEK293T and R2=0.84±0.12 (n=2) for HepG2-mEGFP cells 
one-phase exponential association. The data points from region R2 were excluded in all 
cases.
I also attempted to further test the relationship between expression and gene editing by 
treating cells with targeting ssODN after reactivation of expression with Aza-dC and/or
sodium butyrate. Unfortunately, the combined treatments were toxic for both CHO- 
mEGFP and HEK293T-mEGFP cells (data not shown).
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7.2.2 Discussion
Here, I set out to determine the gene-editing efficiency of the expressing subpopulation 
in epigenetically modulated cell populations that for the most part did not express 
EGFP. As the read-out for gene editing is based on the phenotypic analysis of 
fluorescent EGFP expression, a large majority of cells that did not express EGFP would 
theoretically result in a significant underestimation. I found that this was indeed the case 
when the non-expressing cells were excluded from the analysis in all three cell lines 
examined. One might argue that by excluding non-expressing cells from the analysis, 
the percentages of green fluorescent and therefore gene-edited cells are artificially 
enhanced. However, in my opinion, the adjusted percentages give a much more accurate 
measurement of gene editing in these cell lines.
Similar to previously reported results for CHO-mEGFP cells (7.1.2.3) I observed 
variable EGFP expression levels in both HEK293T-mEGFP and HepG2-mEGFP cells. I 
exploited this fortuitous circumstance to study the relationship between levels of target 
gene expression and gene editing efficiencies in isogenic cell lines and found a highly 
significant correlation in CHO-mEGFP cells. I observed similar, if less pronounced 
correlations, in HEK293T-mEGFP and HepG2-mEGFP cells, although analyses were 
complicated by low gene editing efficiencies and less variable expression.
The positive association between expression and editing levels is consistent with 
abundantly expressed genes being better targets for gene editing than those that are less 
abundantly expressed. However, all three recombinant cell lines have multiple copy 
integrations of the transgene. Therefore, it is possible that such data could be obtained in 
the absence of a link between expression and editing efficiencies if different transgene 
copies were expressed at different levels and regulated independently of each other. On 
the other hand, multiple transgene copies in recombinant cell lines invariably integrate 
into a single locus306,307 and evidence suggests that regulation of all copies is 
coordinated.308
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My own results showing the direct proportionality of total EGFP expression and green 
fluorescence in the gene-edited clone 11-BIO and its sub-clones (Figure 7-6) confirm 
that there is coordinated epigenetic modulation of expression of all EGFP gene copies. 
If there was independent regulation of the individual EGFP copies, one would expect a 
subpopulation of cells in which the fluorescent edEGFP copy is down-regulated, but 
which are still expressing mEGFP from some of the other non-edited copies. 
Specifically, such cells should be located in region R2 analogous to where the parental 
CHO-mEGFP cells are found (Figure 7-6). However, no such cells can be seen on the 
flow cytometry plots of gene-edited (sub-)clones after intracellular staining with a pan- 
EGFP antibody (Figure 7-6).
Such subpopulations are clearly present on the density plots of the CHO-, HEK293T- 
and HepG2-mEGFP cells treated with editing ssODN (cells excluded from region R l; 
Figure 7-8 and Figure 7-9), but this is due to the fact that in contrast to the gene-edited 
(sub-) clones only a minority of cells were successfully edited. The majority of treated 
cells were non-edited and therefore showed mEGFP expression, but no green 
fluorescence.
Also, there are cells that show considerably lower green fluorescence than cells with the 
highest green fluorescent intensity for a particular level of EGFP expression. These cells 
are located between the cells excluded from region Rl and the leading right edge of 
cells in region R l. This observation could be explained by autonomous expression 
regulation of individual EGFP copies, that is, the edEGFP copy could be differentially 
expressed in each cell while the total protein expression remains similar.
However, I have already shown that this is not the case in the gene-edited (sub-)clones. 
More likely, the lower green fluorescence in these cells is explained by the fact that 
onset of fluorescent EGFP production was asynchronous depending on the time it took 
each cell to become gene-edited. Thus, a positive association between target gene 
expression and editing levels is the only remaining viable explanation. This raises the 
question of how target gene expression levels can be related to gene editing efficiency. 
In all probability, this association actually reflects an underlying association between 
target gene transcription and gene editing efficiency.
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Indeed, a variety of published studies support an association between transcription and 
oligonucleotide-mediated gene editing. Evidence includes strand bias in the activities of 
oligonucleotides (transcribed vs non-transcribed strand) , 240,241,253’264 studies in S. 
cerevisiae,262 E. coli,266 and of mammalian episomal targets, 267 as well as comparisons 
of editing frequencies between different cell lines with differential target gene 
expression.263,268 Moreover, conventional gene targeting309 and gene targeting by 
triplex-forming oligonucleotides310 are also positively associated with transcription. 
Although the latter study reports a positive association with transcription, it also shows 
that gene targeting with triplex-forming oligonucleotides is not dependent on 
transcription.310 This suggests that the positive association between transcription and 
gene targeting may be due to improved access for the oligonucleotide.
In an aside, curve fitting of the data derived from cells treated with the control ssODN 
suggests the appearance of green fluorescent cells in these samples as well as a direct 
association with the MFI of EGFP expression. However, I did not employ dead cell 
discrimination in these experiments because of problems with leakage of dead cell 
stains into the whole population after fixation. Unfortunately, the background 
fluorescence of dead HEK-293T and particularly HepG2 cells is increased by 
transfection with Lipofectamine 2000. Thus, low percentages of false positives were 
present in these samples. The apparent positive association between these false positives 
and the MFI of EGFP expression is due to the fact that the measurement error during 
acquisition on the flow cytometer increases with higher MFI.
Whatever the reason for the observed relationship between target gene expression and 
editing efficiency, the finding that in the highest expressing cells significantly increased 
editing rates are possible is very encouraging. Initially, the impressive gene editing 
efficiencies achieved in the highest expressing CHO-mEGFP cells (23.09±1.16%; n=3) 
might seem fanciful considering the problems many laboratories have reported with 
attaining any detectable gene editing.229,232
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However, using the concept of complementary events in probability theory, the formula 
l-(l-x)n can be derived, where x is the chance that one specific copy of the target gene 
is gene-edited and n the number of target gene copies. Thus, the theoretically possible 
percentage of gene edited cells if each of the 38 mEGFP gene copies has a 1% chance 
of being edited is 31.74%. If each copy has a 0.5% chance of being edited, this 
percentage is reduced to 17.34%. Increased gene editing efficiencies in the highest 
expressing HEK293T-mEGFP and HepG2-mEGFP were not quite as impressive, but 
still apparent. This could reflect lower copy numbers and/or the reduced level of 
expression compared to CHO-mEGFP cells.
In conclusion, the data presented here suggest that there is a correlation between 
expression of the target gene and gene editing efficiency. Thus, highly expressed genes 
should be better targets. Direct proof of this hypothesis could easily be obtained by 
targeting mEGFP expressed from a tet-on/off adjustable expression system. However, it 
might be wiser to avoid the problems associated with unstable expression from 
recombinant cell lines altogether and target mammalian genes that can be up- or down- 
regulated with known stimuli. For example, transcription of ApoA-I can be up-regulated 
by PPARa agonists such as fibrates (1.2) or down-regulated by decreasing the glucose 
concentration.
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CHAPTER 8: DETECTION OF 
APOA-I GENE EDITING USING 
FLOW CYTOMETRY
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8.1 Introduction
As shown in the previous chapters (chapter 4-7), the combination of flow cytometry and 
targeting of mEGFP expressing cells was an extremely useful tool for quantification of 
gene editing efficiency. It allowed me to optimize gene editing conditions and study 
possible ways of increasing gene editing efficiencies or selecting for edited cells without 
the help of a marker gene. I was able to isolate gene-edited clones and demonstrate that 
oligonucleotide-mediated gene editing leads to a stable genotype and that it is positively 
associated with expression.
As the conclusion to my studies, I intended to use flow cytometry to examine gene 
editing of apolipoprotein A-I (ApoA-I) and isolate successfully edited ApoA-lM 
expressing cells. Previously I was unable to isolate gene-edited ApoA-I\i expressing 
HepG2 cell clones by limiting dilution, even though PCR-RFLP of the total population 
suggested the presence of edited cells up to 10 d after treatment (section 3.2.1). 
However, a recent report by Favari et al.10 described the use of a monoclonal mouse 
anti-human antibody that specifically recognizes only ApoA-IM homodimers. This 
suggests that the antibody is specific to the conformation of the dimer, so I hoped that I 
would be able to use it in flow cytometry.
Although ApoA-I and ApoA-lM are secreted proteins, it should be possible to capture 
these apolipoproteins by creating an antibody-based affinity matrix on the cell surface 
and subsequently labelling the captured antigen with a detecting fluorescent antibody 
(Manz et al.3u). However, this is a technically challenging procedure. Intracellular 
staining on the other hand would almost certainly allow detection of both variants, but 
requires fixation and permeabilization, thus precluding isolation of live cells. 
Nevertheless, I decided to use intracellular staining for a pilot experiment as I was 
already familiar with the method.
Unfortunately, I could not detect ApoA-lM in CHO-AIM cells by intracellular staining 
with the mouse anti-human ApoA-IM homodimer antibody, even though Western 
blotting with the same antibody confirmed the presence of ApoA-lM homodimers in cell 
lysates and supernatants. Intriguingly though, a polyclonal rabbit anti-human ApoA-I 
antibody gave a strong signal in CHO-AIM cells, but not CHO-AI cells, whilst Western 
blotting with the antibody demonstrated expression in both cell lines.
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8.2 Results
In this pilot experiment I tested whether the mouse anti-human ApoA-lM homodimer 
antibody could be used for flow cytometry. CHO-K1, CHO-AI and CHO-AIM cells 
were fixed, permeabilized and labelled as described in section 2.2.1.8. For each sample 
1 pi polyclonal rabbit anti-human ApoA-I or 250 ng monoclonal mouse anti-human 
ApoA-lM antibody were labelled with the rabbit Alexa Fluor 488 nm IgG or the mouse 
IgG2a Alexa Fluor 647 Zenon labelling kit. After staining, 5xl04 events were acquired 
and gated based on FSC versus SSC. To maximize the resulting information, the 
fluorescent intensities were displayed on density plots even though each sample was 
only stained with one antibody to avoid potential competition.
CHO-K1 CHO-AI CHO-AIM
ApoA-I
ApoA-lM
Ab
1  ' ■ M—L  ,
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Figure 8-1 ApoA-I and ApoA-IM detection by flow cytom etry
CHO-K1, CHO-AI and CHO-AIM cells were stained with either the ApoA-I-Alexa647 or the 
ApoA-IM-Alexa488 antibody. Data are representative o f two independent experiments.
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As shown in the lower panel of Figure 8-1, there was only a very slight increase in 
staining with the ApoA-lM homodimer antibody in CHO-AIM cells (MFI 18.9) 
compared to CHO-K1 and CHO-AI control cells (MFI 15.0 and 14.1 respectively). 
Notably, the ApoA-I antibody did not give any signal over the background defined by 
CHO-K1 cells in the CHO-AI cells, but a distinct population of expressing cells was 
apparent in the CHO-AIM cells. The former observation suggested that there was no 
ApoA-I expression in the CHO-AI cells, while the latter was not surprising, since the 
ApoA-I antibody was selected against a peptide from the C-terminus and thus was not 
expected to distinguish between wild-type and mutant protein.
However, a Western blot performed by my colleague Dr. Ioannis Papaioannou on 
supernatant from the CHO-AI cells with the ApoA-I antibody demonstrated that these 
cells did express ApoA-I (personal communication). Also, the ApoA-lM antibody 
clearly detected the ApoA-lM homodimer in both the lysate and supernatant from CHO- 
AIM cells.
8.3 Discussion
In this experiment, I tested whether the ApoA-I\i antibody could detect ApoA-lM in 
cells as a first step towards potentially using this antibody for the selection of gene- 
edited cells that express ApoA-lM instead of ApoA-I. Unfortunately, the antibody 
binding was not specific for ApoA-lM as both the non-expressing CHO-K1 cells and the 
ApoA-I expressing CHO-AI cells showed a very similar MFI. There are several 
possible explanations for this result.
There simply might not be any ApoA-lM homodimers present in the CHO-AIM cells. It 
is currently unclear if the ApoA-lM homodimers form intracellularly or during HDL 
maturation after secretion from the cells, though the Western blot performed by my 
colleague on cell lysate from CHO-AIM cells suggests the former. Also, intermolecular 
and intramolecular disulphide bonds of many secretory proteins, e.g. insulin, are known 
to form in the oxidative environment found in the lumen of the rough endoplasmatic 
reticulum. Thus, it seems likely that ApoA-lM homodimers could also form in the 
endoplasmatic reticulum of CHO-AIM cells.
203
Alternatively, the fixation process could have masked the ApoA-lM antibody epitope on 
the ApoA-lM homodimers, since the formaldehyde in the fixation buffer cross-links 
amino side chains, particularly of lysine, with close-by nitrogen atoms. Other fixation 
reagents that immobilize proteins by precipitation, such as ethanol or methanol, might 
preserve the antibody epitope. Optimization of the fixation method should at least 
determine if the ApoA-lM antibody can detect ApoA-lM homodimers in the cells. 
However, the time might be better spent on establishing the cell surface capture method.
Interestingly, the ApoA-I antibody did not detect any ApoA-I in CHO-AI cells but did 
give a signal in CHO-AIM cells, although Western blotting of supernatant with the 
same antibody showed ApoA-I secretion from CHO-AI cells. This would suggest that 
ApoA-I is rapidly secreted from the CHO-AI cells, whereas ApoA-lM is largely retained 
in CHO-AIM cells. Indeed, impaired secretion of ApoA-lM has been described in 
hepatocytes from ApoA-lM homo- and heterozygous knock-in mice.312 Also, improperly 
folded proteins are retained in cells,313 so perhaps the ApoA-IM homodimer is 
recognized as such and not secreted as a consequence.
If intracellular ApoA-I is indeed negligible, intracellular staining with the ApoA-I 
antibody could be used to quantify ApoA-lM gene editing efficiencies and optimize 
hepatic targeting in vivo. However, recovery of live gene-edited cells using the cell 
surface affinity-matrix capture method described by Manz et al.3U requires a 
discriminatory antibody, which might still be possible with the ApoA-IM antibody if its 
failure to bind specifically was due to the fixation method. These results are clearly 
encouraging, at least in regards to the possibility of quantifying gene editing of ApoA- 
I m  using flow cytometry, but the ultimate aim is to sort and clone gene-edited cells.
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CHAPTER 9: GENERAL 
DISCUSSION
9.1 Summary
Atherosclerosis is the underlying reason for three quarters of deaths caused by 
cardiovascular disease equating to -20%  of deaths worldwide. Reverse cholesterol 
transport mediated by HDL and ApoA-I plays an important role in limiting the 
formation of atherosclerotic plaque in the body.314 ApoA-lM,64 a point mutated form of 
ApoA-I, is particularly atheroprotective as demonstrated by injection of recombinant 
ApoA-Im/ phospholipid complexes in a clinical phase II trial58 as well as evidence from 
in vitro6*'70,72 and preclinical in vivo studies.59"62 However, a recombinant protein 
therapy requiring tens of grams per treatment would be prohibitively expensive for 
widespread use, but gene therapy could be a cost effective alternative.
Here, I evaluated the use of oligonucleotide-mediated gene editing to introduce the 
ApoA-lM mutation into the ApoA-I sequence in mammalian cells. After initial 
methodological problems with the PCR-RJFLP analysis, I demonstrated successful gene 
editing in an ApoA-I expressing recombinant CHO cell line and also of the endogenous 
ApoA-I gene in HepG2 cells. I excluded the possibility that the diagnostic bands in the 
PCR-RFLP were due to analysis artefacts and confirmed by sequencing the presence of 
gene-edited cells in the population for up to 10 days after treatment.
However, I was unable to isolate viable gene-edited cell clones by limiting dilution and 
this, in addition to the problems with quantitative assessment of PCR-RFLP results, led 
me to employ the mutated EGFP reporter gene system in further experiments. In these 
experiments, I investigated the influence of the transfection reagents Lipofectamine 
2000,146 LPEI,137 fully deacylated LPEI140 and CDAN/DOPE148 on gene editing 
efficiencies. Additional experiments assessed the newly-developed non-toxic 
biopolymer transfection reagents atelocollagen144 and tri-methylated chitosan.141,142 I 
found that Lipofectamine 2000 mediated significantly higher gene editing levels than 
any of the other reagents and that the biopolymers did not lead to any gene editing.
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Furthermore, I examined the influence of phosphorothioate (PTO) and locked nucleic 
acid (LNA) oligonucleotide backbone modifications on editing efficiencies and viability 
of edited cells compared to unmodified (DNA) oligonucleotides. My results 
demonstrated that although PTO- and LNA-modified ssODNs produced higher levels of 
gene-edited cells initially, the viability of gene-edited cells treated with these protected 
oligonucleotides was significantly reduced. Thus, there was a trade-off between toxicity 
of the backbone modifications and viability of edited cells. Other experiments showed 
that 24 h after transfection was the optimal sampling time point and that an 
oligonucleotide with three mismatches performed better than a two mismatch ssODN.
I also used the mEGFP system to investigate ways of increasing gene editing 
efficiencies and selecting for gene-edited cells independent of a marker gene. 
Unfortunately, my findings showed that published data suggesting an increase with 
repeated targeting184 were due to an artefact in sampling time and did not in fact lead to 
an increase in gene editing. On the other hand, co-transfection of targeting 
oligonucleotide with an RFP expressing plasmid seemed to increase gene editing 
efficiency, but curiously there were no double positive cells in the treated population. 
Thus, plasmid co-transfection could not be used to select for gene-edited cells 
independent of the targeted marker gene. Two other attempts at selecting gene-edited 
cells involved sorting for G2/M arrested cells and FRET between the targeting ssODN 
and genomic DNA. Disappointingly, both attempts failed due to technical difficulties.
In other experiments, I addressed the lack of incontrovertible proof that oligonucleotide- 
mediated gene editing can introduce specific mutations into the genomic sequence of
mammalian cells. Rigorously following the four criteria proposed by Albuquerque-Silva
'22,1et a l, I demonstrated that three specific mismatches were introduced into the 
genomic sequence of gene-edited cells.
Moreover, the gene-edited genotype was stable even though green fluorescent cells 
were lost from the population of gene-edited clones. I showed that this was due to 
instability of the phenotype caused by epigenetic down-regulation of the multiple copy 
transgene array in the CHO-mEGFP cells. The observation that a large majority of 
CHO-mEGFP cells did not express mEGFP led me to believe that I had underestimated 
the gene editing efficiency in these cells. Thus, I investigated what percentage of the 
expressing cells was gene-edited.
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Not surprisingly, I found that a much higher percentage of cells in the expressing 
subpopulation were gene-edited. In fact, gene editing efficiency was positively 
associated with expression of the target gene. This result was also confirmed in 
HEK293T-mEGFP and HepG2-mEGFP cells.
Coming to the end of my studies, I intended to return to targeting ApoA-I in HepG2 and 
recombinant CHO-AI cells with the aim of producing isogenic cell lines containing the 
ApoA-lM mutation. Since my previous attempts using limited dilution were 
unsuccessful, I hoped to use flow cytometry for selection of gene-edited cells in these 
experiments. Unfortunately, the ApoA-lM homodimer antibody did not appear to bind 
specifically to the protein in fixed cells.
Interestingly, a control ApoA-I antibody gave a specific signal in CHO-AIM, but not in 
CHO-AI cells even though both cell lines expressed the respective protein variants. This 
suggested that ApoA-lM is retained to a much higher degree in cells than ApoA-I. Thus, 
flow cytometric quantitation of ApoA-I gene editing is possible. Thus, although I did 
not manage to establish gene-edited isogenic cell lines expressing the super- 
atheroprotective ApoA-IM variant in this study, I made significant progress towards it.
9.2 Implications of my results for the chimeraplasty controversy
During my studies I encountered and overcame a number of problems that could 
potentially explain why other laboratories have reported negative results. For example, I 
observed heteroduplex formation during the evaluation of gene editing efficiencies with 
PCR-RFLP (section 3.3). It is a distinct possibility that only this heteroduplex formation 
enabled visual identification of the diagnostic bands in my experiments.
Since my PCR-RFLP was based on the destruction of a restriction site, the heteroduplex 
band co-located with the diagnostic band. In PCR-RFLP analyses based on the creation 
of a restriction site, the heteroduplex band would not be distinguishable from the bands 
characteristic for non-edited cells. Formation of heteroduplexes is dependent on PCR 
conditions which can vary widely even within the same laboratory.
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My experiments (section 4.1.1) also highlight the importance of using the optimal 
transfection reagent for oligonucleotide-mediated gene editing. A recently published 
study by Afifi et al.233 reported negative results when skin fibroblasts were targeted with 
chimeraplasts and ssODNs using DMSO to permeabilize the cells. My results suggest 
that this failure was probably due to insufficient transfection efficiency. Unfortunately, 
no data studying the intracellular location or concentration of the oligonucleotides were 
presented in this publication, so no definite conclusion can be drawn.
I also found that PTO and LNA oligonucleotide backbone modifications initially 
mediate higher gene editing levels, but reduce viability of gene-edited cells significantly 
compared to unmodified ssODNs (section 4.3.1). Location of the backbone 
modifications seems to influence gene editing efficiencies as well (I. Papaioannou, 
paper submitted). Moreover, the number of mismatches between the gene editing 
ssODN and the target sequence significantly influenced editing efficiencies (section 
4.4.1). The importance of the mismatch location246 in the oligonucleotide and strand- 
bias has already been reviewed in section 1.4.5.3.
In other experiments I showed that gene editing efficiency is positively associated with 
expression of the target gene. Thus, endogenous genes that are expressed at low levels 
are likely to be edited less efficiently. For example, correction of the L444P mutation in 
the acid p-glucosidase gene of skin fibroblasts from a Gaucher disease patient was 
unsuccessful using chimeraplasts,229 but this gene is transcribed at 6- fold lower levels 
in skin fibroblasts than in a glioblastoma cell line and 8-fold lower than in astrocytoma 
cells.315
Also, unstable expression in the CHO-mEGFP cells was due to epigenetic down- 
regulation of the transgene array and led to a significant underestimation of gene editing 
efficiencies in these cells. This finding was confirmed in two other recombinant mEGFP 
cells lines. Although continuous application of selection pressure can ameliorate the 
problem of loss of expression,305 it is common practice to withdraw selection pressure 
after isogenic cells have been isolated.
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Furthermore, the large majority of reporter gene cell lines used in oligonucleotide- 
mediated gene editing research contain multiple copies of the respective transgenes. 
Thus, differing levels of epigenetic down-regulation in such cell lines could account for 
some of the variation in reported gene editing efficiencies. Previous research in our 
laboratory has also shown that the quality and stability of chimeraplasts has to be taken 
into account when negative results are obtained.237 Taken together, these points could 
well explain the difficulties of reproducibility associated with chimeraplasty.
Notably, all published negative results described the use of chimeraplasts with the sole 
exception of the study by Afifi et al.m  already discussed above. So far, no other 
negative data has been published on using single-stranded oligonucleotides for gene 
editing. On the contrary, a number of independent research groups from the United 
Kingdom,183>249 Norway,242251 France,184'254 The Netherlands,243'260 Germany,241'247'259 
USA 4 ’ and China2 7 have published positive results when using ssODNs instead 
of chimeraplasts. Furthermore, rigorously applying the four criteria suggested by 
Albuquerque-Silva et al.221 for gene repair validation, I demonstrated that 
oligonucleotide-mediated gene editing with ssODNs can introduce three specific 
nucleotide changes into the genomic sequence of mammalian cells (section 6.2) and that 
these alterations lead to a stable inheritable genotype (section 7.1).
Thus, I propose the following guidelines for oligonucleotide-mediated gene editing 
research. First, ssODNs should be used instead of chimeraplasts. Second, PCR-RFLP 
analysis should be avoided because of heteroduplex formation and problematic 
quantitation. Potential alternatives include flow cytometry if mutation specific 
antibodies are available, or allele specific quantitative RT-PCR. Third, transfection 
efficiency and in particular nuclear localization of the targeting ssODN must be 
evaluated and optimized if necessary. Fourth, the design of the targeting oligonucleotide 
such as backbone modifications, mismatch number and location and length must be 
optimized, as only a few firm rules are available so far. Fifth, the expression level of the 
target gene should be controlled for especially in recombinant cell lines, but also when 
targeting endogenous genes. If possible the expression levels should be maximized.
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9.3 Further Research
Due to time constraints, I was unable to follow up on several interesting research 
avenues. For example, I intended to return to targeting the endogenous ApoA-I gene in 
CHO-AI and HepG2 cells and to isolate gene-edited ApoA-lM expressing cell clones 
using flow cytometry, but was hampered by the non-specific binding of the ApoA-lM 
homodimer antibody (section 8.2). However, the data suggest that the formaldehyde- 
based fixation I used may have hidden the antibody epitope and consequently other 
fixation methods should be evaluated.
Use of the antibody in unfixed cells employing the cell surface capture method 
described by Manz et al.m  should also be attempted. Furthermore, I showed that the 
ApoA-I antibody gives a specific signal in formaldehyde-fixed CHO-AIM cells. Thus, 
gene editing efficiencies of ApoA-I to ApoA-lM can be quantified by flow cytometry, 
avoiding the problems with PCR-RFLP analysis described above.
On a completely different note, I showed that I could introduce three specific nucleotide 
alterations with the same targeting oligonucleotide (section 6.2) and other groups have 
shown similar data.247,255 These results raise the question of how specific 
oligonucleotide-mediated gene editing is when targeting endogenous genes. The answer 
could potentially limit the application of this method for gene therapy, but even a 
negative result would still allow generation of gene-edited cells for research into genetic 
diseases and SNPs. The specificity of gene editing could perhaps be evaluated by 
recovering biotin-labelled oligonucleotides from the genomic DNA of gene-edited cells, 
in experiments similar to how Radecke et al.259 showed physical integration of the 
ssODN. Random priming could be used to amplify the selected sequences or 
alternatively, the sequences could be subcloned into bacterial plasmids.
Further research into ways of selecting or enriching for gene-edited cells independent of 
the target gene could be particularly rewarding. Two of my attempts in this direction 
failed due to technical difficulties (chapter 5), but further optimization might overcome 
these difficulties. Also, results reported by Ferrara et al.279 suggest that CHK1 and 
CHK2 are phosphorylated only in the gene-edited subpopulation of treated cells.
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Confocal microscopy and flow cytometry could be employed to analyse activation of 
the ATM/ATR DNA damage and repair pathway in gene-edited cells with an emphasis 
on CHK1 and CHK2 phosphorylation. If the results by Ferrara et al.219 are confirmed, 
an intracellular kinase assay which is currently being developed by Invitrogen could be 
used for fluorescence activated cell sorting of cells according to their phosphorylated 
CHK1 or CHK2 status. Thus, the need for mutation specific antibodies would be 
circumvented.
Temporary down-regulating of the expression of certain proteins in the DNA damage 
and repair pathways by siRNA could also increase gene editing efficiencies. Of 
particular interest are the mismatch repair pathway proteins, MSH2 and MSH3,243,260 
which have been implicated in the suppression of gene editing. It has been suggested 
that this is due to MSH2 and MSH3 preventing homologous recombination between 
sequences containing non-homologous nucleotides.260,261 However, research in our 
laboratory suggests that MSH2 is activated at a later stage of gene editing, after the 
oligonucleotide is integrated into the genomic sequence (I. Papaioannou, paper 
submitted). In particular, there seems to be a positive influence of MSH2 suppression on 
viability of gene-edited cells, but these findings need to be studied in more detail.
A better understanding of the DNA damage response pathways involved in 
oligonucleotide-mediated gene editing will hopefully lead to enhanced editing 
efficiencies and thus more wide-spread application of this method not only in gene 
therapy, but also in the generation of transgenic cell and animal systems.
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